

(19) World Intellectual Property
Organization
International Bureau




(43) International Publication Date
27 January 2005 (27.01.2005)

PCT

(10) International Publication Number
WO 2005/007656 A1

- (51) International Patent Classification⁷: C07D 471/10, A61K 31/437, A61P 31/18 (74) Agent: OGILVY RENAULT; Suite 1600, 1981 McGill College Avenue, Montreal, Quebec H3A 2Y3 (CA).
- (21) International Application Number: PCT/CA2004/001048 (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (22) International Filing Date: 16 July 2004 (16.07.2004)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 60/487,973 18 July 2003 (18.07.2003) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- (71) Applicant (for all designated States except US): VI-ROCHEM PHARMA INC. [CA/CA]; 275 Armand-Frappier Blvd., Laval, Québec H7V 4A7 (CA).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): CHAN CHUN KONG, Laval [CA/CA]; 27 Levere Street, Kirkland, Québec H9J 3X8 (CA). ZHANG, Ming-Qiang [NL/GB]; 26 Fennec Close, Cherry Hinton Cambridge CB1 9GG (GB). MOINET, Christophe [FR/CA]; 9306 Bretonvilliers Street, Montréal, Québec H2M 2A8 (CA). PROULX, Mélanie [CA/FR]; 17 du Général Zimmer Street, F-67000 Strasbourg (FR). REDDY, Thumkunta, Jagadeeswar [IN/CA]; 12546 Bedford Street, Pierrefonds, Quebec H9A 3K5 (CA). COURCHESNE, Marc [CA/CA]; 967 Ampère, Laval, Québec H7N 6H3 (CA).
- Published:
— with international search report
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: SPIRO COMPOUNDS AND METHODS FOR THE MODULATION OF CHEMOKINE RECEPTOR ACTIVITY



(I)

(57) Abstract: Novel compounds represented by formula (I): wherein Y, Z, X, W, R1, R2 and R3 are as defined herein, or pharmaceutically acceptable salts, hydrates or solvates thereof, are useful for the modulation of CCR5 chemokine receptor activity and the treatment or prevention of diseases associated therewith.

WO 2005/007656 A1

SPIRO COMPOUNDS AND METHODS FOR THE MODULATION OF
CHEMOKINE RECEPTOR ACTIVITY

This application claims the benefit of US
5 provisional application 60/487,973 filed July 18,
2003, the entire disclosure of which is herein
incorporated by reference.

TECHNICAL FIELD

10 The present invention relates to novel spiro
compounds and a method of modulating chemokine
receptor activity using these compounds. The present
invention is also directed to novel spiro compounds
which are useful in the prevention or treatment of
15 diseases associated with the modulation of CCR5
chemokine receptor activity. The present invention
is further directed to a method of blocking cellular
entry of HIV in a subject and to compositions using
these compounds.

20

BACKGROUND ART

Chemokines are chemotactic cytokines that are
released by a wide variety of cells to attract
macrophages, T cells, eosinophils, basophils and
25 neutrophils to sites of inflammation and they also
play a role in the maturation of cells of the immune
system. Chemokines play an important role in immune
and inflammatory responses in various diseases and
disorders, including asthma, rhinitis and allergic
30 diseases, as well as autoimmune pathologies such as
rheumatoid arthritis and atherosclerosis. Chemokines
are small 70 to 80 amino acid proteins with well-

characterized three-dimensional structures, usually stabilized by two disulfide bridges. They are divided into four families on the basis of pattern of conserved cysteine residues. Chemokine receptors
5 have been designated such as, CCR1, CCR2, CCR2A, CCR2B, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10, CXCR1, CXCR2, CXCR3, and CXCR4 and therefore agents which modulate these receptors may be useful in the prevention and treatment of diseases as
10 mentioned above.


One of them, the C-C chemokines family, includes potent chemoattractants of monocytes and lymphocytes such as RANTES (Regulated on Activation, Normal T
15 Expressed and Secreted), eotaxin, MIP-1 α and MIP-1 β (Macrophage Inflammatory Proteins) and human monocyte chemotactic proteins 1-3 (MCP-1, MCP-2 and MCP-3). More specifically, C-C chemokine receptor 5 (CCR5), a β -chemokine receptor with a seven-
20 transmembrane-protein structure, was found to serve as a coreceptor for non-syncytium-inducing or macrophage-tropic HIV-1 (R5 viruses). It was also established that CCR5 is the principal chemokine receptor required for the entry of HIV into the cell
25 during primary infection. Therefore, interfering with the interaction between the viral receptor CCR5 and HIV can block HIV entry into the cell. It would therefore be useful to provide novel compounds which are modulators of chemokine receptor activity.

30

DISCLOSURE OF THE INVENTION

In one aspect, the present invention provides novel compounds represented by formula (I):

5



(I)

or pharmaceutically acceptable salts, hydrates or solvates thereof,


10

wherein Y, Z and X are each independently chosen from CH₂, C=O or CR₄R₅;


W is H, optionally substituted C₁₋₁₀ alkyl (e.g. C₁₋₆ alkyl) optionally substituted C₂₋₁₀ alkenyl (e.g. C₂₋₆ alkenyl), optionally substituted C₂₋₁₀ alkynyl (e.g. C₂₋₆ alkynyl), optionally substituted C₆₋₁₂ aryl, optionally substituted 3 to 10 membered heterocycle, optionally substituted C₆₋₁₂ aralkyl or optionally substituted C₃₋₁₀ heteroaralkyl;

R₁ is H, OH, optionally substituted C₁₋₁₀ alkyl (e.g. C₁₋₆ alkyl), optionally substituted C₂₋₁₀ alkenyl (e.g. C₂₋₆ alkenyl), optionally substituted C₂₋₁₀ alkynyl (e.g. C₂₋₆ alkynyl), optionally substituted C₆₋₁₂ aryl, NR₈R₉, optionally substituted O-C₁₋₆ alkyl,


optionally substituted O-C₆₋₁₂ aryl, optionally substituted O-C₆₋₁₂ aralkyl,




(II)




(III)



(IV)



(V)



(VI)

5

R₂ is optionally substituted C₁₋₁₀ alkyl, optionally substituted C₂₋₁₀ alkenyl, optionally substituted C₂₋₁₀ alkynyl, optionally substituted C₆₋₁₂ aryl or
10 optionally substituted 3 to 10 membered heterocycle;

R₃ is H, optionally substituted C₁₋₁₀ alkyl (e.g. C₁₋₆ alkyl), optionally substituted C₂₋₁₀ alkenyl (e.g. C₂₋₆ alkenyl), optionally substituted C₂₋₁₀ alkynyl (e.g.
15 C₂₋₆ alkynyl), or optionally substituted C₆₋₁₂ aryl;

R₄ and R₅ are each independently H, optionally substituted C₁₋₁₀ alkyl (e.g. C₁₋₆ alkyl), optionally substituted C₂₋₁₀ alkenyl (e.g. C₂₋₆ alkenyl),
20 optionally substituted C₂₋₁₀ alkynyl (e.g. C₂₋₆ alkynyl), or optionally substituted C₆₋₁₂ aryl;

R₆ and R''₆ are each independently H, optionally substituted C₁₋₁₀ alkyl (e.g. C₁₋₄ alkyl), optionally substituted C₂₋₁₀ alkenyl (e.g. C₂₋₄ alkenyl), or
5 optionally substituted C₂₋₁₀ alkynyl (e.g. C₂₋₄ alkynyl) and R₇ is H, optionally substituted C₁₋₁₀ alkyl, optionally substituted C₂₋₁₀ alkenyl, optionally substituted C₂₋₁₀ alkynyl, optionally substituted C₆₋₁₂ aryl, optionally substituted 3 to 10
10 membered heterocycle, optionally substituted C₆₋₁₂ aralkyl or optionally substituted 3 to 10 membered heteroaralkyl, or R''₆ and R₇ can be taken together to form an optionally substituted 3 to 10 membered heterocycle; and

15

R₈ and R₉ are each independently H, optionally substituted C₁₋₁₀ alkyl (e.g. C₁₋₆ alkyl), optionally substituted C₂₋₁₀ alkenyl (e.g. C₂₋₆ alkenyl), or
20 optionally substituted C₂₋₁₀ alkynyl (e.g. C₂₋₆ alkynyl).

In another aspect, there is provided a method of modulating chemokine receptor activity in a subject comprising administering to the subject an effective
25 amount of a compound of formula (I) or composition of the invention.

In still another aspect, there is provided a method for prevention or treatment of certain inflammatory
30 diseases, immunoregulatory diseases, organ transplantation reactions and in the prevention and

treatment of infectious diseases such as HIV
infections in a subject in need of such treatment
comprising administering to the subject a
therapeutically effective amount of a compound of
5 formula (I) or composition of the invention.

In still another aspect, there is provided a method
for the prevention or treatment of diseases
associated with the modulation of CCR5 chemokine
10 receptor activity in a subject in need of such
treatment comprising administering to the subject a
therapeutically effective amount of a compound of
formula (I) or composition of the invention.

15 In still another aspect, there is provided a method
for blocking cellular entry of HIV in a subject
comprising administering to the subject in need
thereof an effective amount of a compound of formula
(I) or composition of the invention to block HIV
20 from cellular entry in said subject.

In still another aspect, there is provided a method
for the prevention or treatment of diseases
associated with the modulation of chemokine receptor
25 activity in a subject in need of such treatment
comprising administering to the subject a
pharmaceutical combination comprising at least one
compound of formula (I) and at least one further
therapeutic agent.

30

In another aspect, there is provided a pharmaceutical formulation comprising the compound of the invention in combination with a pharmaceutically acceptable carrier or excipient.

5


In another aspect of the invention is the use of a compound according to formula (I), for the manufacture of a medicament for the prevention or treatment of diseases associated with the modulation of chemokine receptor activity.

10

In one embodiment, compounds of the present invention comprise those wherein the following embodiments are present, either independently or in combination.

15

In one embodiment, the present invention provides novel compounds represented by formula I:




(I)

20

or pharmaceutically acceptable salts, hydrates or solvates thereof wherein Y, Z, X, W, R₁, R₂ and R₃ are defined above.

25


In one embodiment, the present invention provides novel compounds represented by formula (Ia):



5

or pharmaceutically acceptable salts, hydrates or solvates thereof wherein Y, X, W, R₁, R₂ and R₃ are defined above.


10 In one embodiment, the present invention provides novel compounds represented by formula (Ib):



or pharmaceutically acceptable salts, hydrates or
15 solvates thereof wherein Z, X, W, R₁, R₂ and R₃ are defined above.

In one embodiment, the present invention provides novel compounds represented by formula (Ic):


20



(Ic)

or pharmaceutically acceptable salts, hydrates or
 solvates thereof wherein Y, Z, W, R₁, R₂ and R₃ are
 5 defined above.

In one embodiment, the present invention provides
 novel compounds represented by formula (Id):




(Id)

10

or pharmaceutically acceptable salts, hydrates or
 solvates thereof wherein W, R₁, R₂ and R₃ are defined
 above.

15

In one embodiment, the compounds of the present
 invention are in the (S)-enantiomer as represented
 by formula (Ie):



(Ie)

or pharmaceutically acceptable salts, hydrates or
 solvates thereof wherein Y, Z, X, W, R₁, R₂ and R₃
 5 are defined above.

In one embodiment, W is chosen from optionally
 substituted C₆₋₁₂ aryl or optionally substituted 3 to
 10 membered heterocycle.

10

In a further embodiment, W is optionally substituted
 C₆₋₁₂ aryl.

In a further embodiment, W is optionally substituted
 3 to 10 membered heterocycle.

15

In further embodiments:

W is phenyl;

W is phenyl substituted with a halogen;

W is phenyl substituted with Br;

20 W is phenyl substituted with F;

W is phenyl substituted with Cl;

W is phenyl substituted with at least one halogen;

W is phenyl substituted with a C₁₋₃ alkoxy;

W is phenyl substituted with methoxy;


25 W is phenyl substituted with ethoxy;

W is phenyl substituted with SO₂C₁₋₃alkyl;


- W is phenyl substituted with methanesulfonyl;
W is phenyl substituted with difluoromethoxy;
W is phenyl substituted with trifluoromethoxy;
W is phenyl substituted with trifluoromethyl;
5 W is phenyl substituted with CN;
W is phenyl substituted with pyrrazoyl;
W is phenyl optionally substituted in the para (p)
position.
W is optionally substituted pyridine.

10


In a further embodiment, R_1 is chosen from:




(II)



(III)




(IV)




(V)

, or



(VI)


In a further embodiment, R_1 is:



(II)

5 wherein R_6 is as defined above and R_7 is chosen from optionally substituted C_{1-10} alkyl, optionally substituted C_{6-12} aryl or optionally substituted 3 to 10 membered heterocycle.

10 In further embodiments, R_1 is:



(II)

wherein:

- 15 R_7 is methyl;
 R_7 is ethyl;
 R_7 is isopropyl;
 R_7 is cyclopropyl;
 R_7 is cyclobutyl;
20 R_7 is cyclopentyl;
 R_7 is cyclohexyl;
 R_7 is cycloheptyl;
 R_7 is 4,4-difluorocyclohexyl;

R₇ is CH₂-cyclopropyl;

R₇ is CH₂-cyclobutyl;

R₇ is CH₂-cyclopentyl;

R₇ is CH₂-cyclohexyl.

5

R₇ is phenyl;

R₇ is phenyl substituted with methyl;

R₇ is phenyl substituted with at least one methyl;

R₇ is phenyl substituted with a halogen;

10 R₇ is phenyl substituted with at least one halogen;

R₇ is phenyl substituted with Cl;

R₇ is phenyl substituted with Br;

R₇ is phenyl substituted with F;

R₇ is phenyl substituted with at least one Cl;

15 R₇ is phenyl substituted with methoxy.

R₇ is benzyl;

R₇ is benzyl substituted with methyl;

R₇ is benzyl substituted with at least one methyl;

20 R₇ is benzyl substituted with a halogen;

R₇ is benzyl substituted with at least one halogen;

R₇ is benzyl substituted with Cl;

R₇ is benzyl substituted with Br;


R₇ is benzyl substituted with F;

25 R₇ is benzyl substituted with at least one Cl;

R₇ is benzyl substituted with methoxy.

R₇ is optionally substituted pyridine.


30 In a further embodiment, R₁ is:



(III)

wherein R_6 and R''_6 are as defined above and R_7 is optionally substituted C_{6-12} aryl, or R''_6 and R_7 can be
 5 taken together to form an optionally substituted 3 to 10 membered heterocycle.

In a further embodiment, R_1 is:



(III)

10

wherein:

- R_7 is phenyl;
- R_7 is phenyl substituted with methyl;
- 15 R_7 is phenyl substituted with at least one methyl;
- R_7 is phenyl substituted with a halogen;
- R_7 is phenyl substituted with at least one halogen;
- R_7 is phenyl substituted with Cl;
- R_7 is phenyl substituted with Br;
- 20 R_7 is phenyl substituted with F;
- R_7 is phenyl substituted with at least one Cl;

R₇ is phenyl substituted with methoxy;

R₇ is naphthyl.

R''₆ and R₇ can be taken together to form an optionally substituted piperidine.

5 R''₆ and R₇ can be taken together to form an optionally substituted morpholine.


R''₆ and R₇ can be taken together to form a morpholine.

10 R''₆ and R₇ can be taken together to form an optionally substituted pyrrolidine.

R''₆ and R₇ can be taken together to form a 3,3-difluoropyrrolidine.

In a further embodiment, R₁ is:


15



(IV)

wherein R₆ is as defined above and R₇ is optionally substituted C₁₋₁₀ alkyl.

20 In further embodiments, R₁ is:



(IV)

wherein:

R₇ is methyl;

R₇ is ethyl;


5 R₇ is *tert*-butyl;

R₇ is cyclobutyl;

R₇ is cyclopentyl;

R₇ is cyclohexyl.

10 In a further embodiment, R₁ is:




(V)

wherein R₆ is as defined above and R₇ is chosen from optionally substituted C₁₋₁₀ alkyl, optionally

15 substituted C₆₋₁₂ aryl or optionally substituted 3 to 10 membered heterocycle.

In a further embodiment, R₁ is:



(V)


wherein:

R₇ is optionally substituted phenyl;

R₇ is optionally substituted C₁₋₁₀ alkyl;

5 R₇ is isopropyl.

In a further embodiment, R₁ is:




(VI)

10 wherein R₆'' is as defined above and R₇ is chosen from optionally substituted C₁₋₁₀ alkyl or optionally substituted C₆₋₁₂ aryl.

In a further embodiment, R₁ is:

15



(VI)

wherein:

R₇ is optionally substituted cyclohexyl.

R₇ is optionally substituted phenyl.

In a further embodiment, R₂ is chosen from optionally substituted C₆₋₁₂ aryl or optionally substituted 3 to 10 membered heterocycle.

5

In further embodiments:

R₂ is optionally substituted C₆₋₁₂ aryl.

R₂ is phenyl;

R₂ is phenyl substituted with halogen;

10 R₂ is phenyl substituted with Cl;

R₂ is phenyl substituted with at least one halogen;

R₂ is phenyl substituted with methoxy;

R₂ is phenyl substituted with at least one methoxy.

15 In a further embodiments:

R₂ is optionally substituted 3 to 10 membered heterocycle.

R₂ is optionally substituted thienyl.

R₂ is optionally substituted pyridyl.

20

In a further embodiment, R₃ is chosen from H or optionally substituted C₁₋₄ alkyl.

In one embodiment, R₃ is H.

In one embodiment, R₃ is methyl.

25

The compounds of the present invention may have an asymmetric center. As two optical isomers can independently be obtained from each asymmetric center, compounds of the invention having one
30 asymmetric center can be in the form of the enantiomers, i.e., the (+) enantiomer or (-)

enantiomer, in pure or partially purified form, as well as mixtures of enantiomers.

In one embodiment, the compounds of the present invention are the (+) enantiomer having an enantiomeric excess of 99%.

In one embodiment, the compounds of the present invention are the (+) enantiomer having an enantiomeric excess of 95%.

In one embodiment, the compounds of the present invention are the (+) enantiomer having an enantiomeric excess of 90%.

In one embodiment, the compounds of the present invention are the (-) enantiomer having an enantiomeric excess of 99%.

In one embodiment, the compounds of the present invention are the (-) enantiomer having an enantiomeric excess of 95%.

In one embodiment, the compounds of the present invention are the (-) enantiomer having an enantiomeric excess of 90%.

Compounds of the present invention have also two asymmetric centers. As two optical isomers can independently be obtained from each asymmetric center, compounds of the invention having two

asymmetric centers can be in the form of the diastereomers. It is intended that all the possible diastereomers in mixtures and as pure or partially purified compounds are included in this invention.

5

In one embodiment, the compounds of the present invention are in the form of the (R,R)-diastereomer;

In one embodiment, the compounds of the present
10 invention are in the form of the (S,R)-diastereomer;

In one embodiment, the compounds of the present invention are in the form of the (R,S)-diastereomer;

15 In one embodiment, the compounds of the present invention are in the form of the (S,S)-diastereomer.

In one embodiment, the compounds of the present invention are a (R,R)-diastereomer having an optical
20 purity in excess of 99%.

In one embodiment, the compounds of the present invention are a (R,R)-diastereomer having an optical purity in excess of 95%.

25

In one embodiment, the compounds of the present invention are a (R,R)-diastereomer having an optical purity in excess of 90%.

In one embodiment, the compounds of the present invention are a (S,R)-diastereomer having an optical purity in excess of 99%.

- 5 In one embodiment, the compounds of the present invention are a (S,R)-diastereomer having an optical purity in excess of 95%.

- In one embodiment, the compounds of the present
10 invention are a (S,R)-diastereomer having an optical purity in excess of 90%.

- In one embodiment, the compounds of the present invention are a (R,S)-diastereomer having an optical
15 purity in excess of 99%.

- In one embodiment, the compounds of the present invention are a (R,S)-diastereomer having an optical purity in excess of 95%.
- 20

- In one embodiment, the compounds of the present invention are a (R,S)-diastereomer having an optical purity in excess of 90%.

- 25 In one embodiment, the compounds of the present invention are a (S,S)-diastereomer having an optical purity in excess of 99%.

- In one embodiment, the compounds of the present
30 invention are a (S,S)-diastereomer having an optical purity in excess of 95%.

In one embodiment, the compounds of the present invention are a (S,S)-diastereomer having an optical purity in excess of 90%.

5

In one embodiment, there is provided a method of modulating chemokine receptor activity in a subject comprising administering to the subject a therapeutically effective amount of a compound of
10 formula (I) or composition of the invention.

In another embodiment, there is provided a method for the prevention or treatment of diseases associated with the modulation of chemokine receptor
15 activity in a subject in need of such treatment comprising administering to the subject a therapeutically effective amount of a compound of formula (I) or composition of the invention.

20 In a further embodiment, there is provided a method for prevention or treatment of certain inflammatory diseases, immunoregulatory diseases, organ transplantation reactions and in the prevention and treatment of infectious diseases such as HIV
25 infections in a subject in need of such treatment comprising administering to the subject a therapeutically effective amount of a compound of formula (I) or composition of the invention.

30 In another embodiment, there is provided a method for the prevention or treatment of diseases

associated with the modulation of CCR5 chemokine
receptor activity in a subject in need of such
treatment comprising administering to the subject a
therapeutically effective amount of a compound of
5 formula (I) or composition of the invention.

In still another aspect, there is provided a method
for blocking cellular entry of HIV in a subject in
need thereof comprising administering to the subject
10 a therapeutically effective amount of a compound of
formula (I) to block HIV from cellular entry in said
subject.

In still another aspect, there is provided a method
15 for prevention or treatment of HIV infections in a
subject in need of such treatment comprising
administering to the subject a therapeutically
effective amount of a compound of formula (I) or
composition of the invention.

20

In still another aspect, there is provided a method
for delaying the onset of AIDS or treating AIDS in a
subject in need of such treatment comprising
administering to the subject a therapeutically
25 effective amount of a compound of formula (I) or
composition of the invention.

In a further embodiment, there is provided a method
for the prevention or treatment of diseases
30 associated with the modulation of chemokine receptor
activity in a subject in need of such treatment

comprising administering to the subject a pharmaceutical combination comprising at least one compound of formula (I) and at least one further therapeutic agent.

5

In a further embodiment, there is provided a method for the prevention or treatment of diseases associated with the modulation of CCR5 chemokine receptor activity in a subject in need of such

10 treatment comprising administering to the subject a pharmaceutical combination comprising at least one compound of formula (I) and at least one further therapeutic agent.

15 In still another aspect, there is provided a method for blocking cellular entry of HIV in a subject or for the prevention or treatment of HIV infections in a subject in need of such treatment comprising administering to the subject a pharmaceutical
20 combination comprising at least one compound of formula (I) and at least one further therapeutic agent.

In still another aspect, there is provided a method
25 for delaying the onset of AIDS or treating AIDS in a subject in need of such treatment comprising administering to the subject a pharmaceutical combination comprising at least one compound of formula (I) and at least one further therapeutic
30 agent.

In another embodiment, there is provided a combination useful for the prevention or treatment of diseases associated with the modulation of chemokine receptor activity which is a
5 therapeutically effective amount of a compound of formula (I) and therapeutically effective amount of at least one further therapeutic agent.

In one embodiment, combinations of the present
10 invention comprise those wherein the following embodiments are present, either independently or in combination.

In a further embodiment, the pharmaceutical
15 combinations of this invention may contain at least one further therapeutic agent chosen from an agent used in inflammatory diseases, immunoregulatory diseases and in organ transplantation reactions.

20 In another embodiment, the pharmaceutical combination of this invention may contain at least one further therapeutic agent which is an antiviral agent.

25 In one embodiment, the pharmaceutical combination of this invention may contain at least one further antiviral agent which is chosen from nucleoside and nucleotide analog reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors,
30 protease inhibitors, attachment and fusion

inhibitors, integrase inhibitors or maturation inhibitors.

In one embodiment, the pharmaceutical combinations
5 of this invention may contain at least one other
antiviral agent which is a nucleoside and nucleotide
analog reverse transcriptase inhibitors chosen from
3TC (lamivudine, Epivir®), AZT (zidovudine,
Retrovir®), Emtricitabine (Coviracil®, formerly
10 FTC), d4T (2',3'-dideoxy-2',3'-didehydro-thymidine,
stavudine and Zerit®), tenofovir (Viread®), 2',3'-
dideoxyinosine (ddI, didanosine, Videx®), 2',3'-
dideoxycytidine (ddC, zalcitabine, Hivid®),
Combivir® (AZT/3TC or zidovudine/lamivudine
15 combination), Trivizir® (AZT/3TC/abacavir or
zidovudine/lamivudine/- abacavir combination),
abacavir (1592U89, Ziagen®), SPD-754, ACH-126,443
(Beta-L-Fd4C), Alovudine (MIV-310), DAPD
(amdoxovir), Racivir, 9-[(2-hydroxymethyl)-1,3-
20 dioxolan-4-yl]guanine or 2-amino-9-[(2-
hydroxymethyl)-1,3-dioxolan-4-yl]adenine.

In another embodiment, the pharmaceutical
combination of this invention may contain at least
25 one other antiviral agent which is a non-nucleoside
reverse transcriptase inhibitor chosen from
Nevirapine (Viramune®, NVP, BI-RG-587), delavirdine
(Rescriptor®, DLV), efavirenz (DMP 266, Sustiva®),
(+)-Calanolide A, Capravirine (AG1549, formerly S-
30 1153), DPC083, MIV-150, TMC120, TMC125 or BHAP

(delavirdine), calanolides or L-697,661 (2-Pyridinone 3benzoxazolMeNH derivative).

In another embodiment, the pharmaceutical
5 combination of this invention may contain at least one other antiviral agent which is a protease inhibitor chosen from nelfinavir (Viracept®, NFV), amprenavir (141W94, Agenerase®), indinavir (MK-639, IDV, Crixivan®), saquinavir (Invirase®, Fortovase®,
10 SQV), ritonavir (Norvir®, RTV), lopinavir (ABT-378, Kaletra®), Atazanavir (BMS232632), mozenavir (DMP-450), fosamprenavir (GW433908), RO033-4649, Tipranavir (PNU-140690), TMC114 or VX-385.

15 In another embodiment, the pharmaceutical combination of this invention may contain at least one other antiviral agent which is an attachment and fusion inhibitor chosen from T-20 (enfuvirtide, Fuzeon®), T-1249, Schering C (SCH-C), Schering D
20 (SCH-D), FP21399, PRO-140, PRO 542, PRO 452, TNX-355, GW873140 (AK602), TAK-220, UK-427,857 or soluble CD4, CD4 fragments, CD4-hybrid molecules, BMS-806, BMS-488043, AMD3100, AMD070 or KRH-2731.

25 In another embodiment, the pharmaceutical combination of this invention may contain at least one other antiviral agent which is an integrase inhibitor chosen from S-1360, L-870,810, L-870,812 or C-2507.

30

In another embodiment, the pharmaceutical combination of this invention may contain at least one other antiviral agent which is a maturation inhibitor and is PA-457.

5

In another embodiment, the pharmaceutical combination of this invention may contain at least one other antiviral agent which is a zinc finger inhibitor and is azodicarbonamide (ADA).

10

In another embodiment, the pharmaceutical combination of this invention may contain at least one other antiviral agent which is an antisense drug and is HGTV43.

15

In another embodiment, the pharmaceutical combination of this invention may contain at least one other antiviral agent which is an immunomodulator, immune stimulator or cytokine chosen from interleukin-2 (IL-2, Aldesleukin, Proleukin), granulocyte macrophage colony stimulating factor (GM-CSF), erythropoietin, Multikine, Ampligen, thymomodulin, thymopentin, foscarnet, HE2000, Reticulose, Murabutide, Resveratrol, HRG214, HIV-1 Immunogen (Remune) or EP HIV-1090.

In another embodiment, the pharmaceutical combination of this invention may contain at least one other antiviral agent chosen from 2',3'-dideoxyadenosine, 3'-deoxythymidine, 2',3'-dideoxy-

2',3'-didehydrocytidine and ribavirin; acyclic
nucleosides such as acyclovir, ganciclovir;
interferons such as alpha-, beta-and gamma-
interferon; glucuronation inhibitors such as
5 probenecid; or TIBO drugs, HEPT, TSAO derivatives.

The combinations referred to above may conveniently
be presented for use in the form of a pharmaceutical
formulation and thus pharmaceutical formulations
10 comprising a combination as defined above together
with a pharmaceutically acceptable carrier thereof
comprises a further aspect of the invention.

The individual components of such combinations may
15 be administered either sequentially or
simultaneously in separate or combined
pharmaceutical formulations.

In a further embodiment, the said compound of
20 formula (I) and said therapeutic agent are
administered sequentially.

In a further embodiment, the said compound of
formula (I) and said therapeutic agent are
25 administered simultaneously.

The subject to which the compounds are administered
can be, for example, a mammal or a human.
Preferably, the subject is a human.

30

- In one embodiment, the present invention further provides a pharmaceutical composition comprising at least one compound having the formula (I) or pharmaceutically acceptable salts or
- 5 pharmaceutically acceptable hydrates or pharmaceutically acceptable solvates thereof and at least one pharmaceutically acceptable carrier or excipient.
- 10 In another embodiment, the invention provides the use of a compound having the formula (I) for the manufacture of a medicament for prevention and treatment of diseases associated with the modulation of CCR5 chemokine receptor activity in a host
- 15 comprising administering a therapeutically effective amount of a compound of formula (I).

Unless otherwise defined, all technical and scientific terms used herein have the same meaning

20 as commonly understood by one of ordinary skill in the art to which this invention belongs. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict,

25 the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

30 The term "alkyl" represents a linear, branched or cyclic hydrocarbon moiety having, for example, 1 to

10 carbon atoms, which may have one or more double
 bonds or triple bonds in the chain, and is
 optionally substituted. For example, suitable
 substituents include halogen, amino, amidino, amido,
 5 azido, cyano, guanido, hydroxyl, nitro, nitroso,
 urea, $\text{OS(O)}_2\text{R}_{21}$ (wherein R_{21} is selected from C_{1-6}
 alkyl, C_{6-12} aryl or 3 to 10 membered heterocycle),
 $\text{OS(O)}_2\text{OR}_{22}$ (wherein R_{22} is selected from H, C_{1-6} alkyl,
 C_{6-12} aryl or 3 to 10 membered heterocycle), $\text{S(O)}_2\text{OR}_{23}$
 10 (wherein R_{23} is selected from H, C_{1-6} alkyl, C_{6-12} aryl
 or 3 to 10 membered heterocycle), $\text{S(O)}_{0-2}\text{R}_{24}$ (wherein
 R_{24} is selected from H, C_{1-6} alkyl, C_{6-12} aryl or 3 to
 10 membered heterocycle), $\text{OP(O)OR}_{25}\text{OR}_{26}$, $\text{P(O)OR}_{25}\text{OR}_{26}$
 (wherein R_{25} and R_{26} are each independently selected
 15 from H or C_{1-6} alkyl), C(O)R_{27} (wherein R_{27} is
 selected from H, C_{1-6} alkyl, C_{6-12} aryl or 3 to 10
 membered heterocycle), C(O)OR_{28} (wherein R_{28} is
 selected from H, C_{1-6} alkyl, C_{6-12} aryl, C_{6-12} aralkyl or
 3 to 10 membered heterocycle), $\text{NR}_{29}\text{C(O)R}_{30}$, $\text{C(O)NR}_{29}\text{R}_{30}$
 20 (wherein R_{29} is H or C_{1-6} alkyl and R_{30} is selected
 from H, C_{1-6} alkyl, C_{6-12} aryl, C_{6-12} aralkyl or 3 to 10
 membered heterocycle, or R_{29} and R_{30} are taken
 together with the atoms to which they are attached
 to form a 3 to 10 membered heterocycle), $\text{SO}_2\text{NR}_{31}\text{R}_{32}$,
 25 $\text{NR}_{31}\text{SO}_2\text{R}_{32}$ (wherein R_{31} and R_{32} are each independently
 selected from the group consisting of H, C_{1-6} alkyl,
 C_{6-12} aryl, 3 to 10 membered heterocycle and C_{6-12}
 aralkyl), $\text{C(R}_{33})\text{NR}_{34}$ or $\text{C(R}_{33})\text{NOR}_{34}$ (wherein R_{33} and R_{34}
 are each independently selected from the group
 30 consisting of H, C_{1-6} alkyl, or C_{6-12} aryl).

Preferred substituents for the alkyl groups include halogen (Br, Cl, I or F), cyano, nitro, oxo, amino, COOH, COO-C₁₋₄ alkyl, CO-C₁₋₄ alkyl, and phenyl.

- 5 Examples of alkyl groups include but are not limited to methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, tert-pentyl, hexyl, isohexyl, neohexyl, allyl, vinyl, acetylenyl, ethylenyl, propenyl,
- 10 isopropenyl butenyl, isobutenyl, hexenyl, butadienyl, pentenyl, pentadienyl, hexenyl, hexadienyl, hexatrienyl, heptenyl, heptadienyl, heptatrienyl, octenyl, octadienyl, octatrienyl, octatetraenyl, propynyl, butynyl, pentynyl, hexynyl,
- 15 cyclopropyl, cyclobutyl, cycloheptyl, cyclohexenyl, cyclohex-dienyl and cyclohexyl.

- The term alkyl is also meant to include alkyls in which one or more hydrogen atom is replaced by a
- 20 halogen, i.e. an alkylhalide. Examples include but are not limited to trifluoromethyl, difluoromethyl, fluoromethyl, trichloromethyl, dichloromethyl, chloromethyl, trifluoroethyl, difluoroethyl, fluoroethyl, trichloroethyl, dichloroethyl,
- 25 chloroethyl, chlorofluoromethyl, chlorodifluoromethyl, dichlorofluoroethyl.

- The term "alkenyl" refers to alkyl groups may have one or more double bonds in the chain. The term
- 30 "alkynyl" refers to alkyl groups may have one or more triple bonds in their chain. The alkenyl and

alkynyl groups can be optionally substituted as described above for the alkyl groups.

The term "alkoxy" represents an alkyl which is covalently bonded to the adjacent atom through an oxygen atom. Examples include but are not limited to methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, tert-butoxy, pentyloxy, isopentyloxy, neopentyloxy, tert-pentyloxy, hexyloxy, isohexyloxy and neohexyloxy.

The term "alkylamino" represents an alkyl which is covalently bonded to the adjacent atom through a nitrogen atom and may be monoalkylamino or dialkylamino, wherein the alkyl groups may be the same or different. Examples include but are not limited to methylamino, dimethylamino, ethylamino, diethylamino, methylethylamino, propylamino, isopropylamino, butylamino, isobutylamino, sec-butylamino, tert-butylamino, pentylamino, isopentylamino, neopentylamino, tert-pentylamino, hexylamino, isohexylamino and neohexylamino.

The term "alkyloxy carbonyl" represents an alkyloxy which is covalently bonded to the adjacent atom through carbonyl ($C=O$). Examples include but are not limited to methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, isobutoxycarbonyl, sec-butoxycarbonyl, tert-butoxycarbonyl, pentyloxycarbonyl, isopentyloxycarbonyl, neopentyloxycarbonyl, tert-

pentyloxycarbonyl, hexyloxycarbonyl,
isohexyloxycarbonyl and neohexyloxycarbonyl.

The term "amidino" represents $-C(=NR_{10})NR_{11}R_{12}$,
5 wherein R_{10} , R_{11} and R_{12} are each independently
selected from H, C_{1-6} alkyl, C_{6-12} aryl or C_{6-12}
aralkyl, or R_{11} and R_{12} are taken together with the
nitrogen to which they are attached to form a 3 to
10 membered heterocycle.

10

The term "amido" represents $-CONH_2$, $-CONHR_{13}$ and $-$
 $CONR_{13}R_{14}$ wherein R_{13} and R_{14} are each independently
selected from C_{1-6} alkyl, C_{6-12} aryl, 3 to 10 membered
heterocycle or C_{6-12} aralkyl, or R_{13} and R_{14} are taken
15 together with the nitrogen to which they are
attached to form a 3 to 10 membered heterocycle.

The term "amino" represents a derivative of ammonia
obtained by substituting one or more hydrogen atom
20 and include $-NH_2$, $-NHR_{15}$ and $-NR_{15}R_{16}$, wherein R_{15} and
 R_{16} are each independently selected from C_{1-6} alkyl,
 C_{6-12} aryl or C_{6-12} aralkyl, or R_{15} and R_{16} are taken
together with the nitrogen to which they are
attached to form a 3 to 10 membered heterocycle.

25

The term "aryl" represents a carbocyclic moiety
containing at least one benzenoid-type ring (i.e.
the aryl group may be monocyclic or polycyclic), and
which is optionally substituted with one or more
30 substituents. For example, suitable substituents
include halogen, halogenated C_{1-6} alkyl, halogenated

C_{1-6} alkoxy, amino, amidino, amido, azido, cyano,
 guanido, hydroxyl, nitro, nitroso, urea, $OS(O)_2R_{21}$
 (wherein R_{21} is selected from C_{1-6} alkyl, C_{6-12} aryl or
 3 to 10 membered heterocycle), $OS(O)_2OR_{22}$ (wherein R_{22}
 5 is selected from H, C_{1-6} alkyl, C_{6-12} aryl or 3 to 10
 membered heterocycle), $S(O)_2OR_{23}$ (wherein R_{23} is
 selected from H, C_{1-6} alkyl, C_{6-12} aryl or 3 to 10
 membered heterocycle), $S(O)_{0-2}R_{24}$ (wherein R_{24} is
 selected from H, C_{1-6} alkyl, C_{6-12} aryl or 3 to 10
 10 membered heterocycle), $OP(O)OR_{25}OR_{26}$, $P(O)OR_{25}OR_{26}$
 (wherein R_{25} and R_{26} are each independently selected
 from H or C_{1-6} alkyl), C_{1-6} alkyl, C_{6-12} aralkyl, C_{1-6}
 alkoxy, C_{6-12} aralkyloxy, C_{6-12} aryloxy, 3 to 10
 membered heterocycle, $C(O)R_{27}$ (wherein R_{27} is
 15 selected from H, C_{1-6} alkyl, C_{6-12} aryl or 3 to 10
 membered heterocycle), $C(O)OR_{28}$ (wherein R_{28} is
 selected from H, C_{1-6} alkyl, C_{6-12} aryl, C_{6-12} aralkyl or
 3 to 10 membered heterocycle), $NR_{29}C(O)R_{30}$, $C(O)NR_{29}R_{30}$
 (wherein R_{29} is H or C_{1-6} alkyl and R_{30} is selected
 20 from H, C_{1-6} alkyl, C_{6-12} aryl, C_{6-12} aralkyl or 3 to 10
 membered heterocycle, or R_{29} and R_{30} are taken
 together with the atoms to which they are attached
 to form a 3 to 10 membered heterocycle), $SO_2NR_{31}R_{32}$,
 $NR_{31}SO_2R_{32}$ (wherein R_{31} and R_{32} are each independently
 25 selected from the group consisting of H, C_{1-6} alkyl,
 C_{6-12} aryl, 3 to 10 membered heterocycle and C_{6-12}
 aralkyl), $C(R_{33})NR_{34}$ or $C(R_{33})NOR_{34}$ (wherein R_{33} and R_{34}
 are each independently selected from the group
 consisting of H, C_{1-6} alkyl, or C_{6-12} aryl).

30

Preferred substituents for the aryl groups include halogen (Br, Cl, I or F), cyano, nitro, oxo, amino, C₁₋₄ alkyl (e.g., CH₃, C₂H₅, isopropyl), C₁₋₄ alkoxy (e.g., OCH₃, OC₂H₅), halogenated C₁₋₄ alkyl (e.g., CF₃, CHF₂), halogenated C₁₋₄ alkoxy (e.g., OCF₃, OC₂F₅), COOH, COO-C₁₋₄ alkyl, CO-C₁₋₄ alkyl, C₁₋₄ alkyl-S- (e.g., CH₃S, C₂H₅S), halogenated C₁₋₄ alkyl-S- (e.g., CF₃S, C₂F₅S), benzyloxy, and pyrazolyl.

10 Examples of aryl include but are not limited to phenyl, tolyl, dimethylphenyl, aminophenyl, anilinyll, naphthyl, anthryl, phenanthryl or biphenyl.

15 The term "aralkyl" represents an aryl group attached to the adjacent atom by a C₁₋₆alkyl. Examples include but are not limited to benzyl, benzhydryl, trityl, phenethyl, 3-phenylpropyl, 2-phenylpropyl, 4-phenylbutyl and naphthylmethyl. The aryl and alkyl
20 portions can be optionally substituted as described above.

The term "aralkyloxy" represents an aralkyl which is covalently bonded to the adjacent atom through an
25 oxygen atom. Examples include but are not limited to benzyloxy, benzhydryloxy, trityloxy, phenethyloxy, 3-phenylpropyloxy, 2-phenylpropyloxy, 4-phenylbutyloxy and naphthylmethoxy. The aryl and alkyl portions can be optionally substituted as
30 described above.

The term "aryloxy" represents an aryl which is covalently bonded to the adjacent atom through an oxygen atom. Examples include but are not limited to phenoxy and naphthyloxy. The aryl portion can be
5 optionally substituted as described above.

The term "guanidino" represents $-NR_{17}C(=NR_{18})NR_{19}R_{20}$ wherein R_{17} , R_{18} , R_{19} and R_{20} are each independently selected from H, C_{1-6} alkyl, C_{6-12} aryl or C_{6-12}
10 aralkyl, or R_{19} and R_{20} are taken together with the nitrogen to which they are attached to form a 3 to 10 membered heterocycle.

The term "halogen" is specifically a fluoride atom,
15 chloride atom, bromide atom or iodide atom.

The term "heterocycle" represents an optionally substituted saturated, unsaturated or aromatic cyclic moiety wherein said cyclic moiety is
20 interrupted by at least one heteroatom selected from oxygen (O), sulfur (S) or nitrogen (N). Heterocycles may be monocyclic or polycyclic rings. For example, suitable substituents include halogen, halogenated C_{1-6} alkyl, halogenated C_{1-6} alkoxy, amino, amidino,
25 amido, azido, cyano, guanido, hydroxyl, nitro, nitroso, urea, $OS(O)_2R_{21}$ (wherein R_{21} is selected from C_{1-6} alkyl, C_{6-12} aryl or 3 to 10 membered heterocycle), $OS(O)_2OR_{22}$ (wherein R_{22} is selected from H, C_{1-6} alkyl, C_{6-12} aryl or 3 to 10 membered
30 heterocycle), $S(O)_2OR_{23}$ (wherein R_{23} is selected from H, C_{1-6} alkyl, C_{6-12} aryl or 3 to 10 membered

heterocycle), $S(O)_{0-2}R_{24}$ (wherein R_{24} is selected from H, C_{1-6} alkyl, C_{6-12} aryl or 3 to 10 membered heterocycle), $OP(O)OR_{25}OR_{26}$, $P(O)OR_{25}OR_{26}$ (wherein R_{25} and R_{26} are each independently selected from H or C_{1-6} alkyl), C_{1-6} alkyl, C_{6-12} aralkyl, C_{1-6} alkoxy, C_{6-12} aryl, C_{6-12} aralkyloxy, C_{6-12} aryloxy, $C(O)R_{27}$ (wherein R_{27} is selected from H, C_{1-6} alkyl, C_{6-12} aryl or 3 to 10 membered heterocycle), $C(O)OR_{28}$ (wherein R_{28} is selected from H, C_{1-6} alkyl, C_{6-12} aryl, C_{6-12} aralkyl or 3 to 10 membered heterocycle), $NR_{29}C(O)R_{30}$, $C(O)NR_{29}R_{30}$ (wherein R_{29} is H or C_{1-6} alkyl and R_{30} is selected from H, C_{1-6} alkyl, C_{6-12} aryl, C_{6-12} aralkyl or 3 to 10 membered heterocycle, or R_{29} and R_{30} are taken together with the atoms to which they are attached to form a 3 to 10 membered heterocycle), $SO_2NR_{31}R_{32}$, $NR_{31}SO_2R_{32}$ (wherein R_{31} and R_{32} are each independently selected from the group consisting of H, C_{1-6} alkyl, C_{6-12} aryl, 3 to 10 membered heterocycle and C_{6-12} aralkyl), $C(R_{33})NR_{34}$ or $C(R_{33})NOR_{34}$ (wherein R_{33} and R_{34} are each independently selected from the group consisting of H, C_{1-6} alkyl, or C_{6-12} aryl).

Preferred substituents for the heterocycle groups include halogen (Br, Cl, I or F), cyano, nitro, oxo, amino, C_{1-4} alkyl (e.g., CH_3 , C_2H_5 , isopropyl), C_{1-4} alkoxy (e.g., OCH_3 , OC_2H_5), halogenated C_{1-4} alkyl (e.g., CF_3 , CHF_2), halogenated C_{1-4} alkoxy (e.g., OCF_3 , OC_2F_5), $COOH$, $COO-C_{1-4}$ alkyl, $CO-C_{1-4}$ alkyl, C_{1-4} alkyl-S- (e.g., CH_3S , C_2H_5S), halogenated C_{1-4} alkyl-S- (e.g., CF_3S , C_2F_5S), benzyloxy, and pyrazolyl.

Examples of heterocycles include but are not limited
 to azepinyl, aziridinyl, azetyl, azetidiny,
 diazepinyl, dithiadiazinyl, dioxazepinyl,
 dioxolanyl, dithiazolyl, furanyl, isooxazolyl,
 5 isothiazolyl, imidazolyl, morpholinyl, morpholino,
 oxetanyl, oxadiazolyl, oxiranyl, oxazinyl, oxazolyl,
 piperazinyl, pyrazinyl, pyridazinyl, pyrimidinyl,
 piperidyl, piperidino, pyridyl, pyranyl ,pyrazolyl,
 pyrrolyl, pyrrolidinyl, thiatriazolyl, tetrazolyl,
 10 thiadiazolyl, triazolyl, thiazolyl, thienyl,
 tetrazinyl, thiadiazinyl, triazinyl, thiazinyl,
 thiopyranyl furoisoxazolyl, imidazothiazolyl,
 thienoisothiazolyl, thienothiazolyl,
 imidazopyrazolyl, cyclopentapyrazolyl,
 15 pyrrolopyrrolyl, thienothienyl,
 thiadiazolopyrimidinyl, thiazolothiazinyl,
 thiazolopyrimidinyl, thiazolopyridinyl,
 oxazolopyrimidinyl, oxazolopyridyl, benzoxazolyl,
 benzisothiazolyl, benzothiazolyl, imidazopyrazinyl,
 20 purinyl, pyrazolopyrimidinyl, imidazopyridinyl,
 benzimidazolyl, indazolyl, benzoxathiolyl,
 benzodioxolyl, benzodithiolyl, indolizinyl,
 indolinyl, isoindolinyl, furopyrimidinyl,
 furopyridyl, benzofuranyl, isobenzofuranyl,
 25 thienopyrimidinyl, thienopyridyl, benzothienyl,
 cyclopentaoxazinyl, cyclopentafuranyl, benzoxazinyl,
 benzothiazinyl, quinazolinyl, naphthyridinyl,
 quinolinyl, isoquinolinyl, benzopyranyl,
 pyridopyridazinyl and pyridopyrimidinyl.

30

The term "heteroaralkyl" represents a heterocycle group attached to the adjacent atom by a C₁₋₆ alkyl. The heterocycle and alkyl portions can be optionally substituted as described above.

5

The term "urea" represents -N(R₃₅)CONR₃₆R₃₇ wherein R₃₅ is H or C₁₋₆ alkyl and wherein R₃₆ and R₃₇ are each independently selected from the group consisting of H, C₁₋₆ alkyl, C₆₋₁₂ aryl, 3 to 10 membered heterocycle
10 and C₆₋₁₂ aralkyl, or R₃₆ and R₃₇ are taken together with the nitrogen to which they are attached to form a 3 to 10 membered heterocycle.

The term "independently" means that a substituent
15 can be the same or a different definition for each item.

The term "optionally substituted" represents one or more halogen, halogenated C₁₋₆ alkyl, halogenated C₁₋₆
20 alkoxy, amino, amidino, amido, azido, cyano, guanido, hydroxyl, nitro, nitroso, urea, OS(O)₂R₂₁ (wherein R₂₁ is selected from C₁₋₆ alkyl, C₆₋₁₂ aryl or 3 to 10 membered heterocycle), OS(O)₂OR₂₂ (wherein R₂₂ is selected from H, C₁₋₆ alkyl, C₆₋₁₂ aryl or 3 to 10
25 membered heterocycle), S(O)₂OR₂₃ (wherein R₂₃ is selected from H, C₁₋₆ alkyl, C₆₋₁₂ aryl or 3 to 10 membered heterocycle), S(O)₀₋₂R₂₄ (wherein R₂₄ is selected from H, C₁₋₆ alkyl, C₆₋₁₂ aryl or 3 to 10 membered heterocycle), OP(O)OR₂₅OR₂₆, P(O)OR₂₅OR₂₆
30 (wherein R₂₅ and R₂₆ are each independently selected from H or C₁₋₆ alkyl), C₁₋₆alkyl, C₆₋₁₂aralkyl, C₆₋₁₂

aryl, C₁₋₆alkoxy, C₆₋₁₂aralkyloxy, C₆₋₁₂aryloxy, 3 to 10
membered heterocycle, C(O)R₂₇ (wherein R₂₇ is
selected from H, C₁₋₆ alkyl, C₆₋₁₂ aryl or 3 to 10
membered heterocycle), C(O)OR₂₈ (wherein R₂₈ is
5 selected from H, C₁₋₆ alkyl, C₆₋₁₂ aryl, C₆₋₁₂ aralkyl or
3 to 10 membered heterocycle), NR₂₉C(O)R₃₀, C(O)NR₂₉R₃₀
(wherein R₂₉ is H or C₁₋₆ alkyl and R₃₀ is selected
from H, C₁₋₆ alkyl, C₆₋₁₂ aryl, C₆₋₁₂ aralkyl or 3 to 10
membered heterocycle, or R₂₉ and R₃₀ are taken
10 together with the atoms to which they are attached
to form a 3 to 10 membered heterocycle), SO₂NR₃₁R₃₂,
NR₃₁SO₂R₃₂ (wherein R₃₁ and R₃₂ are each independently
selected from the group consisting of H, C₁₋₆ alkyl,
C₆₋₁₂ aryl, 3 to 10 membered heterocycle and C₆₋₁₂
15 aralkyl), C(R₃₃)NR₃₄ or C(R₃₃)NOR₃₄ (wherein R₃₃ and R₃₄
are each independently selected from the group
consisting of H, C₁₋₆ alkyl, or C₆₋₁₂ aryl).

There is also provided "enantiomers" and
20 "diastereoisomers" of the present invention. It will
be appreciated that the compounds in accordance with
the present invention can contain one or more chiral
centers. The compounds in accordance with the
present invention may thus exist in the form of two
25 different optical isomers, that is (+) or (-)
enantiomers or in the form of different
diastereomers. All such enantiomers, diastereomers
and mixtures thereof, including racemic or other
ratio mixtures of individual enantiomers and
30 diastereomers, are included within the scope of the
invention. The single diastereomer can be obtained

by methods well known to those of ordinary skill in the art, such as HPLC, crystallization and chromatography. The single enantiomer can be obtained by methods well known to those of ordinary skill in the art, such as chiral HPLC, enzymatic resolution and chiral auxiliary derivatization.

The optical purity is numerically equivalent to the "enantiomeric excess". The term "enantiomeric excess" is defined in percentage (%) value as follows: $[\text{mole fraction (major enantiomer)} - \text{mole fraction (minor enantiomer)}] \times 100$. An example of enantiomeric excess of 99% represents a ratio of 99.5% of one enantiomer and 0.5% of the opposite enantiomer.

"Oxidation levels": When there is a sulfur atom present, the sulfur atom can be at different oxidation levels, ie. S, SO, or SO₂. All such oxidation levels are within the scope of the present invention. When there is a nitrogen atom present, the nitrogen atom can be at different oxidation levels, ie. N or NO. All such oxidation levels are within the scope of the present invention.

There is also provided "pharmaceutically acceptable hydrates" of the compounds of the present invention. "Hydrates" exist when the compound of the invention incorporates water. The hydrate may contain one or more molecule of water per molecule of compound of the invention. Illustrative non-limiting examples

include monohydrate, dihydrate, trihydrate and tetrahydrate. The hydrate may contain one or more molecule of compound of the invention per molecule of water. An illustrative non-limiting example
5 include semi-hydrate. In one embodiment, the water may be held in the crystal in various ways and thus, the water molecules may occupy lattice positions in the crystal, or they may form bonds with salts of the compounds as described herein. The hydrate must
10 be "acceptable" in the sense of not being deleterious to the recipient thereof. The hydration may be assessed by methods known in the art such as Loss on Drying techniques (LOD) and Karl Fisher titration.

15 There is also provided "pharmaceutically acceptable salts" of the compounds of the present invention. By the term "pharmaceutically acceptable salts" of compounds are meant those derived from
20 pharmaceutically acceptable inorganic and organic acids and bases. Examples of suitable acids include but are not limited to hydrochloric, hydrobromic, sulphuric, nitric, perchloric, fumaric, maleic, phosphoric, glycollic, lactic, salicylic, succinic,
25 toluene-p-sulphonic, tartaric, acetic, trifluoroacetic, citric, methanesulphonic, formic, benzoic, malonic, naphthalene-2-sulphonic and benzenesulphonic acids. Other acids such as oxalic, while not in themselves pharmaceutically acceptable,
30 may be useful as intermediates in obtaining the

compounds of the invention and their
pharmaceutically acceptable acid addition salts.

Salts derived from appropriate bases include alkali
5 metal, alkaline earth metal or ammonium salts. The
salt(s) must be "acceptable" in the sense of not
being deleterious to the recipient thereof. Non-
limiting examples of such salts known by those of
ordinary skill in the art include without limitation
10 calcium, potassium, sodium, choline,
ethylenediamine, tromethamine, arginine,
glycinelycine, lysine, magnesium and meglumine.

There is also provided a "pharmaceutically
15 acceptable solvates" of the compounds of the present
invention. The term "solvate" means that the
compound of the invention incorporates one or more
pharmaceutically acceptable solvent. The solvate may
contain one or more molecule of solvent per molecule
20 of compound of the invention or may contain one or
more molecule of compound of the invention per
molecule of solvent. In one embodiment, the solvent
may be held in the crystal in various ways and thus,
the solvent molecule may occupy lattice positions in
25 the crystal, or they may form bonds with salts of
the compounds as described herein. The solvate(s)
must be "acceptable" in the sense of not being
deleterious to the recipient thereof. The solvation
may be assessed by methods known in the art such as
30 Loss on Drying techniques (LOD).

Reference hereinafter to a compound according to the invention includes compounds of the general formula (I) and their pharmaceutically acceptable salts, hydrates and solvates.

5.

"Polymorphs": It will be appreciated by those skilled in the art that the compounds in accordance with the present invention can exist in several different crystalline forms due to a different
10 arrangement of molecules in the crystal lattice. This may include solvate or hydrate (also known as pseudopolymorphs) and amorphous forms. All such crystalline forms and polymorphs are included within the scope of the invention. The polymorphs may be
15 characterized by methods well known in the art. Examples of analytical procedures that may be used to determine whether polymorphism occurs include: melting point (including hot-stage microscopy), infrared (not in solution), X-ray powder
20 diffraction, thermal analysis methods (e.g. differential scanning calorimetry (DSC), differential thermal analysis (DTA), thermogravimetric analysis (TGA)), Raman spectroscopy, comparative intrinsic dissolution
25 rate, scanning electron microscopy (SEM).

In one aspect, the present invention provides novel compounds including:

- Compound 1 2-(4-bromobenzyl)-8-(3-phenyl-propyl)-2,8-diaza-spiro[4.5]decan-1-one hydrochloride
- Compound 2 8-(3-phenylpropyl)-2-(4-trifluoromethylbenzyl)-2,8-diaza-spiro[4.5]decan-1-one hydrochloride
- Compound 3 2-(4-chlorobenzyl)-8-(3-phenyl-propyl)-2,8-diaza-spiro[4.5]decan-1-one hydrochloride
- Compound 4 2-(4-fluorobenzyl)-8-(3-phenyl-propyl)-2,8-diaza-spiro[4.5]decan-1-one hydrochloride
- Compound 5 8-(3-phenyl-propyl)-2-(4-trifluoromethoxybenzyl)-2,8-diaza-spiro[4.5]decan-1-one hydrochloride
- Compound 6 2-(4-methylbenzyl)-8-(3-phenyl-propyl)-2,8-diaza-spiro[4.5]decan-1-one hydrochloride
- Compound 7 4-[1-oxo-8-(3-phenyl-propyl)-2,8-diaza-spiro[4.5]dec-2-ylmethyl]-benzonitrile hydrochloride
- Compound 8 2-biphenyl-4-ylmethyl-8-(3-phenyl-propyl)-2,8-diaza-spiro[4.5]decan-1-one hydrochloride
- Compound 9 2-naphthalen-2-ylmethyl-8-(3-phenyl-propyl)-2,8-diaza-spiro[4.5]decan-1-one hydrochloride
- Compound 10 2-(4-bromobenzyl)-8-(3-phenyl-butyl)-2,8-diaza-spiro[4.5]decan-1-one hydrochloride
- Compound 11 2-(4-bromobenzyl)-8-(3,3-diphenyl-propyl)-2,8-diaza-spiro[4.5]decan-1-one hydrochloride
- Compound 12 8-(3,3-diphenyl-propyl)-2-(4-trifluoromethoxy-benzyl)-2,8-diaza-spiro[4.5]decan-1-one

- Compound 13 2-(4-bromobenzyl)-8-(3,3-diphenyl-propyl)-
2,8-diaza-spiro[4.5]decan-3-one
hydrochloride
- Compound 14 8-(3,3-diphenyl-propyl)-2-(3-phenyl-propyl)-
2,8-diaza-spiro[4.5]decan-1-one
hydrochloride
- Compound 15 8-(3,3-diphenyl-propyl)-2-pyridin-4-
ylmethyl-2,8-diaza-spiro[4.5]decan-1-one
dihydrochloride
- Compound 16 8-(3,3-diphenyl-propyl)-2-(4-methoxy-
benzyl)-2,8-diaza-spiro[4.5]decan-1-one
- Compound 17 8-(3,3-diphenyl-propyl)-2-(4-pyrazol-1-yl-
benzyl)-2,8-diaza-spiro[4.5]decan-1-one
hydrochloride
- Compound 18 2-benzothiazol-2-ylmethyl-8-(3,3-diphenyl-
propyl)-2,8-diaza-spiro[4.5]decan-1-one
hydrochloride
- Compound 19 8-(3,3-diphenyl-propyl)-2-(4-
methanesulfonyl-benzyl)-2,8-diaza-
spiro[4.5]decan-1-one hydrochloride
- Compound 20 8-(3,3-diphenyl-propyl)-2-(3-phenyl-allyl)-
2,8-diaza-spiro[4.5]decan-1-one
hydrochloride
- Compound 21 8-(3,3-diphenyl-propyl)-2-phenethyl-2,8-
diaza-spiro[4.5]decan-1-one hydrochloride
- Compound 22 2-(4-benzyloxy-benzyl)-8-(3,3-diphenyl-
propyl)-2,8-diaza-spiro[4.5]decan-1-one
- Compound 23 2-benzofuran-2-ylmethyl-8-(3,3-diphenyl-
propyl)-2,8-diaza-spiro[4.5]decan-1-one
- Compound 24 8-(3,3-diphenyl-propyl)-2-(4-isopropyl-
benzyl)-2,8-diaza-spiro[4.5]decan-1-one

- Compound 25 2-(5-chloro-benzo[b]thiophen-3-ylmethyl)-8-(3,3-diphenyl-propyl)-2,8-diaza-spiro[4.5]decan-1-one
- Compound 26 8-(3,3-diphenyl-propyl)-2-(4-nitro-benzyl)-2,8-diaza-spiro[4.5]decan-1-one
- Compound 27 2-(4-bromo-benzyl)-8-(3-pyridin-2-yl-propyl)-2,8-diaza-spiro[4.5]decan-1-one
- Compound 28 2-[1-(4-bromophenyl)-ethyl]-8-(3,3-diphenyl-propyl)-2,8-diaza-spiro[4.5]decan-1-one hydrochloride
- Compound 29 8-(3,3-diphenyl-propyl)-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]decan-1-one dihydrochloride
- Compound 30 N-(4-[8-(3,3-diphenyl-propyl)-1-oxo-2,8-diaza-spiro[4.5]dec-2-ylmethyl]-phenyl)-acetamide hydrochloride
- Compound 31 8-(3,3-diphenyl-propyl)-2-(6-trifluoromethyl-pyridin-3-ylmethyl)-2,8-diaza-spiro[4.5]decan-1-one dihydrochloride
- Compound 32 4-[8-(3,3-diphenyl-propyl)-1-oxo-2,8-diaza-spiro[4.5]dec-2-ylmethyl]-benzoic acid hydrochloride
- Compound 33 8-(3,3-diphenyl-propyl)-2-pyridin-2-ylmethyl-2,8-diaza-spiro[4.5]decan-1-one dihydrochloride
- Compound 34 8-(3,3-diphenyl-propyl)-2-(4-trifluoromethylsulfanyl-benzyl)-2,8-diaza-spiro[4.5]decan-1-one hydrochloride
- Compound 35 8-(3,3-diphenyl-propyl)-2-(4-methyl-cyclohexylmethyl)-2,8-diaza-spiro[4.5]decan-1-one hydrochloride
- Compound 36 4-[8-(3,3-diphenyl-propyl)-1-oxo-2,8-diaza-spiro[4.5]dec-2-ylmethyl]-benzoic acid methyl ester hydrochloride

- Compound 37 8-(3,3-diphenyl-propyl)-2-(5-trifluoromethyl-furan-2-ylmethyl)-2,8-diazaspiro[4.5]decan-1-one hydrochloride
- Compound 38 8-(3,3-diphenyl-propyl)-2-(4-iodo-benzyl)-2,8-diazaspiro[4.5]decan-1-one
- Compound 39 2-(4-methanesulfonylbenzyl)-8-(3-phenyl-butyl)-2,8-diazaspiro[4.5]decan-1-one hydrochloride
- Compound 40 2-(4-bromobenzyl)-8-[3-hydroxy-3-(2-methoxyphenyl)-3-phenyl-propyl]-2,8-diazaspiro[4.5]decan-1-one
- Compound 41 2-(4-bromobenzyl)-8-[3-hydroxy-3-(3-methoxyphenyl)-3-phenyl-propyl]-2,8-diazaspiro[4.5]decan-1-one
- Compound 42 2-(4-bromobenzyl)-8-(3-hydroxy-3-phenyl-3-thiophen-2-yl-propyl)-2,8-diazaspiro[4.5]decan-1-one
- Compound 43 2-(4-bromobenzyl)-8-(3-hydroxy-3-phenyl-butyl)-2,8-diazaspiro[4.5]decan-1-one
- Compound 44 2-(4-bromobenzyl)-8-[3-(2-methoxyphenyl)-3-phenyl-propyl]-2,8-diazaspiro[4.5]decan-1-one
- Compound 45 2-(4-bromobenzyl)-8-[3-(3-chlorophenyl)-3-hydroxy-3-phenyl-propyl]-2,8-diazaspiro[4.5]decan-1-one
- Compound 46 2-(4-bromobenzyl)-8-[3-(4-chlorophenyl)-3-hydroxy-3-phenyl-propyl]-2,8-diazaspiro[4.5]decan-1-one
- Compound 47 2-(4-bromobenzyl)-8-[3-(3-chlorophenyl)-3-phenyl-propyl]-2,8-diazaspiro[4.5]decan-1-one
- Compound 48 2-(4-bromobenzyl)-8-(3-phenyl-3-thiophen-2-yl-propyl)-2,8-diazaspiro[4.5]decan-1-one

- Compound 49 2-(4-bromobenzyl)-8-[3-(4-chlorophenyl)-3-phenyl-propyl]-2,8-diaza-spiro[4.5]decan-1-one
- Compound 50 2-(4-Bromobenzyl)-8-(3-hydroxy-3-phenylpropyl)-2,8-diaza-spiro[4.5]decan-1-one
- Compound 51 8-(3-Benzyloxy-3-phenylpropyl)-2-(4-bromobenzyl)-2,8-diaza-spiro[4.5]decan-1-one hydrochloride
- Compound 52 2-(4-Bromobenzyl)-8-(3-phenoxy-3-phenylpropyl)-2,8-diaza-spiro[4.5]decan-1-one
- Compound 53 {3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-carbamic acid tert-butyl ester
- Compound 54 N-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-benzamide hydrochloride
- Compound 55 N-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-2,6-dimethyl-benzamide hydrochloride
- Compound 56 Cyclohexanecarboxylic acid {3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride
- Compound 57 N-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-2-phenyl-acetamide hydrochloride
- Compound 58 N-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-2-(2,4,6-trimethyl-phenyl)-acetamide hydrochloride
- Compound 59 N-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-3-phenyl-propionamide hydrochloride

- Compound 60 (3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-methyl-carbamic acid tert-butyl ester
- Compound 61 N-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-N-methyl-benzamide hydrochloride
- Compound 62 Cyclohexanecarboxylic acid {3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-methyl-amide hydrochloride
- Compound 63 N-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-N-methyl-2-phenyl-acetamide hydrochloride
- Compound 64 N-{3-[2-(4-bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-N-methyl-2-(2,4,6-trimethyl-phenyl)-acetamide hydrochloride
- Compound 65 [3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-carbamic acid tert-butyl ester
- Compound 66 {3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-carbamic acid tert-butyl ester
- Compound 67 [3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(3-chloro-phenyl)-propyl]-carbamic acid tert-butyl ester
- Compound 68 N-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-acetamide hydrochloride
- Compound 69 Cyclopropanecarboxylic acid {3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride
- Compound 70 N-{3-[2-(4-bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-isobutyramide hydrochloride
- Compound 71 N-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-3-methyl-butyramide hydrochloride

- Compound 72 N-{3-[2-(4-bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-2-chloro-benzamide hydrochloride
- Compound 73 N-{3-[2-(4-bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-2-methoxy-benzamide hydrochloride
- Compound 74 Pyridine-2-carboxylic acid {3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide dihydrochloride
- Compound 75 N-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-3-chloro-benzamide hydrochloride
- Compound 76 N-{3-[2-(4-bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-3-methoxy-benzamide hydrochloride
- Compound 77 N-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-nicotinamide dihydrochloride
- Compound 78 N-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-4-chloro-benzamide hydrochloride
- Compound 79 N-{3-[2-(4-bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-4-methoxy-benzamide hydrochloride
- Compound 80 N-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-isonicotinamide dihydrochloride
- Compound 81 N-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-3,4-dichloro-benzamide hydrochloride
- Compound 82 N-{3-[2-(4-bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-3,4-dimethoxy-benzamide hydrochloride
- Compound 83 N-{3-[2-(4-bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-2-(2-chloro-phenyl)-acetamide hydrochloride

- Compound 84 N-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-2-(2-methoxy-phenyl)-acetamide hydrochloride
- Compound 85 N-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-2-(3-chloro-phenyl)-acetamide hydrochloride
- Compound 86 N-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-2-(3-methoxy-phenyl)-acetamide hydrochloride
- Compound 87 N-{3-[2-(4-bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-2-pyridin-3-yl-acetamide dihydrochloride
- Compound 88 N-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-2-(4-methoxy-phenyl)-acetamide hydrochloride
- Compound 89 N-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-2-(3,4-dichloro-phenyl)-acetamide hydrochloride
- Compound 90 Tetrahydro-pyran-4-carboxylic acid{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride
- Compound 91 Cyclopentanecarboxylic acid {3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride
- Compound 92 Cyclobutanecarboxylic acid {3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride
- Compound 93 Cycloheptanecarboxylic acid {3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride
- Compound 94 N-{3-[2-(4-bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-2-cyclohexyl-acetamide hydrochloride
- Compound 95 N-{3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-acetamide hydrochloride

- Compound 96 Cyclopropanecarboxylic acid {3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride
- Compound 97 N-{3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-isobutyramide hydrochloride
- Compound 98 N-{3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-3-methyl-butyramide hydrochloride
- Compound 99 2-chloro-N-{3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-benzamide hydrochloride
- Compound 100 2-methoxy-N-{3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-benzamide hydrochloride
- Compound 101 Pyridine-2-carboxylic acid {3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide dihydrochloride
- Compound 102 3-chloro-N-{3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-benzamide hydrochloride
- Compound 103 3-methoxy-N-{3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-benzamide hydrochloride
- Compound 104 N-{3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-nicotinamide dihydrochloride
- Compound 105 4-chloro-N-{3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-benzamide hydrochloride
- Compound 106 4-methoxy-N-{3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-benzamide hydrochloride

- Compound 107 N-{3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-isonicotinamide dihydrochloride
- Compound 108 (R)-cyclohexanecarboxylic acid {3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro [4.5]dec-8-yl]-1-phenyl-propyl}-amide
- Compound 109 3,4-dichloro-N-{3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-benzamide hydrochloride
- Compound 110 3,4-dimethoxy-N-{3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-benzamide hydrochloride
- Compound 111 2-(2-chloro-phenyl)-N-{3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-acetamide hydrochloride
- Compound 112 N-{3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-2-(2-methoxy-phenyl)-acetamide hydrochloride
- Compound 113 2-(3-chlorophenyl)-N-{3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-acetamide hydrochloride
- Compound 114 N-{3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-2-(3-methoxyphenyl)-acetamide hydrochloride
- Compound 115 N-{3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-2-pyridin-3-yl-acetamide dihydrochloride
- Compound 116 N-{3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-2-(4-methoxyphenyl)-acetamide hydrochloride
- Compound 117 2-(3,4-dichlorophenyl)-N-{3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-acetamide hydrochloride

- Compound 118 Tetrahydro-pyran-4-carboxylic acid{3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride
- Compound 119 Cyclopentanecarboxylic acid {3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride
- Compound 120 Cyclobutanecarboxylic acid {3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride
- Compound 121 Cycloheptanecarboxylic acid {3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride
- Compound 122 2-cyclohexyl-N-(3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-acetamide hydrochloride
- Compound 123 (S)-cyclohexanecarboxylic acid {3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide
- Compound 124 N-(3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-2-cyclopentyl-acetamide hydrochloride
- Compound 125 Furan-2-carboxylic acid {3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride
- Compound 126 N-(3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-2-ethyl-butylamide hydrochloride
- Compound 127 Thiophene-2-carboxylic acid {3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride
- Compound 128 N-(3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-2-(3,4-dimethoxyphenyl)-acetamide hydrochloride

- Compound 129 2-cyclopentyl-N-(3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-acetamide hydrochloride
- Compound 130 Furan-2-carboxylic acid {3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide hydrochloride
- Compound 131 2-ethyl-N-(3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-butyramide hydrochloride
- Compound 132 Thiophene-2-carboxylic acid {3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide hydrochloride
- Compound 133 2-(3,4-dimethoxy-phenyl)-N-(3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-acetamide hydrochloride
- Compound 134 Cyclohexanecarboxylic acid {3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide hydrochloride
- Compound 135 N-(3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-benzamide hydrochloride
- Compound 136 N-(3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-2-phenyl-acetamide hydrochloride
- Compound 137 N-(3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-acetamide hydrochloride
- Compound 138 Cyclopropanecarboxylic acid {3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide hydrochloride
- Compound 139 N-(3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-isobutyramide hydrochloride

- Compound 140 N-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-3-methyl-butyramide hydrochloride
- Compound 141 2-chloro-N-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-benzamide hydrochloride
- Compound 142 N-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-2-methoxy-benzamide hydrochloride
- Compound 143 Pyridine-2-carboxylic acid {3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide dihydrochloride
- Compound 144 3-chloro-N-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-benzamide hydrochloride
- Compound 145 N-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-3-methoxy-benzamide hydrochloride
- Compound 146 N-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-nicotinamide dihydrochloride
- Compound 147 4-chloro-N-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-benzamide hydrochloride
- Compound 148 N-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-4-methoxy-benzamide hydrochloride
- Compound 149 N-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-isonicotinamide dihydrochloride
- Compound 150 3,4-dichloro-N-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-benzamide hydrochloride

- Compound 151 N-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-3,4-dimethoxy-benzamide hydrochloride
- Compound 152 2-(2-chlorophenyl)-N-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-acetamide hydrochloride
- Compound 153 N-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-2-(2-methoxyphenyl)-acetamide hydrochloride
- Compound 154 2-(3-chlorophenyl)-N-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-acetamide hydrochloride
- Compound 155 N-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-2-(3-methoxyphenyl)-acetamide hydrochloride
- Compound 156 N-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-benzamide hydrochloride
- Compound 157 (*S*)-cyclohexanecarboxylic acid [3-(2-benzyl-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-amide
- Compound 158 N-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-2-(4-methoxyphenyl)-acetamide hydrochloride
- Compound 159 N-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-2-phenyl-acetamide hydrochloride
- Compound 160 2-(3,4-dichlorophenyl)-N-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-acetamide hydrochloride
- Compound 161 Cyclopentanecarboxylic acid [3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl]-amide hydrochloride

- Compound 162 Cyclobutanecarboxylic acid {3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride
- Compound 163 Cycloheptanecarboxylic acid {3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride
- Compound 164 2-cyclohexyl-N-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl}-acetamide hydrochloride
- Compound 165 2-cyclopentyl-N-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl}-acetamide hydrochloride
- Compound 166 Furan-2-carboxylic acid {3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride
- Compound 167 2-ethyl-N-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl}-butyramide hydrochloride
- Compound 168 Thiophene-2-carboxylic acid {3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride
- Compound 169 2-(3,4-dimethoxyphenyl)-N-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl}-acetamide hydrochloride
- Compound 170 Cyclohexanecarboxylic acid {3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride

- Compound 171 4-methyl-cyclohexanecarboxylic acid {3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride
- Compound 172 2-methoxy-N-[3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diazaspiro[4.5]dec-8-yl)-1-phenyl-propyl]-benzamide dihydrochloride
- Compound 173 3-chloro-N-[3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diazaspiro[4.5]dec-8-yl)-1-phenyl-propyl]-benzamide dihydrochloride
- Compound 174 4-chloro-N-[3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diazaspiro[4.5]dec-8-yl)-1-phenyl-propyl]-benzamide dihydrochloride
- Compound 175 4-methoxy-N-[3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diazaspiro[4.5]dec-8-yl)-1-phenyl-propyl]-benzamide dihydrochloride
- Compound 176 Cyclohexanecarboxylic acid [3-[2-(4-bromobenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-(3-chloro-phenyl)-propyl]-amide hydrochloride
- Compound 177 N-[3-[2-(4-bromobenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-(3-chlorophenyl)-propyl]-benzamide hydrochloride
- Compound 178 N-[3-[2-(4-bromobenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-(3-chlorophenyl)-propyl]-2-phenyl-acetamide hydrochloride
- Compound 179 {1-(3-chlorophenyl)-3-[2-(4-methoxybenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-propyl}-carbamic acid tert-butyl ester
- Compound 180 {1-(3,4-dichlorophenyl)-3-[2-(4-methoxybenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-propyl}-carbamic acid tert-butyl ester
- Compound 181 N-[3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diazaspiro[4.5]dec-8-yl)-1-phenyl-propyl]-acetamide dihydrochloride

- Compound 182 Cyclopropanecarboxylic acid [3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-amide dihydrochloride
- Compound 183 N-[3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-isobutyramide dihydrochloride
- Compound 184 3-methyl-N-[3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-butyramide dihydrochloride
- Compound 185 2-chloro-N-[3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-benzamide dihydrochloride
- Compound 186 Pyridine-2-carboxylic acid [3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-amide trihydrochloride
- Compound 187 3-methoxy-N-[3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-benzamide dihydrochloride
- Compound 188 N-[3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-nicotinamide trihydrochloride
- Compound 189 N-[3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-isonicotinamide trihydrochloride
- Compound 190 3,4-dichloro-N-[3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-benzamide dihydrochloride
- Compound 191 3,4-dimethoxy-N-[3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-benzamide dihydrochloride
- Compound 192 2-(2-chlorophenyl)-N-[3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-acetamide dihydrochloride
- Compound 193 2-(2-methoxyphenyl)-N-[3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-acetamide dihydrochloride

- Compound 194 N-[3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-benzamide dihydrochloride
- Compound 195 2-(3-chloro-phenyl)-N-[3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-acetamide dihydrochloride
- Compound 196 2-(3-methoxyphenyl)-N-[3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-acetamide dihydrochloride
- Compound 197 2-(4-methoxyphenyl)-N-[3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-acetamide dihydrochloride
- Compound 198 N-[3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-2-phenyl-acetamide dihydrochloride
- Compound 199 2-(3,4-dichloro-phenyl)-N-[3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-acetamide dihydrochloride
- Compound 200 Cyclopentanecarboxylic acid [3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-amide dihydrochloride
- Compound 201 (1-(3-chlorophenyl)-3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl)-carbamic acid tert-butyl ester
- Compound 202 Cyclobutanecarboxylic acid [3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-amide dihydrochloride
- Compound 203 Cycloheptanecarboxylic acid [3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-amide dihydrochloride
- Compound 204 2-cyclohexyl-N-[3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-acetamide dihydrochloride

- Compound 205 2-cyclopentyl-N-[3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-acetamide dihydrochloride
- Compound 206 Furan-2-carboxylic acid [3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-amide dihydrochloride
- Compound 207 2-ethyl-N-[3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-butyramide dihydrochloride
- Compound 208 Thiophene-2-carboxylic acid [3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-amide dihydrochloride
- Compound 209 2-(3,4-dimethoxyphenyl)-N-[3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-acetamide dihydrochloride
- Compound 210 Cyclohexanecarboxylic acid [3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-amide dihydrochloride
- Compound 211 4-methyl-cyclohexanecarboxylic acid [3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-amide dihydrochloride
- Compound 212 [3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(3-methoxyphenyl)-propyl]-carbamic acid tert-butyl ester
- Compound 213 [3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(3-methoxyphenyl)-propyl]-carbamic acid tert-butyl ester
- Compound 214 (S)-N-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-acetamide hydrochloride
- Compound 215 (S)-cyclopropanecarboxylic acid {3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride

- Compound 216 (S)-N-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl}-isobutyramide hydrochloride
- Compound 217 (S)-N-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl}-3-methyl-butyramide hydrochloride
- Compound 218 (S)-cyclopentanecarboxylic acid {3-[2-(4-bromobenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride
- Compound 219 (S)-cyclobutanecarboxylic acid {3-[2-(4-bromobenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride
- Compound 220 [3-[2-(4-methoxybenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-(4-methoxyphenyl)-propyl]-carbamic acid tert-butyl ester
- Compound 221 {3-[2-(4-bromobenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-pyridin-2-yl-propyl}-carbamic acid tert-butyl ester
- Compound 222 {3-[2-(4-methoxybenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-pyridin-2-yl-propyl}-carbamic acid tert-butyl ester
- Compound 223 {1-(3,4-dichlorophenyl)-3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-propyl}-carbamic acid tert-butyl ester
- Compound 224 2-cyclopropyl-N-{3-[2-(4-methoxybenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl}-acetamide hydrochloride
- Compound 225 2-cyclopropyl-N-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl}-acetamide hydrochloride
- Compound 226 [3-[2-(4-bromobenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-(4-methoxyphenyl)-propyl]-carbamic acid tert-butyl ester

- Compound 227 N-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-2-cyclopropyl-acetamide hydrochloride
- Compound 228 [3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(3,4-dimethoxyphenyl)-propyl]-carbamic acid tert-butyl ester
- Compound 229 {1-(3,4-dimethoxyphenyl)-3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-carbamic acid tert-butyl ester
- Compound 230 Tetrahydro-pyran-4-carboxylic acid {3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride
- Compound 231 [3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(3-methoxyphenyl)-propyl]-carbamic acid tertbutyl ester
- Compound 232 (S)-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-carbamic acid tert-butyl ester
- Compound 233 {3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-pyridin-2-yl-propyl}-carbamic acid tert-butyl ester
- Compound 234 {1-(3,4-dimethoxyphenyl)-3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-carbamic acid tert-butyl ester
- Compound 235 {1-(4-chlorophenyl)-3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-carbamic acid tert-butyl ester
- Compound 236 {1-(2-chlorophenyl)-3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-carbamic acid tert-butyl ester
- Compound 237 {3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl}-carbamic acid tert-butyl ester

- Compound 238 [3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(4-methoxyphenyl)-propyl]-carbamic acid tert-butyl ester
- Compound 239 [3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(4-chlorophenyl)-propyl]-carbamic acid tert-butyl ester
- Compound 240 [3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(2-chlorophenyl)-propyl]-carbamic acid tert-butyl ester
- Compound 241 {3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl}-carbamic acid tert-butyl ester
- Compound 242 {1-(4-chlorophenyl)-3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-carbamic acid tert-butyl ester
- Compound 243 {1-(2-chlorophenyl)-3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-carbamic acid tert-butyl ester
- Compound 244 {3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl}-carbamic acid tert-butyl ester
- Compound 245 (S)-N-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-isobutyramide
- Compound 246 [3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(2-methoxyphenyl)-propyl]-carbamic acid tert-butyl ester
- Compound 247 [3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(2-methoxy-phenyl)-propyl]-carbamic acid tert-butyl ester
- Compound 248 [1-(2-chlorophenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-propyl]-carbamic acid tert-butyl ester

- Compound 249 [1-(3-chlorophenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-propyl]-carbamic acid tert-butyl ester
- Compound 250 [1-(3,4-dichlorophenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-propyl]-carbamic acid tert-butyl ester
- Compound 251 [3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-thiophen-2-yl-propyl]-carbamic acid tert-butyl ester
- Compound 252 (S)-8-[3-(cyclopropanecarbonyl-amino)-3-phenyl-propyl]-2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]decane hydrochloride
- Compound 253 (S)-8-[3-(cyclopentanecarbonyl-amino)-3-phenyl-propyl]-2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]decane hydrochloride
- Compound 254 (S)-8-[3-(cyclohexanecarbonyl-amino)-3-phenyl-propyl]-2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]decane hydrochloride
- Compound 255 (S)-8-[3-(cyclopropanecarbonyl-amino)-3-phenyl-propyl]-2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]decane hydrochloride
- Compound 256 (S)-8-(3-isobutyrylamino-3-phenyl-propyl)-2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]decane hydrochloride
- Compound 257 (S)-8-[3-(cyclopentanecarbonyl-amino)-3-phenyl-propyl]-2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]decane hydrochloride
- Compound 258 (S)-8-[3-(cyclohexanecarbonyl-amino)-3-phenyl-propyl]-2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]decane hydrochloride
- Compound 259 N-(3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl)-isobutyramide hydrochloride

- Compound 260 Cyclobutanecarboxylic acid {3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl}-amide hydrochloride
- Compound 261 Cyclopentanecarboxylic acid {3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl}-amide hydrochloride
- Compound 262 N-{3-[2-(4-bromo-enzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl}-propionamide hydrochloride
- Compound 263 N-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl}-2-methoxy-acetamide hydrochloride
- Compound 264 Cyclohexanecarboxylic acid {3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl}-amide hydrochloride
- Compound 265 Cyclopropanecarboxylic acid {3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl}-amide hydrochloride
- Compound 266 N-{3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl}-isobutyramide hydrochloride
- Compound 267 [3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(2-methoxyphenyl)-propyl]-carbamic acid tert-butyl ester
- Compound 268 Cyclobutanecarboxylic acid {3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl}-amide hydrochloride
- Compound 269 Cyclopentanecarboxylic acid {3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl}-amide hydrochloride

- Compound 270 N-(3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl)-propionamide hydrochloride
- Compound 271 2-methoxy-N-(3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl)-acetamide hydrochloride
- Compound 272 Cyclohexanecarboxylic acid {3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl)-amide hydrochloride
- Compound 273 Cyclopropane carboxylic acid{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl)-amide hydrochloride
- Compound 274 N-(3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl)-isobutyramide hydrochloride
- Compound 275 Cyclobutanecarboxylic acid {3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl)-amide hydrochloride
- Compound 276 Cyclopentanecarboxylic acid {3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl)-amide hydrochloride
- Compound 277 N-(3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl)-propionamide hydrochloride
- Compound 278 N-(3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl)-2-methoxy-acetamide hydrochloride
- Compound 279 Cyclohexanecarboxylic acid {3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl)-amide hydrochloride
- Compound 280 Cyclohexanecarboxylic acid [3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-thiophen-2-yl-propyl]-amide

dihydrochloride

- Compound 281 N-[3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-thiophen-2-yl-propyl]-isobutyramide dihydrochloride
- Compound 282 Cyclobutanecarboxylic acid [3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-thiophen-2-yl-propyl]-amide dihydrochloride
- Compound 283 Cyclopentanecarboxylic acid [3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-thiophen-2-yl-propyl]-amide dihydrochloride
- Compound 284 N-[3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-thiophen-2-yl-propyl]-propionamide dihydrochloride
- Compound 285 Cyclohexanecarboxylic acid [3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-thiophen-2-yl-propyl]-amide dihydrochloride
- Compound 286 Cyclopropanecarboxylic acid [3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(3-chlorophenyl)-propyl]-amide hydrochloride
- Compound 287 N-[3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(3-chlorophenyl)-propyl]-isobutyramide hydrochloride
- Compound 288 Cyclobutanecarboxylic acid [3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(3-chlorophenyl) propyl]-amide hydrochloride
- Compound 289 Cyclopentanecarboxylic acid [3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(3-chlorophenyl)-propyl]-amide hydrochloride

- Compound 290 N-[3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(3-chlorophenyl)-propyl]-propionamide hydrochloride
- Compound 291 N-[3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(3-chlorophenyl)-propyl]-2-methoxy-acetamide hydrochloride
- Compound 292 2-Cyclopropyl-N-((S)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-acetamide hydrochloride
- Compound 293 2-Cyclopropyl-N-((S)-3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-acetamide hydrochloride
- Compound 294 Cyclopentanecarboxylic acid [(S)-3-(2-benzyl-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-amide hydrochloride
- Compound 295 Cyclopropanecarboxylic acid [(S)-3-(2-benzyl-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-amide hydrochloride
- Compound 296 Cyclohexanecarboxylic acid [3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(3-chlorophenyl)-propyl]-amide hydrochloride
- Compound 297 Cyclopropanecarboxylic acid {1-(3-chlorophenyl)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-amide hydrochloride
- Compound 298 N-{1-(3-Chloro-phenyl)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-isobutyramide hydrochloride
- Compound 299 Cyclobutanecarboxylic acid {1-(3-chlorophenyl)-3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-amide hydrochloride

- Compound 300 Cyclopentanecarboxylic acid {1-(3-chlorophenyl)-3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-amide hydrochloride
- Compound 301 N-{1-(3-Chlorophenyl)-3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-propionamide hydrochloride
- Compound 302 N-{1-(3-Chlorophenyl)-3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-2-methoxy-acetamide hydrochloride
- Compound 303 Cyclohexanecarboxylic acid {1-(3-chlorophenyl)-3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-amide hydrochloride
- Compound 304 Cyclopropanecarboxylic acid {1-(3-chlorophenyl)-3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-amide hydrochloride
- Compound 305 N-{1-(3-Chlorophenyl)-3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-isobutyramide hydrochloride
- Compound 306 Cyclobutanecarboxylic acid {1-(3-chlorophenyl)-3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-amide hydrochloride
- Compound 307 Cyclopentanecarboxylic acid {1-(3-chlorophenyl)-3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-amide hydrochloride

- Compound 308 N-{1-(3-Chlorophenyl)-3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-propyl}-propionamide hydrochloride
- Compound 309 N-{1-(3-Chlorophenyl)-3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-propyl}-2-methoxyacetamide hydrochloride
- Compound 310 Cyclopropanecarboxylic acid [1-(3-chlorophenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diazaspiro[4.5]dec-8-yl)-propyl]-amide dihydrochloride
- Compound 311 N-[1-(3-Chlorophenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diazaspiro[4.5]dec-8-yl)-propyl]-isobutyramide dihydrochloride
- Compound 312 Cyclobutanecarboxylic acid [1-(3-chlorophenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diazaspiro[4.5]dec-8-yl)-propyl]-amide dihydrochloride
- Compound 313 Cyclopentanecarboxylic acid [1-(3-chlorophenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diazaspiro[4.5]dec-8-yl)-propyl]-amide dihydrochloride
- Compound 314 N-[1-(3-Chlorophenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diazaspiro[4.5]dec-8-yl)-propyl]-propionamide dihydrochloride
- Compound 315 N-[1-(3-Chlorophenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diazaspiro[4.5]dec-8-yl)-propyl]-2-methoxyacetamide dihydrochloride
- Compound 316 Cyclohexanecarboxylic acid [1-(3-chlorophenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diazaspiro[4.5]dec-8-yl)-propyl]-amide dihydrochloride
- Compound 317 Cyclopropanecarboxylic acid [(S)-3-(1-oxo-2-pyridin-2-ylmethyl-2,8-diazaspiro[4.5]dec-8-yl)-1-phenyl-propyl]-amide dihydrochloride

- Compound 318 Cyclopentanecarboxylic acid [(S)-3-(1-oxo-2-pyridin-2-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-amide dihydrochloride
- Compound 319 Cyclopropanecarboxylic acid [(S)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-amide dihydrochloride
- Compound 320 Cyclopentanecarboxylic acid [(S)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-amide dihydrochloride
- Compound 321 Cyclopropanecarboxylic acid [(S)-3-(1-oxo-2-pyridin-4-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-amide dihydrochloride
- Compound 322 Cyclopentanecarboxylic acid [(S)-3-(1-oxo-2-pyridin-4-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-amide dihydrochloride
- Compound 323 Cyclopropanecarboxylic acid {(S)-3-[1-oxo-2-(1-oxy-pyridin-2-ylmethyl)-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride
- Compound 324 Cyclopentanecarboxylic acid {(S)-3-[1-oxo-2-(1-oxy-pyridin-2-ylmethyl)-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride
- Compound 325 Cyclopropanecarboxylic acid {(S)-3-[1-oxo-2-(1-oxy-pyridin-3-ylmethyl)-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride
- Compound 326 Cyclopentanecarboxylic acid {(S)-3-[1-oxo-2-(1-oxy-pyridin-3-ylmethyl)-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride
- Compound 327 Cyclopropanecarboxylic acid {(S)-3-[1-oxo-2-(1-oxy-pyridin-4-ylmethyl)-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride

- Compound 328 Cyclopentanecarboxylic acid {(S)-3-[1-oxo-2-(1-oxy-pyridin-4-ylmethyl)-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride
- Compound 329 Cyclopentanecarboxylic acid {3-[2-(4-bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-pyridin-2-yl-propyl}-amide dihydrochloride
- Compound 330 N-{3-[2-(4-Bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-pyridin-2-yl-propyl}-propionamide dihydrochloride
- Compound 331 N-{3-[2-(4-Bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-pyridin-2-yl-propyl}-2-methoxy-acetamide dihydrochloride
- Compound 332 Cyclopropanecarboxylic acid {3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-pyridin-2-yl-propyl}-amide dihydrochloride
- Compound 333 N-{3-[2-(4-Methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-pyridin-2-yl-propyl}-isobutyramide dihydrochloride
- Compound 334 Cyclobutanecarboxylic acid {3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-pyridin-2-yl-propyl}-amide dihydrochloride
- Compound 335 Cyclopentanecarboxylic acid {3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-pyridin-2-yl-propyl}-amide dihydrochloride
- Compound 336 N-{3-[2-(4-Methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-pyridin-2-yl-propyl}-propionamide dihydrochloride
- Compound 337 2-Methoxy-N-{3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-pyridin-2-yl-propyl}-acetamide dihydrochloride
- Compound 338 Cyclopropanecarboxylic acid {3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-pyridin-2-yl-propyl}-amide dihydrochloride

- Compound 339 N-{3-[2-(4-Methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-pyridin-2-yl-propyl}-isobutyramide dihydrochloride
- Compound 340 Cyclobutanecarboxylic acid {3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-pyridin-2-yl-propyl}-amide dihydrochloride
- Compound 341 Cyclopropanecarboxylic acid {3-[2-(4-bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-pyridin-2-yl-propyl}-amide dihydrochloride
- Compound 342 N-{3-[2-(4-Bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-pyridin-2-yl-propyl}-isobutyramide dihydrochloride
- Compound 343 Cyclobutanecarboxylic acid {3-[2-(4-bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-pyridin-2-yl-propyl}-amide dihydrochloride
- Compound 344 Cyclopentanecarboxylic acid {3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-pyridin-2-yl-propyl}-amide dihydrochloride
- Compound 345 N-{3-[2-(4-Methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-pyridin-2-yl-propyl}-propionamide dihydrochloride
- Compound 346 N-{(S)-3-[2-(4-Methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-nicotinamide
- Compound 347 (R)-Tetrahydro-furan-2-carboxylic acid {(S)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide
- Compound 348 (S)-Tetrahydro-furan-2-carboxylic acid {(S)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide
- Compound 349 Tetrahydro-furan-3-carboxylic acid {(S)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide

- Compound 350 (R)-N-[(S)-3-[2-(4-Methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl]-2-phenyl-propionamide
- Compound 351 3-Oxo-cyclopentanecarboxylic acid [(S)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl]-amide
- Compound 352 (S)-N-[(S)-3-[2-(4-Methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl]-2-phenyl-propionamide
- Compound 353 (R)-N-[(S)-3-(1-Oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-2-phenyl-propionamide
- Compound 354 (S)-N-[(S)-3-(1-Oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-2-phenyl-propionamide
- Compound 355 (R)-Tetrahydro-furan-2-carboxylic acid [(S)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-amide
- Compound 356 (S)-Tetrahydro-furan-2-carboxylic acid [(S)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-amide
- Compound 357 Tetrahydro-furan-3-carboxylic acid [(S)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-amide
- Compound 358 3-Oxo-cyclopentanecarboxylic acid [(S)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-amide
- Compound 359 N-[(S)-3-(1-Oxo-2-pyridin-2-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-isobutyramide
- Compound 360 N-[(S)-3-(1-Oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-isobutyramide

- Compound 361 N-[(S)-3-(1-Oxo-2-pyridin-4-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-isobutyramide
- Compound 362 N-[(S)-3-[1-Oxo-2-(1-oxy-pyridin-4-ylmethyl)-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl]-isobutyramide
- Compound 363 N-[(S)-3-[1-Oxo-2-(1-oxy-pyridin-2-ylmethyl)-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl]-isobutyramide
- Compound 364 N-[(S)-3-[1-Oxo-2-(1-oxy-pyridin-3-ylmethyl)-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl]-isobutyramide
- Compound 365 1-Methyl-cyclopentanecarboxylic acid [(S)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl]-amide
- Compound 366 1-Methyl-cyclohexanecarboxylic acid[(S)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl]-amide
- Compound 367 2-Cyclopentyl-N-[(S)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl]-propionamide
- Compound 368 2-Cyclopentyl-N-[(S)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl]-propionamide
- Compound 369 1-Methyl-cyclopentanecarboxylic acid [(S)-3-(1-oxo-2-pyridin-3-ylmethy-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-amide
- Compound 370 1-Methyl-cyclohexanecarboxylic acid[(S)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-amide
- Compound 371 2-Cyclopentyl-N-[(S)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-propionamide

- Compound 372 2-Cyclopentyl-N-[(S)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-propionamide
- Compound 373 Cyclopropanecarboxylic acid [3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(2-methoxy-phenyl)-propyl]-amide hydrochloride
- Compound 374 N-[3-[2-(4-Bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(2-methoxy-phenyl)-propyl]-isobutyramide hydrochloride
- Compound 375 Cyclobutanecarboxylic acid [3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(2-methoxy-phenyl)-propyl]-amide hydrochloride
- Compound 376 Tetrahydro-pyran-2-carboxylic acid ((S)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide
- Compound 377 N-{3-[2-(4-Methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl}-2,2-dimethyl-propionamide hydrochloride
- Compound 378 N-{3-[2-(4-Methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl}-2,2-dimethyl-propionamide hydrochloride
- Compound 379 N-(1-(3-Chloro-phenyl)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl)-2,2-dimethyl-propionamide hydrochloride
- Compound 380 N-(1-(3-Chloro-phenyl)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl)-2,2-dimethyl-propionamide hydrochloride
- Compound 381 N-[1-(3-Chloro-phenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-propyl]-2,2-dimethyl-propionamide dihydrochloride
- Compound 382 N-(1-(2-Chloro-phenyl)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl)-2,2-dimethyl-propionamide hydrochloride

- Compound 383 N-{1-(4-Chloro-phenyl)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-propyl}-2,2-dimethylpropionamide hydrochloride
- Compound 384 1-Methyl-cyclopropanecarboxylic acid {3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl}-amide hydrochloride
- Compound 385 1-Methyl-cyclopropanecarboxylic acid {3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl}-amide hydrochloride
- Compound 386 1-Methyl-cyclopropanecarboxylic acid [3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diazaspiro[4.5]dec-8-yl)-1-thiophen-2-yl-propyl]-amide dihydrochloride
- Compound 387 1-Methyl-cyclopropanecarboxylic acid {1-(3-chloro-phenyl)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-propyl}-amide hydrochloride
- Compound 388 1-Methyl-cyclopropanecarboxylic acid {1-(3-chloro-phenyl)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-propyl}-amide hydrochloride
- Compound 389 1-Methyl-cyclopropanecarboxylic acid [1-(3-chloro-phenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diazaspiro[4.5]dec-8-yl)-propyl]-amide dihydrochloride
- Compound 390 1-Methyl-cyclopropanecarboxylic acid {1-(2-chloro-phenyl)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-propyl}-amide hydrochloride

- Compound 391 1-Methyl-cyclopropanecarboxylic acid {1-(4-chloro-phenyl)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-amide hydrochloride
- Compound 392 Tetrahydro-pyran-2-carboxylic acid [(S)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-amide
- Compound 393 Cyclopentanecarboxylic acid [3-[2-(4-bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(2-methoxy-phenyl)-propyl]-amide hydrochloride
- Compound 394 N-[3-[2-(4-Bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(2-methoxy-phenyl)-propyl]-propionamide hydrochloride
- Compound 395 N-[3-[2-(4-Bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(2-methoxy-phenyl)-propyl]-2-methoxy-acetamide hydrochloride
- Compound 396 N-[3-[2-(4-Bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(2-methoxy-phenyl)-propyl]-2-cyclopropyl-acetamide hydrochloride
- Compound 397 Cyclohexanecarboxylic acid [3-[2-(4-bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(2-methoxy-phenyl)-propyl]-amide hydrochloride
- Compound 398 Cyclopropanecarboxylic acid [3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(2-methoxy-phenyl)-propyl]-amide hydrochloride
- Compound 399 N-[3-[2-(4-Methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(2-methoxy-phenyl)-propyl]-isobutyramide hydrochloride
- Compound 400 Cyclobutanecarboxylic acid [3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(2-methoxy-phenyl)-propyl]-amide hydrochloride

- Compound 401 Cyclopentanecarboxylic acid [3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(2-methoxy-phenyl)-propyl]-amide hydrochloride
- Compound 402 N-[3-[2-(4-Methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(2-methoxy-phenyl)-propyl]-propionamide hydrochloride
- Compound 403 2-Methoxy-N-[3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(2-methoxy-phenyl)-propyl]-acetamide hydrochloride
- Compound 404 2-Cyclopropyl-N-[3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(2-methoxy-phenyl)-propyl]-acetamide hydrochloride
- Compound 405 Cyclohexanecarboxylic acid [3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(2-methoxy-phenyl)-propyl]-amide hydrochloride
- Compound 406 Cyclopropanecarboxylic acid [3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(2-methoxy-phenyl)-propyl]-amide hydrochloride
- Compound 407 N-[3-[2-(4-Methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(2-methoxy-phenyl)-propyl]-isobutyramide hydrochloride
- Compound 408 Cyclobutanecarboxylic acid [3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(2-methoxy-phenyl)-propyl]-amide hydrochloride
- Compound 409 Cyclopentanecarboxylic acid [3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(2-methoxy-phenyl)-propyl]-amide hydrochloride
- Compound 410 N-[3-[2-(4-Methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(2-methoxy-phenyl)-propyl]-propionamide hydrochloride
- Compound 411 N-[3-[2-(4-Methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(2-methoxy-phenyl)-propyl]-2-methoxy-acetamide hydrochloride

- Compound 412 2-Cyclopropyl-N-[3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(2-methoxy-phenyl)-propyl]-acetamide hydrochloride
- Compound 413 Cyclopropanecarboxylic acid [3-[2-(4-bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(4-methoxy-phenyl)-propyl]-amide hydrochloride
- Compound 414 N-[3-[2-(4-Bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(4-methoxy-phenyl)-propyl]-isobutyramide hydrochloride
- Compound 415 Cyclobutanecarboxylic acid [3-[2-(4-bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(4-methoxy-phenyl)-propyl]-amide hydrochloride
- Compound 416 Cyclopentanecarboxylic acid [3-[2-(4-bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(4-methoxy-phenyl)-propyl]-amide hydrochloride
- Compound 417 N-[3-[2-(4-Bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(4-methoxy-phenyl)-propyl]-propionamide hydrochloride
- Compound 418 N-[3-[2-(4-Bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(4-methoxy-phenyl)-propyl]-2-methoxy-acetamide hydrochloride
- Compound 419 Cyclopropanecarboxylic acid [3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(4-methoxy-phenyl)-propyl]-amide hydrochloride
- Compound 420 N-[3-[2-(4-Methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(4-methoxy-phenyl)-propyl]-isobutyramide hydrochloride
- Compound 421 Cyclobutanecarboxylic acid [3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(4-methoxy-phenyl)-propyl]-amide hydrochloride

- Compound 422 Cyclopentanecarboxylic acid [3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-(4-methoxy-phenyl)-propyl]-amide hydrochloride
- Compound 423 N-[3-[2-(4-Methoxy-benzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-(4-methoxy-phenyl)-propyl]-propionamide hydrochloride
- Compound 424 Cyclohexanecarboxylic acid [3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-(2-methoxy-phenyl)-propyl]-amide hydrochloride
- Compound 425 Cyclopentanecarboxylic acid [1-(3-methoxy-phenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diazaspiro[4.5]dec-8-yl)-propyl]-amide dihydrochloride
- Compound 426 N-[1-(3-Methoxy-phenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diazaspiro[4.5]dec-8-yl)-propyl]-propionamide dihydrochloride
- Compound 427 2-Methoxy-N-[1-(3-methoxy-phenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diazaspiro[4.5]dec-8-yl)-propyl]-acetamide dihydrochloride
- Compound 428 3-Hydroxy-cyclopentanecarboxylic acid ((S)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide
- Compound 429 3-Hydroxy-cyclopentanecarboxylic acid [(S)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diazaspiro[4.5]dec-8-yl)-1-phenyl-propyl]-amide
- Compound 430 Cyclopropanecarboxylic acid {1-(2-chloro-phenyl)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-propyl}-amide hydrochloride

- Compound 431 N-{1-(2-Chloro-phenyl)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-isobutyramide hydrochloride
- Compound 432 Cyclobutanecarboxylic acid {1-(2-chloro-phenyl)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-amide hydrochloride
- Compound 433 Cyclopentanecarboxylic acid {1-(2-chloro-phenyl)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-amide hydrochloride
- Compound 434 N-{1-(2-Chloro-phenyl)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-propionamide hydrochloride
- Compound 435 N-{1-(2-Chloro-phenyl)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-2-methoxy-acetamide hydrochloride
- Compound 436 Cyclohexanecarboxylic acid {1-(2-chloro-phenyl)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-amide hydrochloride
- Compound 437 Cyclopropanecarboxylic acid {1-(2-chloro-phenyl)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-amide hydrochloride
- Compound 438 N-{1-(2-Chloro-phenyl)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-isobutyramide hydrochloride
- Compound 439 Cyclobutanecarboxylic acid {1-(2-chloro-phenyl)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-amide hydrochloride
- Compound 440 Cyclopentanecarboxylic acid {1-(2-chloro-phenyl)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-amide hydrochloride

- Compound 441 N-{1-(2-Chloro-phenyl)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-propionamide hydrochloride
- Compound 442 N-{1-(2-Chloro-phenyl)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-2-methoxy-acetamide hydrochloride
- Compound 443 Cyclohexanecarboxylic acid {1-(2-chloro-phenyl)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-amide hydrochloride
- Compound 444 Cyclopropanecarboxylic acid [1-(2-chloro-phenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-propyl]-amide dihydrochloride
- Compound 445 N-[1-(2-Chloro-phenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-propyl]-isobutyramide dihydrochloride
- Compound 446 Cyclobutanecarboxylic acid [1-(2-chloro-phenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-propyl]-amide dihydrochloride
- Compound 447 Cyclopentanecarboxylic acid [1-(2-chloro-phenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-propyl]-amide dihydrochloride
- Compound 448 N-[1-(2-Chloro-phenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-propyl]-propionamide dihydrochloride
- Compound 449 N-[1-(2-Chloro-phenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-propyl]-2-methoxy-acetamide dihydrochloride
- Compound 450 Cyclohexanecarboxylic acid [1-(2-chloro-phenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-propyl]-amide dihydrochloride

- Compound 451 Cyclopropanecarboxylic acid {1-(4-chloro-phenyl)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-amide hydrochloride
- Compound 452 N-{1-(4-Chloro-phenyl)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-isobutyramide hydrochloride
- Compound 453 Cyclobutanecarboxylic acid {1-(4-chloro-phenyl)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-amide hydrochloride
- Compound 454 Cyclopentanecarboxylic acid {1-(4-chloro-phenyl)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-amide hydrochloride
- Compound 455 N-{1-(4-Chloro-phenyl)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-propionamide hydrochloride
- Compound 456 N-{1-(4-Chloro-phenyl)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-2-methoxy-acetamide hydrochloride
- Compound 457 Cyclohexanecarboxylic acid {1-(4-chloro-phenyl)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-amide hydrochloride
- Compound 458 N-{1-(4-Chloro-phenyl)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-propionamide hydrochloride
- Compound 459 N-{1-(4-Chloro-phenyl)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-2-methoxy-acetamide hydrochloride
- Compound 460 Cyclohexanecarboxylic acid {1-(4-chloro-phenyl)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-amide hydrochloride

- Compound 461 Cyclopropanecarboxylic acid [1-(4-chloro-phenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-propyl]-amide dihydrochloride
- Compound 462 N-[1-(4-Chloro-phenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-propyl]-isobutyramide dihydrochloride
- Compound 463 Cyclobutanecarboxylic acid [1-(4-chloro-phenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-propyl]-amide dihydrochloride
- Compound 464 Cyclopentanecarboxylic acid [1-(4-chloro-phenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-propyl]-amide dihydrochloride
- Compound 465 N-[1-(4-Chloro-phenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-propyl]-propionamide dihydrochloride
- Compound 466 N-[1-(4-Chloro-phenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-propyl]-2-methoxy-acetamide dihydrochloride
- Compound 467 Cyclohexanecarboxylic acid [1-(4-chloro-phenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-propyl]-amide dihydrochloride
- Compound 468 Cyclopropanecarboxylic acid [3-[2-(4-bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(2-chloro-phenyl)-propyl]-amide hydrochloride
- Compound 469 Cyclopropanecarboxylic acid [3-[2-(4-bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(4-chloro-phenyl)-propyl]-amide hydrochloride
- Compound 470 Cyclopropanecarboxylic acid {1-(3,4-dichloro-phenyl)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-amide hydrochloride

- Compound 471 Cyclopropanecarboxylic acid {1-(3,4-dichloro-phenyl)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-amide hydrochloride
- Compound 472 Cyclopropanecarboxylic acid [1-(3,4-dichloro-phenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-propyl]-amide dihydrochloride
- Compound 473 Cyclopentanecarboxylic acid [3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(2-chloro-phenyl)-propyl]-amide hydrochloride
- Compound 474 Cyclopentanecarboxylic acid [3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(4-chloro-phenyl)-propyl]-amide hydrochloride
- Compound 475 Cyclopentanecarboxylic acid {(S)-3-[2-(4-fluoro-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride
- Compound 476 Cyclopentanecarboxylic acid {(S)-3-[2-(4-chloro-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride
- Compound 477 Cyclopentanecarboxylic acid {(S)-3-[2-(4-cyano-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride
- Compound 478 Cyclopentanecarboxylic acid {(S)-3-[2-(4-difluoromethoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride
- Compound 479 Cyclopentanecarboxylic acid {(S)-3-[1-oxo-2-(4-trifluoromethoxy-benzyl)-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride

- Compound 480 Cyclopentanecarboxylic acid {(S)-3-[2-(4-methylsulfanyl-benzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride
- Compound 481 Cyclopentanecarboxylic acid {(S)-3-[1-oxo-2-(4-pyrazol-1-yl-benzyl)-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride
- Compound 482 Cyclopentanecarboxylic acid [(S)-3-(2-isobutyl-1-oxo-2,8-diazaspiro[4.5]dec-8-yl)-1-phenyl-propyl]-amide hydrochloride
- Compound 483 Cyclopentanecarboxylic acid {(S)-3-[2-(4-methanesulfonyl-benzyl)-3-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride
- Compound 484 Cyclopentanecarboxylic acid {(S)-3-[2-(4-methoxy-benzyl)-3-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride
- Compound 485 Cyclopropanecarboxylic acid {(S)-3-[2-(4-fluoro-benzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride
- Compound 486 Cyclopropanecarboxylic acid {(S)-3-[2-(4-chloro-benzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride
- Compound 487 Cyclopropanecarboxylic acid {(S)-3-[2-(4-cyano-benzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride
- Compound 488 Cyclopropanecarboxylic acid {(S)-3-[2-(4-difluoromethoxy-benzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride
- Compound 489 Cyclopropanecarboxylic acid {(S)-3-[1-oxo-2-(4-pyrazol-1-yl-benzyl)-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride

- Compound 490 Cyclopropanecarboxylic acid [(S)-3-(2-cyclohexylmethyl-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-amide hydrochloride
- Compound 491 Cyclopropanecarboxylic acid [(S)-3-(2-isobutyl-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-amide hydrochloride
- Compound 492 Cyclopropanecarboxylic acid {(S)-3-[2-(4-methanesulfonyl-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride
- Compound 493 Cyclopropanecarboxylic acid {(S)-3-[2-(4-methoxy-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride
- Compound 494 N-[(S)-3-(2-Benzyl-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-isobutyramide hydrochloride
- Compound 495 N-[(S)-3-[2-(4-Fluoro-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl]-isobutyramide hydrochloride
- Compound 496 Cyclopropanecarboxylic acid {(S)-3-[1-oxo-2-(4-trifluoromethoxy-benzyl)-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride
- Compound 497 Cyclopropanecarboxylic acid {(S)-3-[2-(4-methylsulfanyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride
- Compound 498 N-[(S)-3-[2-(4-Chloro-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl]-isobutyramide hydrochloride
- Compound 499 N-[(S)-3-[2-(4-Cyano-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl]-isobutyramide hydrochloride
- Compound 500 N-[(S)-3-[2-(4-Difluoromethoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl]-isobutyramide hydrochloride

- Compound 501 N-((S)-3-[1-Oxo-2-(4-trifluoromethoxy-benzyl)-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-isobutyramide hydrochloride
- Compound 502 N-((S)-3-[2-(4-Methylsulfanyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-isobutyramide hydrochloride
- Compound 503 N-((S)-3-[2-(4-Methoxy-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-isobutyramide hydrochloride
- Compound 504 2-Methoxy-cyclopent-1-enecarboxylic acid ((S)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide
- Compound 505 2-Methoxy-cyclopent-1-enecarboxylic acid ((S)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl)-amide
- Compound 506 Cyclopentanecarboxylic acid {1-(3,4-dichloro-phenyl)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-amide hydrochloride
- Compound 507 Cyclopentanecarboxylic acid {1-(3,4-dichloro-phenyl)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-amide hydrochloride
- Compound 508 Cyclopentanecarboxylic acid [1-(3,4-dichloro-phenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-propyl]-amide dihydrochloride
- Compound 509 N-((S)-3-[2-(4-Methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-propionamide hydrochloride
- Compound 510 N-((S)-3-[2-(4-Methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-2,2-dimethyl-propionamide hydrochloride

- Compound 511 Thiophene-2-carboxylic acid {(S)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride
- Compound 512 Thiophene-3-carboxylic acid {(S)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride
- Compound 513 (R)-Tetrahydro-furan-2-carboxylic acid {(S)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride
- Compound 514 (S)-Tetrahydro-furan-2-carboxylic acid {(S)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride
- Compound 515 Tetrahydro-furan-3-carboxylic acid {(S)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride
- Compound 516 3-Oxo-cyclopentanecarboxylic acid {(S)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride
- Compound 517 4,4-Difluoro-cyclohexanecarboxylic acid {(S)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride
- Compound 518 Tetrahydro-pyran-4-carboxylic acid {(S)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride
- Compound 519 4,6-Dimethyl-pyrimidine-5-carboxylic acid {(S)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide trihydrochloride

- Compound 520 Adamantane-1-carboxylic acid {(S)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride
- Compound 521 N-[(S)-3-[2-(4-Methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl]-propionamide hydrochloride
- Compound 522 N-[(S)-3-[2-(4-Methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl]-2,2-dimethyl-propionamide hydrochloride
- Compound 523 Thiophene-2-carboxylic acid {(S)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride
- Compound 524 Thiophene-3-carboxylic acid {(S)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride
- Compound 525 4,4-Difluoro-cyclohexanecarboxylic acid {(S)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride
- Compound 526 Tetrahydro-pyran-4-carboxylic acid {(S)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride
- Compound 527 N-[(S)-3-[2-(4-Methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl]-nicotinamide dihydrochloride
- Compound 528 Pyrimidine-5-carboxylic acid {(S)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide trihydrochloride
- Compound 529 4,6-Dimethyl-pyrimidine-5-carboxylic acid {(S)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide trihydrochloride

- Compound 530 Adamantane-1-carboxylic acid {(S)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride
- Compound 531 N-{(S)-3-[2-(4-Ethoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-isobutyramide hydrochloride
- Compound 532 Cyclopropanecarboxylic acid {(S)-3-[2-(4-ethoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride
- Compound 533 4,4-Difluoro-cyclohexanecarboxylic acid {(S)-3-[2-(4-methoxy-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride
- Compound 534 2-Cyclopropyl-N-{(S)-3-[2-(4-methanesulfonyl-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-acetamide hydrochloride
- Compound 535 4,4-Difluoro-cyclohexanecarboxylic acid {(S)-3-[2-(4-methanesulfonyl-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride
- Compound 536 N-{3-[2-(4-Bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenylpropyl}-benzenesulfonamide hydrochloride
- Compound 537 Propane-2-sulfonic acid {(S)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride
- Compound 538 Propane-2-sulfonic acid {(S)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride

- Compound 539 Piperidine-1-carboxylic acid {3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride
- Compound 540 Piperidine-1-carboxylic acid {3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride
- Compound 541 Piperidine-1-carboxylic acid {3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}amide hydrochloride
- Compound 542 1-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-3-phenyl-urea hydrochloride
- Compound 543 1-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-3-(2-chloro-phenyl)-urea hydrochloride
- Compound 544 1-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-3-(2-methoxy-phenyl)-urea hydrochloride
- Compound 545 1-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-3-(3-chloro-phenyl)-urea hydrochloride
- Compound 546 1-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-3-(3-methoxy-phenyl)-urea hydrochloride
- Compound 547 1-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-3-(4-chloro-phenyl)-urea hydrochloride
- Compound 548 1-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-3-(4-methoxy-phenyl)-urea hydrochloride
- Compound 549 1-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-3-(2,6-dimethyl-phenyl)-urea hydrochloride
- Compound 550 1-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-3-naphthalen-1-yl-urea hydrochloride

- Compound 551 1-(3-[2-(4-methoxybenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl)-3-phenyl-urea hydrochloride
- Compound 552 1-(2-chlorophenyl)-3-{3-[2-(4-methoxybenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl}-urea hydrochloride
- Compound 553 1-(3-[2-(4-methoxybenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl)-3-(2-methoxyphenyl)-urea hydrochloride
- Compound 554 1-(3-chlorophenyl)-3-{3-[2-(4-methoxybenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl}-urea hydrochloride
- Compound 555 1-(3-[2-(4-methoxybenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl)-3-(3-methoxyphenyl)-urea hydrochloride
- Compound 556 -{3-[2-(4-methoxybenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl}-3-(4-methoxyphenyl)-urea hydrochloride
- Compound 557 1-(2,6-dimethylphenyl)-3-{3-[2-(4-methoxybenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl}-urea hydrochloride
- Compound 558 1-(3-[2-(4-methoxybenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl)-3-naphthalen-1-yl-urea hydrochloride
- Compound 559 1-(3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl)-3-phenyl-urea hydrochloride
- Compound 560 1-(2-chlorophenyl)-3-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl}-urea hydrochloride
- Compound 561 1-(3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl)-3-(2-methoxyphenyl)-urea hydrochloride

- Compound 562 1-(3-chlorophenyl)-3-(3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-urea hydrochloride
- Compound 563 1-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-3-(3-methoxyphenyl)-urea hydrochloride
- Compound 564 1-(4-chlorophenyl)-3-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-urea hydrochloride
- Compound 565 1-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-3-(4-methoxyphenyl)-urea hydrochloride
- Compound 566 1-(2,6-dimethylphenyl)-3-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-urea hydrochloride
- Compound 567 1-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-3-naphthalen-1-yl-urea hydrochloride
- Compound 568 Morpholine-4-carboxylic acid {(S)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride
- Compound 569 Morpholine-4-carboxylic acid {(S)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride
- Compound 570 3,3-Difluoro-pyrrolidine-1-carboxylic acid {(S)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride
- Compound 571 3,3-Difluoro-pyrrolidine-1-carboxylic acid {(S)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride

- Compound 572 {3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-carbamic acid methyl ester hydrochloride
- Compound 573 {3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-carbamic acid ethyl ester hydrochloride
- Compound 574 {3-[2-(4-Methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-pyridin-2-yl-propyl}-carbamic acid cyclohexyl ester
- Compound 575 {(S)-3-[2-(4-Methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-carbamic acid cyclohexyl ester
- Compound 576 {(S)-3-[2-(4-Methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-carbamic acid cyclobutyl ester
- Compound 577 {(S)-3-[2-(4-Methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-carbamic acid cyclopentyl ester
- Compound 578 [(S)-3-(1-Oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-carbamic acid cyclobutyl ester
- Compound 579 [(S)-3-(1-Oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-carbamic acid cyclopentyl ester
- Compound 580 [(S)-3-(1-Oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-carbamic acid 1-methyl-cyclopentyl ester
- Compound 581 [(S)-3-(1-Oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-carbamic acid cyclohexyl ester
- Compound 582 {3-[2-(4-Bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl}-carbamic acid ethyl ester hydrochloride
- Compound 583 {3-[2-(4-Methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl}-carbamic acid ethyl ester hydrochloride

- Compound 584 [3-(1-Oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-thiophen-2-yl-propyl]-carbamic acid ethyl ester dihydrochloride
- Compound 585 {1-(2-Chloro-phenyl)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-carbamic acid ethyl ester hydrochloride
- Compound 586 {1-(2-Chloro-phenyl)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-carbamic acid ethyl ester hydrochloride
- Compound 587 [1-(2-Chloro-phenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-propyl]-carbamic acid ethyl ester dihydrochloride
- Compound 588 [3-[2-(4-Bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(3-chloro-phenyl)-propyl]-carbamic acid ethyl ester hydrochloride
- Compound 589 {1-(3-Chloro-phenyl)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-carbamic acid ethyl ester hydrochloride
- Compound 590 {1-(3-Chloro-phenyl)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-carbamic acid ethyl ester hydrochloride
- Compound 591 [1-(3-Chloro-phenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-propyl]-carbamic acid ethyl ester dihydrochloride
- Compound 592 {1-(4-Chloro-phenyl)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-carbamic acid ethyl ester hydrochloride

- Compound 593 [1-(4-Chloro-phenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-propyl]-carbamic acid ethyl ester dihydrochloride
- Compound 594 {3-[2-(4-Bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl}-carbamic acid methyl ester hydrochloride
- Compound 595 {3-[2-(4-Methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl}-carbamic acid methyl ester hydrochloride
- Compound 596 {3-[2-(4-Methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl}-carbamic acid methyl ester hydrochloride
- Compound 597 [3-(1-Oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-thiophen-2-yl-propyl]-carbamic acid methyl ester dihydrochloride
- Compound 598 {1-(2-Chloro-phenyl)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-carbamic acid methyl ester hydrochloride
- Compound 599 {1-(2-Chloro-phenyl)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-carbamic acid methyl ester hydrochloride
- Compound 600 [1-(2-Chloro-phenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-propyl]-carbamic acid methyl ester dihydrochloride
- Compound 601 [3-[2-(4-Bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(3-chloro-phenyl)-propyl]-carbamic acid methyl ester hydrochloride
- Compound 602 {1-(3-Chloro-phenyl)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-carbamic acid methyl ester hydrochloride

- Compound 603 {3-[2-(4-Bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-pyridin-2-yl-propyl}-carbamic acid ethyl ester hydrochloride
- Compound 604 {3-[2-(4-Methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-pyridin-2-yl-propyl}-carbamic acid ethyl ester dihydrochloride
- Compound 605 [3-[2-(4-Bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(4-methoxy-phenyl)-propyl]-carbamic acid ethyl ester hydrochloride
- Compound 606 [3-[2-(4-Methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(4-methoxy-phenyl)-propyl]-carbamic acid ethyl ester hydrochloride
- Compound 607 [3-[2-(4-Methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(4-methoxy-phenyl)-propyl]-carbamic acid ethyl ester hydrochloride
- Compound 608 [1-(4-Methoxy-phenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-propyl]-carbamic acid ethyl ester dihydrochloride
- Compound 609 [3-[2-(4-Bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(3,4-dimethoxy-phenyl)-propyl]-carbamic acid ethyl ester hydrochloride
- Compound 610 {1-(3,4-Dimethoxy-phenyl)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-carbamic acid ethyl ester hydrochloride
- Compound 611 {1-(3,4-Dimethoxy-phenyl)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-carbamic acid ethyl ester hydrochloride
- Compound 612 [1-(3,4-Dimethoxy-phenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-propyl]-carbamic acid ethyl ester dihydrochloride

- Compound 613 [3-[2-(4-Bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(3-methoxy-phenyl)-propyl]-carbamic acid ethyl ester hydrochloride
- Compound 614 [3-[2-(4-Methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(3-methoxy-phenyl)-propyl]-carbamic acid ethyl ester hydrochloride
- Compound 615 [3-[2-(4-Methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(3-methoxy-phenyl)-propyl]-carbamic acid ethyl ester hydrochloride
- Compound 616 [1-(3-Methoxy-phenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-propyl]-carbamic acid ethyl ester dihydrochloride
- Compound 617 [3-[2-(4-Bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(4-methoxy-phenyl)-propyl]-carbamic acid methyl ester hydrochloride
- Compound 618 [3-[2-(4-Methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(4-methoxy-phenyl)-propyl]-carbamic acid methyl ester hydrochloride
- Compound 619 [3-[2-(4-Methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(4-methoxy-phenyl)-propyl]-carbamic acid methyl ester hydrochloride
- Compound 620 [3-[2-(4-Bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(3,4-dimethoxy-phenyl)-propyl]-carbamic acid methyl ester hydrochloride
- Compound 621 [1-(3,4-Dimethoxy-phenyl)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl]-carbamic acid methyl ester hydrochloride

- Compound 622 {1-(3,4-Dimethoxy-phenyl)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-propyl}-carbamic acid methyl ester hydrochloride
- Compound 623 [1-(3,4-Dimethoxy-phenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diazaspiro[4.5]dec-8-yl)-propyl]-carbamic acid methyl ester dihydrochloride
- Compound 624 [3-[2-(4-Bromo-benzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-(3-methoxy-phenyl)-propyl]-carbamic acid methyl ester hydrochloride
- Compound 625 [3-[2-(4-Methoxy-benzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-(3-methoxy-phenyl)-propyl]-carbamic acid methyl ester hydrochloride
- Compound 626 [3-[2-(4-Methanesulfonyl-benzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-(3-methoxy-phenyl)-propyl]-carbamic acid methyl ester hydrochloride
- Compound 627 [1-(3-Methoxy-phenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diazaspiro[4.5]dec-8-yl)-propyl]-carbamic acid methyl ester dihydrochloride
- Compound 628 {1-(3-Chloro-phenyl)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-propyl}-carbamic acid methyl ester hydrochloride
- Compound 629 [1-(3-Chloro-phenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diazaspiro[4.5]dec-8-yl)-propyl]-carbamic acid methyl ester dihydrochloride
- Compound 630 {1-(4-Chloro-phenyl)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-propyl}-carbamic acid methyl ester hydrochloride

- Compound 631 [1-(4-Chloro-phenyl)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-propyl]-carbamic acid methyl ester hydrochloride
- Compound 632 [1-(4-Chloro-phenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diazaspiro[4.5]dec-8-yl)-propyl]-carbamic acid methyl ester dihydrochloride
- Compound 633 [3-[2-(4-Bromo-benzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-(2-methoxy-phenyl)-propyl]-carbamic acid methyl ester hydrochloride
- Compound 634 [3-[2-(4-Bromo-benzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-(2-methoxy-phenyl)-propyl]-carbamic acid ethyl ester hydrochloride
- Compound 635 [3-[2-(4-Methoxy-benzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-(2-methoxy-phenyl)-propyl]-carbamic acid methyl ester hydrochloride
- Compound 636 [3-[2-(4-Methoxy-benzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-(2-methoxy-phenyl)-propyl]-carbamic acid ethyl ester hydrochloride
- Compound 637 [3-[2-(4-Methanesulfonyl-benzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-(2-methoxy-phenyl)-propyl]-carbamic acid methyl ester hydrochloride
- Compound 638 [3-[2-(4-Methanesulfonyl-benzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-(2-methoxy-phenyl)-propyl]-carbamic acid ethyl ester hydrochloride
- Compound 639 (4-Bromophenyl)-[8-(3,3-diphenylpropyl)-2,8-diazaspiro[4.5]dec-2-yl]-methanone hydrochloride

- Compound 640 4-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-2-phenyl-butyric acid methyl ester
- Compound 641 4-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-2-phenyl-butyric acid methyl ester
- Compound 642 4-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-2-phenyl-butyric acid methyl ester
- Compound 643 4-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-2,N-diphenyl-butyramide hydrochloride
- Compound 644 N-benzyl-4-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-2-phenyl-butyramide hydrochloride
- Compound 645 2-(4-bromobenzyl)-8-(4-oxo-3-phenyl-4-piperidin-1-yl-butyl)-2,8-diaza-spiro[4.5]decan-1-one hydrochloride
- Compound 646 4-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-N-cyclohexyl-2-phenyl-butyramide hydrochloride
- Compound 647 4-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-N-cyclohexyl-n-methyl-2-phenyl-butyramide hydrochloride
- Compound 648 4-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-N-cyclopropyl-2-phenyl-butyramide hydrochloride
- Compound 649 4-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-N-cyclobutyl-2-phenyl-butyramide hydrochloride
- Compound 650 N-cyclohexyl-4-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-n-methyl-2-phenyl-butyramide hydrochloride
- Compound 651 N-cyclopropyl-4-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-2-phenyl-butyramide hydrochloride

- Compound 652 N-cyclobutyl-4-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-2-phenyl-butyramide hydrochloride
- Compound 653 4-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-N-cyclopentyl-2-phenyl-butyramide hydrochloride
- Compound 654 4-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-N-isopropyl-2-phenyl-butyramide hydrochloride
- Compound 655 N-benzyl-4-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-2-phenyl-butyramide hydrochloride
- Compound 656 2-(4-methanesulfonylbenzyl)-8-(4-oxo-3-phenyl-4-piperidin-1-yl-butyl)-2,8-diaza-spiro[4.5]decan-1-one hydrochloride
- Compound 657 N-cyclohexyl-4-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-2-phenyl-butyramide hydrochloride
- Compound 658 N-cyclopentyl-4-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-2-phenyl-butyramide hydrochloride
- Compound 659 N-isopropyl-4-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-2-phenyl-butyramide hydrochloride
- Compound 660 4-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-2,N-diphenyl-butyramide hydrochloride
- Compound 661 N-benzyl-4-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-2-phenyl-butyramide hydrochloride
- Compound 662 2-(4-methoxybenzyl)-8-(4-oxo-3-phenyl-4-piperidin-1-yl-butyl)-2,8-diaza-spiro[4.5]decan-1-one hydrochloride
- Compound 663 N-cyclohexyl-4-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-2-phenyl-butyramide hydrochloride

- Compound 664 N-cyclopropyl-4-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-2-phenyl-butylamide hydrochloride
- Compound 665 N-cyclobutyl-4-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-2-phenyl-butylamide hydrochloride
- Compound 666 N-cyclopentyl-4-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-2-phenyl-butylamide hydrochloride
- Compound 667 N-isopropyl-4-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-2-phenyl-butylamide hydrochloride
- Compound 668 Cyclopropanecarboxylic acid {(S)-1-(3-chloro-phenyl)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-amide hydrochloride
- Compound 669 Cyclopropanecarboxylic acid {(S)-1-(3-fluoro-phenyl)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-amide hydrochloride
- Compound 670 Cyclopropanecarboxylic acid {(S)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl}-amide hydrochloride
- Compound 671 Cyclopropanecarboxylic acid {(S)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-thiophen-3-yl-propyl}-amide hydrochloride
- Compound 672 N-{(S)-1-(3-Chloro-phenyl)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-isobutylamide hydrochloride
- Compound 673 N-{(S)-1-(3-Fluoro-phenyl)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-isobutylamide hydrochloride

- Compound 674 N-((S)-3-[2-(4-Methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl)-isobutyramide hydrochloride
- Compound 675 N-((S)-3-[2-(4-Methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-thiophen-3-yl-propyl)-isobutyramide hydrochloride
- Compound 676 N-((S)-3-[2-(4-Chloro-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-isobutyramide hydrochloride
- Compound 677 N-((S)-3-[2-(4-Fluoro-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-isobutyramide hydrochloride
- Compound 678 N-((S)-3-[2-(4-Cyano-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-isobutyramide hydrochloride
- Compound 679 N-((S)-3-[2-(4-Ethoxy-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-isobutyramide hydrochloride
- Compound 680 N-((S)-3-[2-(4-Difluoromethoxy-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-isobutyramide hydrochloride
- Compound 681 N-((S)-3-[3-Oxo-2-(4-trifluoromethoxy-benzyl)-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-isobutyramide hydrochloride
- Compound 682 N-((S)-3-[3-Oxo-2-(4-trifluoromethyl-benzyl)-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-isobutyramide hydrochloride
- Compound 683 N-((S)-3-[3-Oxo-2-(4-pyrazol-1-yl-benzyl)-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-isobutyramide hydrochloride
- Compound 684 Cyclopropanecarboxylic acid ((S)-3-[2-(4-chloro-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide hydrochloride
- Compound 685 Cyclopropanecarboxylic acid ((S)-3-[2-(4-fluoro-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide hydrochloride

- Compound 686 Cyclopropanecarboxylic acid ((S)-3-[2-(4-cyano-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide hydrochloride
- Compound 687 Cyclopropanecarboxylic acid ((S)-3-[2-(4-ethoxy-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide hydrochloride
- Compound 688 Cyclopropanecarboxylic acid ((S)-3-[2-(4-difluoromethoxy-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide hydrochloride
- Compound 689 Cyclopropanecarboxylic acid ((S)-3-[2-(4-trifluoromethoxy-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide hydrochloride
- Compound 690 Cyclopropanecarboxylic acid ((S)-3-[2-(4-trifluoromethyl-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide hydrochloride
- Compound 691 Cyclopropanecarboxylic acid ((S)-3-[3-oxo-2-(4-pyrazol-1-yl-benzyl)-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide hydrochloride
- Compound 692 2-Cyclopropyl-N-((S)-3-[2-(4-methoxy-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-acetamide hydrochloride
- Compound 693 N-((S)-3-[2-(4-Chloro-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-2-cyclopropyl-acetamide hydrochloride
- Compound 694 N-((S)-3-[2-(4-Fluoro-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-2-cyclopropyl-acetamide hydrochloride
- Compound 695 N-((S)-3-[2-(4-Cyano-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-2-cyclopropyl-acetamide hydrochloride

- Compound 696 N-((S)-3-[2-(4-Ethoxy-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-2-cyclopropyl-acetamide hydrochloride
- Compound 697 N-((S)-3-[2-(4-Difluoromethoxy-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-2-cyclopropyl-acetamide hydrochloride
- Compound 698 N-((S)-3-[2-(4-Trifluoromethoxy-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-2-cyclopropyl-acetamide hydrochloride
- Compound 699 N-((S)-3-[2-(4-Trifluoromethyl-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-2-cyclopropyl-acetamide hydrochloride
- Compound 700 2-Cyclopropyl-N-((S)-3-[3-oxo-2-(4-pyrazol-1-yl-benzyl)-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-acetamide hydrochloride
- Compound 701 4,4-Difluoro-cyclohexanecarboxylic acid ((S)-3-[2-(4-chloro-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide hydrochloride
- Compound 702 4,4-Difluoro-cyclohexanecarboxylic acid ((S)-3-[2-(4-fluoro-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide hydrochloride
- Compound 703 4,4-Difluoro-cyclohexanecarboxylic acid ((S)-3-[2-(4-cyano-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide hydrochloride
- Compound 704 4,4-Difluoro-cyclohexanecarboxylic acid ((S)-3-[2-(4-ethoxy-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide hydrochloride
- Compound 705 4,4-Difluoro-cyclohexanecarboxylic acid ((S)-3-[3-oxo-2-(4-pyrazol-1-yl-benzyl)-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide hydrochloride

- Compound 706 Cyclopropanecarboxylic acid {(S)-1-(3-chloro-phenyl)-3-[2-(4-methoxy-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-amide hydrochloride
- Compound 707 Cyclopropanecarboxylic acid {(S)-1-(3-fluoro-phenyl)-3-[2-(4-methoxy-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-amide hydrochloride
- Compound 708 Cyclopropanecarboxylic acid {(S)-3-[2-(4-methoxy-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl}-amide hydrochloride
- Compound 709 Cyclopropanecarboxylic acid {(S)-3-[2-(4-methoxy-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-thiophen-3-yl-propyl}-amide hydrochloride
- Compound 710 N-{(S)-1-(3-Chloro-phenyl)-3-[2-(4-methoxy-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-isobutyramide hydrochloride
- Compound 711 N-{(S)-1-(3-Fluoro-phenyl)-3-[2-(4-methoxy-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-isobutyramide hydrochloride
- Compound 712 N-{(S)-3-[2-(4-Methoxy-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl}-isobutyramide hydrochloride
- Compound 713 N-{(S)-3-[2-(4-Methoxy-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-thiophen-3-yl-propyl}-isobutyramide hydrochloride
- Compound 714 Propane-2-sulfonic acid {(S)-3-[2-(4-methoxy-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride
- Compound 715 3-{(S)-3-[2-(4-Methoxy-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-1,1-dimethyl-urea hydrochloride

Compound 716 Morpholine-4-carboxylic acid ((S)-3-[2-(4-methoxy-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide hydrochloride

Compound 717 3,3-Difluoro-pyrrolidine-1-carboxylic acid ((S)-3-[2-(4-methoxy-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide hydrochloride

Compound 718 ((S)-3-[2-(4-Methoxy-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-carbamic acid methyl ester hydrochloride

Compound 719 ((S)-3-[2-(4-Methoxy-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-carbamic acid ethyl ester hydrochloride

and pharmaceutically acceptable salts, hydrates or solvates thereof. While the compounds are listed above as their hydrochloride salts, this aspect of the invention includes their non-salt forms, as well
5 as pharmaceutically acceptable salts, hydrates and solvates thereof.

It will be appreciated that the amount of a compound of the invention required for use in treatment will
10 vary not only with the particular compound selected but also with the route of administration, the nature of the condition for which treatment is required and the age and condition of the patient and will be ultimately at the discretion of the
15 attendant physician or veterinarian. In general however a suitable dose will be in the range of from about 0.1 to about 750 mg/kg of body weight per day, preferably in the range of 0.5 to 60 mg/kg/day, most preferably in the range of 1 to 20 mg/kg/day.

The desired dose may conveniently be presented in a single dose or as divided dose administered at appropriate intervals, for example as two, three,
5 four or more doses per day.

The compound is conveniently administered in unit dosage form; for example containing 10 to 1500 mg, conveniently 20 to 1000 mg, most conveniently 50 to
10 700 mg of active ingredient per unit dosage form.

Ideally the active ingredient should be administered to achieve peak plasma concentrations of the active compound of from about 1 to about 75 μ M, preferably
15 about 2 to 50 μ M, most preferably about 3 to about 30 μ M. This may be achieved, for example, by the intravenous injection of a 0.1 to 5% solution of the active ingredient, optionally in saline, or orally administered as a bolus containing about 1 to about
20 500 mg of the active ingredient. Desirable blood levels may be maintained by a continuous infusion to provide about 0.01 to about 5.0 mg/kg/hour or by intermittent infusions containing about 0.4 to about 15 mg/kg of the active ingredient.

25

While it is possible that, for use in therapy, a compound of the invention may be administered as the raw chemical it is preferable to present the active ingredient as a pharmaceutical formulation. The
30 invention thus further provides a pharmaceutical formulation comprising a compound of formula (I) or

a pharmaceutically acceptable derivative thereof together with one or more pharmaceutically acceptable carriers therefor and, optionally, other therapeutic and/or prophylactic ingredients. The carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.

10 Pharmaceutical formulations include those suitable for oral, rectal, nasal, topical (including buccal and sub-lingual), transdermal, vaginal or parenteral (including intramuscular, sub-cutaneous and intravenous) administration or in a form suitable
15 for administration by inhalation or insufflation. The formulations may, where appropriate, be conveniently presented in discrete dosage units and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step
20 of bringing into association the active compound with liquid carriers or finely divided solid carriers or both and then, if necessary, shaping the product into the desired formulation.

25 Pharmaceutical formulation suitable for oral administration may conveniently be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution,
30 a suspension or as an emulsion. The active ingredient may also be presented as a bolus,

electuary or paste. Tablets and capsules for oral administration may contain conventional excipients such as binding agents, fillers, lubricants, disintegrants, or wetting agents. The tablets may
5 be coated according to methods well known in the art. Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for constitution with
10 water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, emulsifying agents, non-aqueous vehicles (which may include edible oils), or preservatives.

15

The compounds according to the invention may also be formulated for parenteral administration (e.g. by injection, for example bolus injection or continuous infusion) and may be presented in unit dose form in
20 ampoules, pre-filled syringes, small volume infusion or in multi-dose containers with an added preservative. The compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulatory agents
25 such as suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredient may be in powder form, obtained by aseptic isolation of sterile solid or by lyophilisation from solution, for constitution with a suitable vehicle, e.g.
30 sterile, pyrogen-free water, before use.

For topical administration to the epidermis, the compounds according to the invention may be formulated as ointments, creams or lotions, or as a transdermal patch. Such transdermal patches may
5 contain penetration enhancers such as linalool, carvacrol, thymol, citral, menthol and t-anethole. Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents. Lotions
10 may be formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilizing agents, dispersing agents, suspending agents, thickening agents, or colouring agents.

15 Formulations suitable for topical administration in the mouth include lozenges comprising active ingredient in a flavoured base, usually sucrose and acacia or tragacanth; pastilles comprising the
20 active ingredient in an inert base such as gelatin and glycerin or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.

25 Pharmaceutical formulations suitable for rectal administration wherein the carrier is a solid are most preferably presented as unit dose suppositories. Suitable carriers include cocoa butter and other materials commonly used in the art,
30 and the suppositories may be conveniently formed by admixture of the active compound with the softened

or melted carrier(s) followed by chilling and shaping in moulds.

Formulations suitable for vaginal administration may
5 be presented as pessaries, tampons, creams, gels, pastes, foams or sprays containing in addition to the active ingredient such carriers as are known in the art to be appropriate.

10 For intra-nasal administration the compounds of the invention may be used as a liquid spray or dispersible powder or in the form of drops. Drops may be formulated with an aqueous or non-aqueous base also comprising one more dispersing agents,
15 solubilising agents or suspending agents. Liquid sprays are conveniently delivered from pressurized packs.

For administration by inhalation the compounds
20 according to the invention are conveniently delivered from an insufflator, nebulizer or a pressurized pack or other convenient means of delivering an aerosol spray. Pressurized packs may comprise a suitable propellant such as
25 dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount.

30

Alternatively, for administration by inhalation or insufflation, the compounds according to the invention may take the form of a dry powder composition, for example a powder mix of the
5 compound and a suitable powder base such as lactose or starch. The powder composition may be presented in unit dosage form in, for example, capsules or cartridges or e.g. gelatin or blister packs from which the powder may be administered with the aid of
10 an inhalator or insufflator.

When desired the above described formulations adapted to give sustained release of the active ingredient may be employed.

15

When the compound (I) or a pharmaceutically acceptable salt, hydrate or solvate thereof is used in combination with a second therapeutic active agent, the dose of each compound may be either the
20 same as or different from that when the compound is used alone. Conventional doses and regimens are readily appreciated by those skilled in the art, including doses described in the Physicians' Desk Reference, 56th edition, 2002.

25

The present invention is directed to the use of the compounds as modulators of CCR5 chemokine receptor activity. In particular, the compounds of the invention have been found to have activity in
30 binding to the CCR5 receptor in the biological assay, as described in Example 15, generally with an

IC₅₀ value of less than 25 μ M. The terms "modulator" or "modulation" are meant to include antagonism, agonism, mixed and partial antagonism and agonism.

- 5 Certain compounds of the present invention have also been tested in an assay for HIV activity, as described in Example 15, and generally having an IC₅₀ value of less than 1 μ M.
- 10 The purity and mass of the following examples were characterized by mass spectra (LC/MS) and or NMR spectra.

- The following general schemes and examples are
- 15 provided to illustrate various embodiments of the present invention and shall not be considered as limiting in scope.


The following abbreviations may be used as follows:

20

br	broad
DCC	1,3-dicyclohexylcarbodiimide
DCE	1,2-dichloroethane
DCM	dichloromethane
25 DIPEA	<i>N,N</i> -diisopropylethylamine
DMF	<i>N,N</i> -dimethylformamide
Hal	halogen
LAH	lithium aluminium hydride
TFA	trifluoroacetic acid
30 THF	tetrahydrofuran

The semi-preparative HPLC purification procedures used are described below:

- 5 Column: Phenomenex Luna C₁₈(2), 5 microns, 10 x 250 mm
- Buffer A: 3 mM HCl in H₂O (pH 2.4-2.6)
- Buffer B: acetonitrile
- Method A: 15-55% B in 30 min. (1.4%/min)
- 10 - Method B: 10-60% B in 50 min. (1%/min)
- Method C: 20-50% B in 21 min. (1.4%/min)
- Method D: 10-60% B in 42 min. (1.2%/min)
- Method E: 15-45% B in 21 min. (1.4%/min)
- or
- 15 Buffer A: H₂O
- Buffer B: acetonitrile
- Method F: 15-55% B in 40 min. (1%/min)




20

Scheme 1.

Preparation 1

2-(4-Bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]decane-8-carboxylic acid tert-butyl ester




5 Sodium hydride 600 mg (14.7 mmol) (60% suspension in mineral oil) was added in a 500 mL round bottom flask under nitrogen followed by 20 mL of anhydrous DMF and 2.5 g (9.8 mmol) of 1-oxo-2,8-diaza-
10 spiro[4.5]decane-8-carboxylic acid tert-butyl ester previously dissolved in 20 mL of anhydrous DMF. After agitating one hour at room temperature, 2.5 g (9.8 mmol) of 4-bromobenzylbromide diluted in 20 mL of anhydrous DMF were added and the reaction mixture
15 was agitated an additional hour at room temperature. Then 100 mL of water were added and the solution was extracted with diethyl ether (2 x 150 mL). The combined organic layers were dried (Na₂SO₄), filtered and evaporated under reduced pressure to yield 4.63
20 g 2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]decane-8-carboxylic acid tert-butyl ester as a yellow oil.

¹H NMR (400 MHz, DMSO-*d*₆): δ [ppm] 7.51 (d, 2H), 7.12 (d, 2H), 4.31 (s, 2H), 3.8 (br d, 2H), 3.14 (t, 2H),
25 2.86 (br s, 2H), 1.89 (t, 2H), 1.54 (t x d, 2H), 1.37 (s, 9H), 1.32 (br d, 2H).

Preparation 2

2-(4-Bromobenzyl)-2,8-diaza-spiro[4.5]decan-1-one hydrochloride




- 5 To 4.62 g of crude 2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]decane-8-carboxylic acid *tert*-butyl ester from preparation 1 was added 50 mL of 4N solution of dioxane/HCl. The reaction mixture was agitated 15 minutes at room temperature and 3.05 g
10 (77.8%) of 2-(4-bromobenzyl)-2,8-diaza-spiro[4.5]decan-1-one hydrochloride was collected, as a colorless solid by filtration followed by trituration with diethyl ether.

¹H NMR (400 MHz, DMSO-*d*₆): δ [ppm] 9.15 (br s, 1H),
15 8.83 (br s, 1H), 7.51 (d, 2H), 7.14 (d, 2H), 4.31 (s, 2H), 3.24 (br d, 2H), 3.15 (t, 2H), 2.92 (q, 2H), 1.95-1.84 (m, 4H), 1.56 (br d, 2H).

Preparation 3

- 20 2-(4-Methylsulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]decane-8-carboxylic acid *tert*-butyl ester



- This spiro compound was prepared as described in preparation 1, starting from 7 g (27.5 mmol) of 1-
25 oxo-2,8-diaza-spiro[4.5]decane-8-carboxylic acid *tert*-butyl ester, excepted it was purified by flash


chromatography on silica gel (ethyl acetate/hexanes 0:100 to 20:80) yielding 8.05 g (74.9%) of 2-(4-methylsulfanylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]decane-8-carboxylic acid tert-butyl ester as a pale yellow solid.

^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ [ppm] 7.21 (d, 2H), 7.11 (d, 2H), 4.3 (s, 2H), 3.8 (br d, 2H), 3.13 (t, 2H), 2.88 (br s, 2H), 2.43 (s, 3H), 1.89 (t, 2H), 1.54 (t x d, 2H), 1.38 (s, 9H), 1.31 (br d, 2H).

10

Preparation 4

2-(4-Methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]decane-8-carboxylic acid tert-butyl ester




15 To a solution of 7.73 g (19.8 mmol) of 2-(4-methylsulfanylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]decane-8-carboxylic acid tert-butyl ester in 100 mL of THF, was added 18.2 g (29.7 mmol) of Oxone® in 100 mL of water. The reaction mixture was
20 agitated overnight at room temperature. An aqueous solution of sodium hydroxide (1N, 100 mL) was added and the solution was extracted with DCM (2 x 200 mL). The combined organic layers were dried (Na_2SO_4), filtered and evaporated under reduced pressure to
25 yield 6.62 g (79.1%) of 2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]decane-8-carboxylic acid tert-butyl ester as a white solid.

¹H NMR (400 MHz, DMSO-d₆): δ [ppm] 7.81 (d, 2H), 7.37 (d, 2H), 4.41 (s, 2H), 3.76 (br d, 2H), 3.15 (t, 2H), 3.14 (s, 3H), 2.86 (br s, 2H), 1.89 (t, 2H), 1.52 (t x d, 2H), 1.33 (s, 9H), 1.29 (br d, 2H).
5 LC/MS: m/z 423.2 (MH⁺).

Preparation 5

2-(4-Methanesulfonylbenzyl)-2,8-diaza-spiro[4.5]decan-1-one hydrochloride




10

As described in preparation 2, 6.62 g (15.6 mmol) of 2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]decane-8-carboxylic acid *tert*-butyl ester was deprotected under acidic conditions giving
15 access to 5.25 g (93.7%) of 2-(4-methanesulfonylbenzyl)-2,8-diaza-spiro[4.5]decan-1-one hydrochloride as a white solid.

¹H NMR (400 MHz, DMSO-d₆): δ [ppm] 9.04 (br s, 1H), 8.74 (br s, 1H), 7.83 (d, 2H), 7.39 (d, 2H), 4.42 (s, 2H), 3.21 (br d, 2H), 3.15 (t, 2H), 3.13 (s, 3H), 2.89 (q, 2H), 1.92 (t, 2H), 1.84 (t x d, 2H), 1.55 (br d, 2H).
20

Preparation 6

25 2-(4-Bromobenzyl)-3-oxo-2,8-diaza-spiro[4.5]decane-8-carboxylic acid *tert*-butyl ester




This spiro compound was prepared as described in preparation 1, starting from 300 mg (1.18 mmol) of 3-oxo-2,8-diaza-spiro[4.5]decane-8-carboxylic acid tert-butyl ester which was purified by flash chromatography on silica gel (ethyl acetate/hexanes 0:100 to 60:40) yielding 290 mg (58%) of 2-(4-bromobenzyl)-3-oxo-2,8-diaza-spiro[4.5]decane-8-carboxylic acid tert-butyl ester as a colorless oil.

¹H NMR (400 MHz, DMSO-*d*₆): δ [ppm] 7.52 (d, 2H), 7.16 (d, 2H), 4.31 (s, 2H), 3.32 (m, 2H), 3.16 (br s, 2H), 3.02 (s, 2H), 2.25 (s, 2H), 1.4 (m, 4H), 1.35 (s, 9H).

15 Preparation 7


2-(4-Bromobenzyl)-2,8-diaza-spiro[4.5]decan-3-one hydrochloride



As described in preparation 2, 290 mg (0.68 mmol) of 2-(4-bromobenzyl)-3-oxo-2,8-diaza-spiro[4.5]decane-8-carboxylic acid tert-butyl ester was deprotected under acidic conditions giving to 212 mg (86.6%) of 2-(4-bromobenzyl)-2,8-diaza-spiro[4.5]decan-3-one hydrochloride as a white solid.

¹H NMR (400 MHz, DMSO-*d*₆): δ [ppm] 8.63 (br s, 2H), 7.52 (d, 2H), 7.17 (d, 2H), 4.32 (s, 2H), 3.07 (s, 2H), 3.00 (m, 4H), 2.33 (s, 2H), 1.65 (m, 4H).

Example 1. 2-(4-Bromobenzyl)-8-(3,3-diphenylpropyl)-2,8-diaza-spiro[4.5]decan-3-one hydrochloride (Compound 13)














5 A mixture of 28.7 mg (80 μ mol) of 2-(4-bromobenzyl)-2,8-diaza-spiro[4.5]decan-3-one hydrochloride, 24.4 mg (88 μ mol) of 3,3-diphenylpropyl bromide and 33.1 mg (240 μ mol) of potassium carbonate in 1.5 mL of anhydrous DMF was heated overnight at 60°C. After cooling to room temperature, 0.5 mL of water was added and the solution was extracted with DCM (2 x 2 mL). The crude material was purified by semi-preparative HPLC (method A) yielding 22.6 mg (51%) of **Compound 13** as a white solid.

^1H NMR (400 MHz, DMSO- d_6): δ [ppm] 9.96 (br s, 1H), 7.52 (d, 2H), 7.34-7.25 (m, 8H), 7.19-7.13 (m, 4H), 4.31 (s, 2H), 3.96 (q, 1H), 3.36 (m, 4H), 3.05 (d, 1H), 2.96-2.83 (m, 4H), 2.47 (s, 2H), 2.3 (d, 1H), 1.75 (m, 4H).








LC/MS: m/z 519.0 (MH^+).

Table 1 of compounds illustrates some of the compounds of the present invention that were synthesized using the procedure described in scheme 1.



12		8-(3,3-diphenyl-propyl)-2-(4-trifluoromethoxy-benzyl)-2,8-diaza-spiro[4.5]decan-1-one	522.608 100% (LC/MS)
13		2-(4-bromobenzyl)-8-(3,3-diphenyl-propyl)-2,8-diaza-spiro[4.5]decan-3-one hydrochloride	553.969 > 95% (LC/MS)
14		8-(3,3-diphenyl-propyl)-2-(3-phenyl-propyl)-2,8-diaza-spiro[4.5]decan-1-one hydrochloride	503.126 100% (LC/MS)
15		8-(3,3-diphenyl-propyl)-2-pyridin-4-ylmethyl-2,8-diaza-spiro[4.5]decan-1-one dihydrochloride	512.521 100% (LC/MS)
16		8-(3,3-diphenyl-propyl)-2-(4-methoxy-benzyl)-2,8-diaza-spiro[4.5]decan-1-one	468.637 93% (LC/MS)
17		8-(3,3-diphenyl-propyl)-2-(4-pyrazol-1-yl-benzyl)-2,8-diaza-spiro[4.5]decan-1-one hydrochloride	541.135 98% (LC/MS)


hydrochloride

18		2-benzothiazol-2-ylmethyl-8-(3,3-diphenyl-propyl)-2,8-diaza-spiro[4.5]decan-1-one hydrochloride	532.149	93% (LC/MS)
19		8-(3,3-diphenyl-propyl)-2-(4-methanesulfonyl-benzyl)-2,8-diaza-spiro[4.5]decan-1-one hydrochloride	553.163	98+ (LC/MS)
20		8-(3,3-diphenyl-propyl)-2-(3-phenyl-allyl)-2,8-diaza-spiro[4.5]decan-1-one hydrochloride	501.11	98% (LC/MS)
21		8-(3,3-diphenyl-propyl)-2-phenethyl-2,8-diaza-spiro[4.5]decan-1-one hydrochloride	489.099	98% (LC/MS)
22		2-(4-benzyloxy-benzyl)-8-(3,3-diphenyl-propyl)-2,8-diaza-spiro[4.5]decan-1-one	544.735	100% (LC/MS)
23		2-benzofuran-2-ylmethyl-8-(3,3-diphenyl-propyl)-2,8-diaza-spiro[4.5]decan-1-one	478.633	90% (LC/MS)
24		8-(3,3-diphenyl-propyl)-2-(4-isobutyl-benzyl)-2,8-diaza-spiro[4.5]decan-1-one	480.692	100%

isopropyl-benzyl)-2,8-diaza-
spiro[4.5]decan-1-one

(LC/MS)


25



2-(5-chloro-benzo[b]thiophen-3-
ylmethyl)-8-(3,3-diphenyl-propyl)-
2,8-diaza-spiro[4.5]decan-1-one

529.145 100%
(LC/MS)


26



8-(3,3-diphenyl-propyl)-2-(4-nitro-
benzyl)-2,8-diaza-spiro[4.5]decan-
1-one

483.609 100%
(LC/MS)


27



2-(4-bromo-benzyl)-8-(3-pyridin-2-
yl-propyl)-2,8-diaza-
spiro[4.5]decan-1-one

442.398 97%
(HPLC)


28



2-[1-(4-bromophenyl)-ethyl]-8-(3,3-
diphenyl-propyl)-2,8-diaza-
spiro[4.5]decan-1-one
hydrochloride

567.995 98+
(LC/MS)


29



8-(3,3-diphenyl-propyl)-2-pyridin-
3-ylmethyl-2,8-diaza-
spiro[4.5]decan-1-one
dihydrochloride

512.521 98+
(LC/MS)


30



N-{4-[8-(3,3-diphenyl-propyl)-1-
oxo-2,8-diaza-spiro[4.5]dec-2-
ylmethyl]-phenyl}-acetamide
hydrochloride

532.124 98+
(LC/MS)








31





8-(3,3-diphenyl-propyl)-2-(6-
trifluoromethyl-pyridin-3-ylmethyl)-
2,8-diaza-spiro[4.5]decan-1-one

580.519 90+
(LC/MS)

dihydrochloride

32		4-[8-(3,3-diphenyl-propyl)-1-oxo-2,8-diaza-spiro[4.5]dec-2-ylmethyl]-benzoic acid hydrochloride	519.081	98+ (LC/MS)
33		8-(3,3-diphenyl-propyl)-2-pyridin-2-ylmethyl-2,8-diaza-spiro[4.5]decan-1-one dihydrochloride	512.521	98+ (LC/MS)
34		8-(3,3-diphenyl-propyl)-2-(4-trifluoromethylsulfanyl-benzyl)-2,8-diaza-spiro[4.5]decan-1-one hydrochloride	575.136	90+ (LC/MS)
35		8-(3,3-diphenyl-propyl)-2-(4-methyl-cyclohexylmethyl)-2,8-diaza-spiro[4.5]decan-1-one hydrochloride	495.147	98+ (LC/MS)
36		4-[8-(3,3-diphenyl-propyl)-1-oxo-2,8-diaza-spiro[4.5]dec-2-ylmethyl]-benzoic acid methyl ester hydrochloride	533.108	90.7% (LC/MS)
37		8-(3,3-diphenyl-propyl)-2-(5-trifluoromethyl-furan-2-ylmethyl)-2,8-diaza-spiro[4.5]decan-1-one hydrochloride	533.031	98+ (LC/MS)
38		8-(3,3-diphenyl-propyl)-2-(4-iodo-benzyl)-2,8-diaza-spiro[4.5]decan-1-one	564.504	>95% (1H NMR)




Scheme 2.

Preparation 8

2-(4-Bromobenzyl)-8-(3-oxo-3-phenylpropyl)-2,8-diazaspiro[4.5]decan-1-one

10




To a stirred solution of 2-(4-bromobenzyl)-2,8-diazaspiro[4.5]decan-1-one hydrochloride (2.30 g, 6.39 mmol) in DMF (43 mL) was added DIPEA (4.2 mL, 3.80

mmol) followed by 3-chloro-1-phenyl-propan-1-one
(1.08 g, 6.39 mmol). The reaction mixture was stirred
at room temperature for 18 hours and then a saturated
solution of NaHCO₃ was added and the mixture was
5 extracted with ethyl acetate (3 x 30 mL). The
combined organic extracts were washed with water (3 x
30 mL) and brine (30 mL), dried over Na₂SO₄, filtered
and concentrated. The crude product was purified by
flash chromatography on silica gel (0% to 5%
10 methanol/DCM) to give 2.53 g (87%) of 2-(4-
bromobenzyl)-8-(3-oxo-3-phenylpropyl)-2,8-diaza-
spiro[4.5]decan-1-one.

¹H NMR (400 MHz, CDCl₃): δ [ppm] 7.98-7.95 (m, 2H),
7.59-7.54 (m, 1H), 7.49-7.42 (m, 4H), 7.10-7.07 (m,
15 2H), 4.39 (s, 2H), 3.21 (t, 2H), 3.14 (t, 2H), 2.93-
2.90 (m, 2H), 2.84 (t, 2H), 2.19-2.14 (m, 2H), 2.05-
1.98 (m, 2H), 1.90 (t, 2H), 1.44-1.41 (m, 2H).

**Example 2. 2-(4-Bromobenzyl)-8-[3-hydroxy-3-(2-
20 methoxyphenyl)-3-phenylpropyl]-2,8-diaza-
spiro[4.5]decan-1-one (Compound 40)**




To a stirred solution of 2-(4-bromobenzyl)-8-(3-oxo-
3-phenylpropyl)-2,8-diaza-spiro[4.5]decan-1-one (157
25 mg, 0.35 mmol) in THF (3.5 mL) at 0°C was added a
1.0 M solution of 2-methoxyphenylmagnesium bromide

(1.4 mL, 1.4 mmol). The reaction mixture was warmed to room temperature and stirred for 18 hours. Water was added and the mixture was extracted with ethyl acetate (3 x 10 mL). The combined organic extracts were washed with brine (10 mL), dried over Na₂SO₄, filtered and concentrated. The crude product was purified by semi-preparative HPLC (method F) to give 133 mg (69%) of **Compound 40** as a yellow oil.

¹H NMR (400 MHz, CDCl₃): δ [ppm] 7.90 (d, 1H), 7.52-7.39 (m, 4H), 7.24 (m, 3H), 7.15 (m, 1H), 7.08-7.01 (m, 3H), 6.79 (d, 1H), 4.42-4.33 (m, 2H), 3.48 (s, 3H), 3.11 (t, 2H), 3.05 (m, 1H), 2.78 (m, 1H), 2.64 (m, 1H), 2.50-2.45 (m, 2H), 2.34 (m, 1H), 2.23 (m, 1H), 2.00-1.88 (m, 3H), 1.85 (m, 2H), 1.45-1.40 (m, 2H).

Example 3. 2-(4-Bromobenzyl)-8-[3-(2-methoxyphenyl)-3-phenylpropyl]-2,8-diaza-spiro[4.5]decan-1-one (Compound 44)



To trifluoroacetic acid (1.4 mL) at room temperature was added portion wise sodium borohydride (67 mg, 1.775 mmol). This mixture was stirred at room temperature for 30 minutes and then a solution of 2-(4-bromobenzyl)-8-[3-hydroxy-3-(2-methoxyphenyl)-3-phenylpropyl]-2,8-diaza-spiro[4.5]decan-1-one (40 mg, 0.071 mmol) in DCM (0.5 mL) was slowly added.


- The reaction mixture was stirred at room temperature for 20 hours and then poured into an ice cold solution of sodium hydroxide (5 mL). The mixture was extracted with ethyl acetate (3 x 5 mL) and the combined organic extracts were washed with brine (5 mL), dried over Na₂SO₄, filtered and concentrated. The crude product was purified by flash chromatography on silica gel (0% to 4% methanol/DCM) to give 24 mg (61%) of **Compound 44** as a yellow oil.
- ¹H NMR (400 MHz, CDCl₃): δ [ppm] 7.43 (d, 2H), 7.38-7.32 (m, 1H), 7.26-7.2 (m, 5H), 7.12-6.94 (m, 5H), 6.35 (t, 1H), 4.36 (s, 2H), 3.7 (s, 3H), 3.2-2.9 (m, 5H), 2.1-1.9 (m, 2H), 1.85 (t, 2H).
- Table 2 of compounds illustrates some of the compounds of the present invention that were synthesized using the procedure described in scheme 2.

20

Table 2.

CPD # MOLSTRUCTURE

40




COMPOUND NAME

2-(4-bromobenzyl)-8-[3-hydroxy-3-(2-methoxyphenyl)-3-phenylpropyl]-2,8-diaza-spiro[4.5]decan-1-one

MOLWT PURITY

563.532 93% BY HPLC


41



2-(4-bromobenzyl)-8-(3-hydroxy-3-(3-methoxyphenyl)-3-phenyl-propyl)-2,8-diaza-spiro[4.5]decan-1-one

563.532 99% BY
HPLC


42



2-(4-bromobenzyl)-8-(3-hydroxy-3-phenyl-3-thiophen-2-yl-propyl)-2,8-diaza-spiro[4.5]decan-1-one

539.535 97% BY
HPLC


43



2-(4-bromobenzyl)-8-(3-hydroxy-3-phenyl-butyl)-2,8-diaza-spiro[4.5]decan-1-one

471.436 99% BY
HPLC


44



2-(4-bromobenzyl)-8-(3-(2-methoxyphenyl)-3-phenyl-propyl)-2,8-diaza-spiro[4.5]decan-1-one





547.534 99% BY
HPLC


45



2-(4-bromobenzyl)-8-(3-(3-chlorophenyl)-3-hydroxy-3-phenyl-propyl)-2,8-diaza-spiro[4.5]decan-1-one


567.952 94% BY
HPLC

46		2-(4-bromobenzyl)-8-[3-(4-chlorophenyl)-3-hydroxy-3-phenyl-propyl]-2,8-diaza-spiro[4.5]decan-1-one	567.952 97% BY HPLC
47		2-(4-bromobenzyl)-8-[3-(3-chlorophenyl)-3-phenyl-propyl]-2,8-diaza-spiro[4.5]decan-1-one	551.953 96% BY HPLC
48		2-(4-bromobenzyl)-8-[3-phenyl-3-thiophen-2-yl-propyl]-2,8-diaza-spiro[4.5]decan-1-one	523.536 89% BY HPLC
49		2-(4-bromobenzyl)-8-[3-(4-chlorophenyl)-3-phenyl-propyl]-2,8-diaza-spiro[4.5]decan-1-one	551.953 96% BY HPLC



Scheme 3.

5 **Example 4. 2-(4-Bromobenzyl)-8-(3-hydroxy-3-phenylpropyl)-2,8-diaza-spiro[4.5]decan-1-one (Compound 50)**




To a cold stirred solution of 2-(4-bromobenzyl)-8-
 10 (3-oxo-3-phenylpropyl)-2,8-diaza-spiro[4.5]decan-1-one (350 mg, 0.769 mmol) in THF-methanol (7:3, 4.0 mL) was added $NaBH_4$ (85 mg, 2.3 mmol). After stirring for one hour, the reaction mixture was then quenched with an aqueous solution of sodium
 15 hydroxide (1N). The reaction mixture was portioned in a separating funnel and the aqueous solution was then extracted with ethyl acetate (3 x 10 mL). The combined organic extracts were washed with brine and dried over sodium sulfate. Evaporation of the
 20 solvent gave **Compound 50** as an oil (300 mg, 85.4%).

¹H NMR (400 MHz, CDCl₃): δ [ppm] 7.44 (d x d, 2H),
7.40-7.3 (m, 4H), 7.26-7.23 (m, 1H), 7.09 (d x d,
2H), 4.94 (d x d, 1H), 4.39 (s, 2H), 3.14 (t, 2H),
3.1-2.9 (m, 2H), 2.7-2.5 (m, 2H), 2.3-1.8 (m, 9H),
5 1.6-1.4 (m, 2H).

Example 5. 8-(3-Benzyloxy-3-phenylpropyl)-2-(4-
bromobenzyl)-2,8-diaza-spiro[4.5]decan-1-one
hydrochloride

10 **(Compound 51)**




To an ice-cold stirred suspension of sodium hydride
(23 mg, 60% in mineral oil, 0.6 mmol) in THF (0.5
mL) was added dropwise a solution of 2-(4-
15 bromobenzyl)-8-(3-hydroxy-3-phenylpropyl)-2,8-diaza-
spiro[4.5]decan-1-one (91.4 mg, 0.2 mmol) in THF
(0.6 mL). After stirring the reaction mixture at 0°C
for 45 minutes benzyl bromide (0.071 mL, 0.6 mmol)
was added and the mixture was then stirred
20 overnight. The mixture was quenched with water and
extracted with ethyl acetate (3 x 5 mL). The
combined organic extracts were washed with brine,
dried (Na₂SO₄), concentrated, and purified by semi-
preparative HPLC (method B) to yield **Compound 51** as
25 a white solid (13.0 mg, 22%).

¹H NMR (400 MHz, DMSO-*d*₆): δ [ppm] 7.53-7.41 (m, 9H),
7.37 (t, 2H), 7.29 (m, 1H), 7.14 (t, 2H), 5.65 (d x

d, 1H), 4.69 (m, 1H), 4.59(d, 2H), 4.31 (d, 2H),
3.62 (m, 1H), 3.45 (m, 2H), 3.32 (m, 2H), 3.17 (t x
d, 2H), 2.15 (m, 2H), 2.02-1.89 (m, 5H), 1.75 (m,
1H).

5

**Example 6. 2-(4-Bromobenzyl)-8-(3-phenoxy-3-
phenylpropyl)-2,8-diaza-spiro[4.5]decan-1-one**
(Compound 52)




10 To a stirred solution of 2-(4-bromobenzyl)-8-(3-
hydroxy-3-phenylpropyl)-2,8-diaza-spiro[4.5]decan-1-
one (65 mg, 0.142 mmol) and phenol (13.3 mg, 0.142
mmol) in THF was added triphenylphosphine (37 mg,
0.142 mmol) followed by diethylazodicarboxylate
15 (DEAD) (0.023 mL, 0.142 mmol). After stirring for
24 hours, the reaction mixture was then concentrated
and purified on silica gel preparative TLC using 20%
ethyl acetate-hexanes as eluent. **Compound 52** was
isolated as oil (12 mg, 15.8%).

20 ¹H NMR (CDCl₃, 400 MHz): δ [ppm] 7.40-7.0 (m, 11H),
6.82-6.76 (m, 3H), 5.19 (d x d, 1H), 4.32 (s, 2H),
3.06 (t, 2H), 2.72 (m, 2H), 2.5-1.7 (m, 10H), 1.4-
1.25 (m, 2H).


LC/MS: m/z 534.5 (MH⁺).

25



Scheme 4.

5 **Example 7. (3-[2-(4-Bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenylpropyl)-carbamic acid tert-butyl ester (Compound 53)**



To a solution of 2.16 g (6 mmol) of 2-(4-
 10 bromobenzyl)-2,8-diaza-spiro[4.5]decan-1-one
 hydrochloride in 100 mL of anhydrous DCE were added
 successively 1.5 g (6 mmol) of (3-oxo-1-
 phenylpropyl)-carbamic acid tert-butyl ester and 836
 μL (6 mmol) of triethylamine. The reaction mixture
 15 was agitated at room temperature for 10 minutes
 before adding 2 g (9 mmol) of sodium
 triacetoxyborohydride. After an overnight agitation,
 60 mL of saturated solution of sodium bicarbonate was
 added. The solution was then extracted with DCM,
 20 dried over sodium sulfate, filtered and concentrated


in vacuo. The crude mixture was purified by flash chromatography on silica gel eluting with methanol/DCM (0% to 5%) giving **Compound 53** as a white solid (2.97 g, 88.9%).

5 ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ [ppm] 7.51 (d, 2H), 7.45 (d, 1H), 7.27 (m, 4H), 7.19 (m, 1H), 7.12 (d, 2H), 4.52 (q, 1H), 4.32 (s, 2H), 3.11 (t, 2H), 2.69 (m, 2H), 2.17 (m, 2H), 1.91 (br t, 2H), 1.82 (t, 2H), 1.71 (m, 4H), 1.33 (s, 9H), 1.29 (m, 2H).

10

Preparation 9

8-(3-Amino-3-phenylpropyl)-2-(4-bromobenzyl)-2,8-diaza-spiro[4.5]decan-1-one




15 To 2.97 g (5.33 mmol) of {3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenylpropyl}-carbamic acid tert-butyl ester was added 48 mL of a 20% TFA solution in DCM. The reaction mixture was agitated one hour at room temperature before
20 neutralizing with 120 mL of an aqueous solution of sodium hydroxide (1N). The solution was then extracted with DCM, dried over sodium sulfate, filtered and evaporated in vacuo yielding 8-(3-amino-3-phenylpropyl)-2-(4-bromobenzyl)-2,8-diaza-spiro[4.5]decan-1-one as a pale yellow oil (2.43 g,
25 100%).

¹H NMR (400 MHz, DMSO-d₆): δ [ppm] 7.51 (d, 2H), 7.32-7.24 (m, 4H), 7.17 (m, 1H), 7.12 (d, 2H), 4.31 (s, 2H), 3.81 (t, 1H), 3.1 (t, 2H), 2.72 (d x d, 2H), 2.25-2.16 (m, 2H), 1.98 (br s, 2H), 1.86 (br q, 2H),
5 1.81 (t, 2H), 1.73-1.59 (m, 4H), 1.29 (br d, 2H).

Example 8. N-{3-[2-(4-Bromobenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenylpropyl}-benzamide hydrochloride

10 **(Compound 54)**











To 100 mg (100 μmol, loading of 1 mmol/g) of phenylcarboxyl activated ester on polymeric 4-hydroxy-2,3,5,6-tetrafluorobenzamido (TFP) resin
15 (see preparation in J.M. Salvino et al. *J. Comb. Chem.* **2000**, 2, 691-697), preswollen with 0.5 mL of anhydrous DMF, was added 27.3 mg (60 μmol) of 8-(3-amino-3-phenylpropyl)-2-(4-bromobenzyl)-2,8-diazaspiro[4.5]decan-1-one dissolved in 1 mL of DMF. The
20 reaction was agitated overnight at room temperature. The mixture was filtered and washed with DCM (2 x 2 mL). The filtrates were collected and evaporated in vacuo. The crude mixture was purified by semi-preparative HPLC (method A) and 14.1 mg (39.4%) of
25 **Compound 54** was isolated as a colorless solid.






¹H NMR (400 MHz, DMSO-*d*₆): δ [ppm] 9.64 (br s, 1H),
 8.91 (d, 1H), 7.88 (d, 2H), 7.55-7.42 (m, 7H), 7.35
 (t, 2H), 7.25 (t, 1H), 7.14 (d, 2H), 5.12 (m, 1H),
 4.33 (s, 2H), 3.46 (m, 2H), 3.16 (m, 4H), 2.97 (m,
 5 2H), 2.35 (m, 1H), 2.2 (m, 1H), 1.98 (m, 3H), 1.83
 (t, 1H), 1.6 (br d, 2H).
 LC/MS: *m/z* 562.0 (MH⁺).






Table 3 of compounds illustrates some of the
 10 compounds of the present invention that were
 synthesized using the procedure described in scheme
 4.






15 Table 3.






CPD #	MOLSTRUCTURE	COMPOUND NAME	MOLWT	PURITY
53		{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-carbamic acid tert-butyl ester	556.541	>95% (1H NMR)
54		N-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-benzamide hydrochloride	596.994	98+ (LC/MS)
55		N-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-2,6-dimethyl-benzamide hydrochloride	625.047	98+ (LC/MS)






56		Cyclohexanecarboxylic acid {3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride	603.041	98+ (LC/MS)
57		N-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-2-phenyl-acetamide hydrochloride	611.02	98+ (LC/MS)
58		N-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-2-(2,4,6-trimethyl-phenyl)-acetamide hydrochloride	653.101	98+ (LC/MS)
59		N-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-3-phenyl-propionamide hydrochloride	625.047	98+ (LC/MS)
60		{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-methyl-carbamic acid tert-butyl ester	570.568	>95% (1H NMR)







61		N-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-N-methyl-benzamide hydrochloride	611.02	98+ (LC/MS)
62		Cyclohexanecarboxylic acid {3-[2-(4-bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-methyl-amide hydrochloride	617.068	98+ (LC/MS)
63		N-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-N-methyl-2-phenyl-acetamide hydrochloride	625.047	98+ (LC/MS)
64		N-{3-[2-(4-bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-N-methyl-2-(2,4,6-trimethyl-phenyl)-acetamide hydrochloride	667.128	98+ (LC/MS)
65		[3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-carbamic acid tert-butyl ester	478.633	95% BY HPLC






66		{3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-carbamic acid tert-butyl ester	555.736	94% (LC-MS)
67		[3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(3-chloro-phenyl)-propyl]-carbamic acid tert-butyl ester	590.986	>95% (1H NMR)
68		N-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-acetamide hydrochloride	534.923	94.6% (LC/MS)
69		Cyclopropanecarboxylic acid {3-[2-(4-bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride	560.961	95.2% (LC/MS)
70		N-{3-[2-(4-bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-isobutyramide hydrochloride	562.976	95% (LC/MS)






71		N-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-3-methyl-butamide hydrochloride	577.003	98+ (LC/MS)
72		N-{3-[2-(4-bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-2-chloro-benzamide hydrochloride	631.439	98+ (LC/MS)
73		N-{3-[2-(4-bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-2-methoxy-benzamide hydrochloride	627.019	98+ (LC/MS)
74		Pyridine-2-carboxylic acid {3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide dihydrochloride	634.443	93.7 % (LC/MS)
75		N-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-3-chloro-benzamide hydrochloride	631.439	98+ (LC/MS)

76		N-{3-[2-(4-bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-3-methoxy-benzamide hydrochloride	627.019	98+ (LC/MS)
77		N-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-nicotinamide dihydrochloride	634.443	98+ (LC/MS)
78		N-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-4-chloro-benzamide hydrochloride	631.439	98+ (LC/MS)
79		N-{3-[2-(4-bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-4-methoxy-benzamide hydrochloride	627.019	98+ (LC/MS)
80		N-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-isonicotinamide dihydrochloride	634.443	98+ (LC/MS)


81		N-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-3,4-dichloro-benzamide hydrochloride	665.884	98+ (LC/MS)
82		N-{3-[2-(4-bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-3,4-dimethoxy-benzamide hydrochloride	657.045	98+ (LC/MS)
83		N-{3-[2-(4-bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-2-(2-chloro-phenyl)-acetamide hydrochloride	645.465	94.8% (LC/MS)
84		N-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-2-(2-methoxy-phenyl)-acetamide hydrochloride	641.046	98+ (LC/MS)
85		N-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-2-(3-chloro-phenyl)-acetamide hydrochloride	645.465	92.9% (LC/MS)

86		N-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-2-(3-methoxy-phenyl)-acetamide hydrochloride	641.046	98+ (LC/MS)
87		N-{3-[2-(4-bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-2-pyridin-3-yl-acetamide dihydrochloride	648.469	95+ (LC/MS)
88		N-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-2-(4-methoxy-phenyl)-acetamide hydrochloride	641.046	98+ (LC/MS)
89		N-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-2-(3,4-dichloro-phenyl)-acetamide hydrochloride	679.911	95+ (LC/MS)
90		Tetrahydro-pyran-4-carboxylic acid{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride	605.013	95+ (LC/MS)
91		Cyclopentanecarboxylic acid {3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride	589.014	98+ (LC/MS)



97		N-{3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-isobutyramide hydrochloride	514.106	98+ (LC/MS)
98		N-{3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-3-methyl-butyramide hydrochloride	528.133	98+ (LC/MS)
99		2-chloro-N-{3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-benzamide hydrochloride	582.568	95+ (LC/MS)
100		2-methoxy-N-{3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-benzamide hydrochloride	578.149	98+ (LC/MS)
101		Pyridine-2-carboxylic acid {3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide dihydrochloride	585.572	98+ (LC/MS)


102



3-chloro-N-{3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-benzamide hydrochloride

582.568 98+
(LC/MS)


103



3-methoxy-N-{3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-benzamide hydrochloride

578.149 98+
(LC/MS)


104



N-{3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-nicotinamide dihydrochloride

585.572 98+
(LC/MS)


105



4-chloro-N-{3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-benzamide hydrochloride






582.568 98+
(LC/MS)







106













4-methoxy-N-{3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-benzamide hydrochloride






578.149 98+
(LC/MS)













112		N-{3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-2-(2-methoxyphenyl)-acetamide hydrochloride	592.176	98+ (LC/MS)
113		2-(3-chlorophenyl)-N-{3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-acetamide hydrochloride	596.595	98+ (LC/MS)
114		N-{3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-2-(3-methoxyphenyl)-acetamide hydrochloride	592.176	98+ (LC/MS)
115		N-{3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-2-pyridin-3-yl-acetamide dihydrochloride	599.599	90+ (LC/MS)
116		N-{3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-2-(4-methoxyphenyl)-acetamide hydrochloride	592.176	98+ (LC/MS)
117		2-(3,4-dichlorophenyl)-N-{3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-acetamide hydrochloride	631.04	95+ (LC/MS)













123		(S)-cyclohexanecarboxylic acid {3-[2-(4-bromobenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide	566.58	99% BY HPLC
124		N-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl}-2-cyclopentyl-acetamide hydrochloride	603.041	98+ (LC/MS)
125		Furan-2-carboxylic acid {3-[2-(4-bromobenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride	586.955	98+ (LC/MS)
126		N-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl}-2-ethyl-butylamide hydrochloride	591.03	98+ (LC/MS)
127		Thiophene-2-carboxylic acid {3-[2-(4-bromobenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride	603.022	98+ (LC/MS)





































153		N-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-2-(2-methoxyphenyl)-acetamide hydrochloride	640.241	98+ (LC/MS)
154		2-(3-chlorophenyl)-N-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-acetamide hydrochloride	644.66	93% (LC/MS)
155		N-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-2-(3-methoxyphenyl)-acetamide hydrochloride	640.241	98+ (LC/MS)
156		N-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-benzamide hydrochloride	596.188	98+ (LC/MS)
157		(S)-cyclohexanecarboxylic acid [3-(2-benzyl-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-amide	487.684	>95% (HPLC)













163		Cycloheptanecarboxylic acid {3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride	616.262	98+ (LC/MS)
164		2-cyclohexyl-N-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-acetamide hydrochloride	616.262	98+ (LC/MS)
165		2-cyclopentyl-N-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-acetamide hydrochloride	602.236	98+ (LC/MS)
166		Furan-2-carboxylic acid {3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride	586.149	98+ (LC/MS)
167		2-ethyl-N-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-butyramide hydrochloride	590.225	98+ (LC/MS)













173		3-chloro-N-[3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-benzamide dihydrochloride	589.992	98+ (LC/MS)
174		4-chloro-N-[3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-benzamide dihydrochloride	589.992	98+ (LC/MS)
175		4-methoxy-N-[3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-benzamide dihydrochloride	585.572	98+ (LC/MS)
176		Cyclohexanecarboxylic acid [3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(3-chloro-phenyl)-propyl]-amide hydrochloride	637.486	94.3% (LC/MS)
177		N-[3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(3-chlorophenyl)-propyl]-benzamide hydrochloride	631.439	98+ (LC/MS)
178		N-[3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(3-chlorophenyl)-propyl]-2-phenyl-acetamide hydrochloride	645.465	98+ (LC/MS)






179		{1-(3-chlorophenyl)-3-[2-(4-methoxybenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-propyl}-carbamic acid tert-butyl ester	542.116 >95% (1H NMR)
180		{1-(3,4-dichlorophenyl)-3-[2-(4-methoxybenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-propyl}-carbamic acid tert-butyl ester	576.561 >95% (1H NMR)
181		N-[3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diazaspiro[4.5]dec-8-yl)-1-phenyl-propyl]-acetamide dihydrochloride	493.476 90+ (LC/MS)
182		Cyclopropanecarboxylic acid [3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diazaspiro[4.5]dec-8-yl)-1-phenyl-propyl]-amide dihydrochloride	519.513 98+ (LC/MS)
183		N-[3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diazaspiro[4.5]dec-8-yl)-1-phenyl-propyl]-isobutyramide dihydrochloride	521.529 98+ (LC/MS)
184		3-methyl-N-[3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diazaspiro[4.5]dec-8-yl)-1-phenyl-propyl]-butyramide dihydrochloride	535.556 98+ (LC/MS)






















195		2-(3-chloro-phenyl)-N-[3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-acetamide dihydrochloride	604.018	98+ (LC/MS)
196		2-(3-methoxyphenyl)-N-[3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-acetamide dihydrochloride	599.599	93.3% (LC/MS)
197		2-(4-methoxyphenyl)-N-[3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-acetamide dihydrochloride	599.599	98+ (LC/MS)
198		N-[3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-2-phenyl-acetamide dihydrochloride	569.573	93.3% (LC/MS)
199		2-(3,4-dichloro-phenyl)-N-[3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-acetamide dihydrochloride	638.463	91.5% (LC/MS)




















210		Cyclohexanecarboxylic acid [3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diazaspiro[4.5]dec-8-yl)-1-phenyl-propyl]-amide dihydrochloride	561.594	98+ (LC/MS)
211		4-methyl-cyclohexanecarboxylic acid [3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diazaspiro[4.5]dec-8-yl)-1-phenyl-propyl]-amide dihydrochloride	575.621	92.1% (LC/MS)
212		[3-[2-(4-bromobenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-(3-methoxyphenyl)-propyl]-carbamic acid tert-butyl ester	586.567	>99% (LC-MS)
213		[3-[2-(4-methoxybenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-(3-methoxyphenyl)-propyl]-carbamic acid tert-butyl ester	537.697	>99% (LC-MS)
214		(S)-N-[3-[2-(4-bromobenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl]-acetamide hydrochloride	534.923	98+ (LC/MS)
215		(S)-cyclopropanecarboxylic acid [3-[2-(4-bromobenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl]-amide hydrochloride	560.961	98+ (LC/MS) ₄

















220		[3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(4-methoxyphenyl)-propyl]-carbamic acid tert-butyl ester	537.697	95% BY HPLC
221		{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-pyridin-2-yl-propyl}-carbamic acid tert-butyl ester	557.529	99% BY HPLC
222		{3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-pyridin-2-yl-propyl}-carbamic acid tert-butyl ester	508.659	99% BY HPLC
223		{1-(3,4-dichlorophenyl)-3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-carbamic acid tert-butyl ester	624.626	>95% (1H NMR)
224		2-cyclopropyl-N-{3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-acetamide hydrochloride	526.117	98+ (LC/MS)
225		2-cyclopropyl-N-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-acetamide hydrochloride	574.182	94.4% (LC/MS)
226		[3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(4-methoxyphenyl)-propyl]-carbamic acid tert-butyl ester	586.567	95% BY HPLC








227		N-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-2-cyclopropyl-acetamide hydrochloride	574.987	98+ (LC/MS)
228		[3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(3,4-dimethoxyphenyl)-propyl]-carbamic acid tert-butyl ester	616.593	99% BY HPLC
229		{1-(3,4-dimethoxyphenyl)-3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-carbamic acid tert-butyl ester	567.722	97% BY HPLC
230		Tetrahydro-pyran-4-carboxylic acid {3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride	604.208	>95% (HPLC)







231		[3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(3-methoxy-phenyl)-propyl]-carbamic acid tertbutyl ester	585.762	>99% (HPLC)
232		(S)-[3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl]-carbamic acid tert-butyl ester	555.736	>99% (HPLC)
233		[3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-pyridin-2-yl-propyl]-carbamic acid tert-butyl ester	556.724	95% BY HPLC
234		{1-(3,4-dimethoxyphenyl)-3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-carbamic acid tert-butyl ester	615.787	97% BY HPLC
235		{1-(4-chlorophenyl)-3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-carbamic acid tert-butyl ester	542.116	>90% (HNMR)






236		{1-(2-chlorophenyl)-3-[2-(4-methoxybenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-propyl}-carbamic acid tert-butyl ester	542.116	>90% (HNMR)
237		{3-[2-(4-methoxybenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl}-carbamic acid tert-butyl ester	513.699	>90% (HNMR)
238		[3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-(4-methoxyphenyl)-propyl]-carbamic acid tert-butyl ester	585.762	95% BY HPLC
239		[3-[2-(4-bromobenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-(4-chlorophenyl)-propyl]-carbamic acid tert-butyl ester	590.986	>90% (HNMR)
240		[3-[2-(4-bromobenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-(2-chlorophenyl)-propyl]-carbamic acid tert-butyl ester	590.986	>90% (HNMR)
241		{3-[2-(4-bromobenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl}-carbamic acid tert-butyl ester	562.569	>90% (HNMR)






242		{1-(4-chlorophenyl)-3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-carbamic acid tert-butyl ester	590.181	>90% (HNMR)
243		{1-(2-chlorophenyl)-3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-carbamic acid tert-butyl ester	590.181	>90% (HNMR)
244		{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl}-carbamic acid tert-butyl ester	561.764	>90% (HNMR)
245		(S)-N-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-isobutyramide	525.71	98+ (LC/MS)
246		[3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(2-methoxyphenyl)-propyl]-carbamic acid tert-butyl ester	586.567	89% BY HPLC
247		[3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(2-methoxy-phenyl)-propyl]-carbamic acid tert-butyl ester	537.697	86% BY HPLC
248		[1-(2-chlorophenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-propyl]-carbamic acid tert-butyl ester	513.078	>90% (HNMR)






249		[1-(3-chlorophenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-propyl]-carbamic acid tert-butyl ester	513.078	>90% (HNMR)
250		[1-(3,4-dichlorophenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-propyl]-carbamic acid tert-butyl ester	547.523	>90% (HNMR)
251		[3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-thiophen-2-yl-propyl]-carbamic acid tert-butyl ester	484.661	>90% (HNMR)
252		(S)-8-[3-(cyclopropanecarbonyl-amino)-3-phenyl-propyl]-2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]decane hydrochloride	560.155	98+ (LC/MS)
253		(S)-8-[3-(cyclopentanecarbonyl-amino)-3-phenyl-propyl]-2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]decane hydrochloride	588.209	98+ (LC/MS)
254		(S)-8-[3-(cyclohexanecarbonyl-amino)-3-phenyl-propyl]-2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]decane hydrochloride	602.236	98+ (LC/MS)
255		(S)-8-[3-(cyclopropanecarbonyl-amino)-3-phenyl-propyl]-2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]decane hydrochloride	512.09	98+ (LC/MS)






256		(S)-8-(3-isobutyrylamino-3-phenyl-propyl)-2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]decane hydrochloride	514.106	98+ (LC/MS)
257		(S)-8-[3-(cyclopentanecarbonyl-amino)-3-phenyl-propyl]-2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]decane hydrochloride	540.144	98+ (LC/MS)
258		(S)-8-[3-(cyclohexanecarbonyl-amino)-3-phenyl-propyl]-2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]decane hydrochloride	554.171	98+ (LC/MS)
259		N-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl}-isobutyramide hydrochloride	569.005	98+ (LC/MS)
260		Cyclobutanecarboxylic acid {3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl}-amide hydrochloride	581.016	98+ (LC/MS)
261		Cyclopentanecarboxylic acid {3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl}-amide hydrochloride	595.042	98+ (LC/MS)
262		N-{3-[2-(4-bromo-enzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl}-propionamide hydrochloride	554.978	98+ (LC/MS)

263		N-(3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl)-2-methoxy-acetamide hydrochloride	570.977	98+ (LC/MS)
264		Cyclohexanecarboxylic acid {3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl}-amide hydrochloride	609.069	98+ (LC/MS)
265		Cyclopropanecarboxylic acid {3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl}-amide hydrochloride	518.118	98+ (LC/MS)
266		N-(3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl)-isobutyramide hydrochloride	520.134	98+ (LC/MS)
267		[3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(2-methoxyphenyl)-propyl]-carbamic acid tert-butyl ester	585.762	89% BY HPLC
268		Cyclobutanecarboxylic acid {3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl}-amide hydrochloride	532.145	98+ (LC/MS)



274		N-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl}-isobutyramide hydrochloride	568.199	98+ (LC/MS)
275		Cyclobutanecarboxylic acid {3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl}-amide hydrochloride	580.21	95.2% (LC/MS)
276		Cyclopentanecarboxylic acid {3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl}-amide hydrochloride	594.237	98+ (LC/MS)
277		N-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl}-propionamide hydrochloride	554.172	98+ (LC/MS)
278		N-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl}-2-methoxyacetamide hydrochloride	570.171	98+ (LC/MS)

- 279  Cyclohexanecarboxylic acid [3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl]-amide hydrochloride 608.264 98+ (LC/MS)
- 280  Cyclohexanecarboxylic acid [3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-thiophen-2-yl-propyl]-amide dihydrochloride 525.542 98+ (LC/MS)
- 281  N-[3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-thiophen-2-yl-propyl]-isobutyramide dihydrochloride 527.557 98+ (LC/MS)
- 282  Cyclobutanecarboxylic acid [3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-thiophen-2-yl-propyl]-amide dihydrochloride 539.568 98+ (LC/MS)
- 283  Cyclopentanecarboxylic acid [3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-thiophen-2-yl-propyl]-amide dihydrochloride 553.595 98+ (LC/MS)

284		N-[3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-thiophen-2-yl-propyl]-propionamide dihydrochloride	513.531	80.8% (LC/MS)
285		Cyclohexanecarboxylic acid [3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-thiophen-2-yl-propyl]-amide dihydrochloride	567.622	94.3% (LC/MS)
286		Cyclopropanecarboxylic acid [3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(3-chlorophenyl)-propyl]-amide hydrochloride	595.406	98+ (LC/MS)
287		N-[3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(3-chlorophenyl)-propyl]-isobutyramide hydrochloride	597.421	98+ (LC/MS)
288		Cyclobutanecarboxylic acid [3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(3-chlorophenyl)-propyl]-amide hydrochloride	609.432	98+ (LC/MS)

















289		Cyclopentanecarboxylic acid [3-[2-(4-bromobenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-(3-chlorophenyl)-propyl]-amide hydrochloride	623.459	98+ (LC/MS)
290		N-[3-[2-(4-bromobenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-(3-chlorophenyl)-propyl]-propionamide hydrochloride	583.395	98+ (LC/MS)
291		N-[3-[2-(4-bromobenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-(3-chlorophenyl)-propyl]-2-methoxyacetamide hydrochloride	599.394	98+ (LC/MS)







Table 3a of compounds illustrates some additional compounds of the present invention that were synthesized using the procedure described in scheme 4.







Table 3a.







CPD #	MOLSTRUCTURE	COMPOUND NAME	MOLWT	PURITY
-------	--------------	---------------	-------	--------

292		Chiral 2-Cyclopropyl-N-((S)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-acetamide hydrochloride	574.182	99% (LC/MS)
293		Chiral 2-Cyclopropyl-N-((S)-3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-acetamide hydrochloride	526.117	99% (LC/MS)
294		Chiral Cyclopentanecarboxylic acid [(S)-3-(2-benzyl-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-amide hydrochloride	510.118	98+ (LC/MS)
295		Chiral Cyclopropanecarboxylic acid [(S)-3-(2-benzyl-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-amide hydrochloride	482.064	91.6% (LC/MS)
296		Cyclohexanecarboxylic acid [3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(3-chlorophenyl)-propyl]-amide hydrochloride	637.486	98% (LC/MS)
297		Cyclopropanecarboxylic acid {1-(3-chloro-phenyl)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-amide hydrochloride	546.535	98% (LC/MS)
298		N-{1-(3-Chloro-phenyl)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-isobutyramide hydrochloride	548.551	98% (LC/MS)

299		Cyclobutanecarboxylic acid {1-(3-chlorophenyl)-3-[2-(4-methoxybenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-propyl}-amide hydrochloride	560.562	98% (LC/MS)
300		Cyclopentanecarboxylic acid {1-(3-chlorophenyl)-3-[2-(4-methoxybenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-propyl}-amide hydrochloride	574.589	98% (LC/MS)
301		N-{1-(3-Chlorophenyl)-3-[2-(4-methoxybenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-propyl}-propionamide hydrochloride	534.524	95% (LC/MS)
302		N-{1-(3-Chlorophenyl)-3-[2-(4-methoxybenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-propyl}-2-methoxy-acetamide hydrochloride	550.523	98% (LC/MS)
303		Cyclohexanecarboxylic acid {1-(3-chlorophenyl)-3-[2-(4-methoxybenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-propyl}-amide hydrochloride	588.616	98% (LC/MS)
304		Cyclopropanecarboxylic acid {1-(3-chlorophenyl)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-propyl}-amide hydrochloride	594.6	98% (LC/MS)







305		N-{1-(3-Chlorophenyl)-3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-isobutyramide hydrochloride	596.616	98% (LC/MS)
306		Cyclobutanecarboxylic acid {1-(3-chlorophenyl)-3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-amide hydrochloride	608.627	98% (LC/MS)
307		Cyclopentanecarboxylic acid {1-(3-chlorophenyl)-3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-amide hydrochloride	622.654	98% (LC/MS)
308		N-{1-(3-Chlorophenyl)-3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-propionamide hydrochloride	582.589	98% (LC/MS)
309		N-{1-(3-Chlorophenyl)-3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-2-methoxy-acetamide hydrochloride	598.588	95% (LC/MS)
310		Cyclopropanecarboxylic acid [1-(3-chlorophenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-propyl]-amide dihydrochloride	553.958	93.2% (LC/MS)







311		N-[1-(3-Chlorophenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-propyl]-isobutyramide dihydrochloride	555.974	94.1% (LC/MS)
312		Cyclobutanecarboxylic acid [1-(3-chlorophenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-propyl]-amide dihydrochloride	567.985	98% (LC/MS)
313		Cyclopentanecarboxylic acid [1-(3-chlorophenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-propyl]-amide dihydrochloride	582.012	98% (LC/MS)
314		N-[1-(3-Chlorophenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-propyl]-propionamide dihydrochloride	541.948	93.8% (LC/MS)
315		N-[1-(3-Chlorophenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-propyl]-2-methoxy-acetamide dihydrochloride	557.946	94.4% (LC/MS)
316		Cyclohexanecarboxylic acid [1-(3-chlorophenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-propyl]-amide dihydrochloride	596.039	94.7% (LC/MS)







317		Cyclopropanecarboxylic acid [(S)-3-(1-oxo-2-pyridin-2-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-amide dihydrochloride	519.513	98% (LC/MS)
318		Cyclopentanecarboxylic acid [(S)-3-(1-oxo-2-pyridin-2-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-amide dihydrochloride	547.567	98% (LC/MS)
319		Cyclopropanecarboxylic acid [(S)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-amide dihydrochloride	519.513	98% (LC/MS)
320		Cyclopentanecarboxylic acid [(S)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-amide dihydrochloride	547.567	98% (LC/MS)
321		Cyclopropanecarboxylic acid [(S)-3-(1-oxo-2-pyridin-4-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-amide dihydrochloride	519.513	98% (LC/MS)
322		Cyclopentanecarboxylic acid [(S)-3-(1-oxo-2-pyridin-4-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-amide dihydrochloride	547.567	98% (LC/MS)







323		Cyclopropanecarboxylic acid ((S)-3-[1-oxo-2-(1-oxy-pyridin-2-ylmethyl)-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide hydrochloride	499.052	98% (LC/MS)
324		Cyclopentanecarboxylic acid ((S)-3-[1-oxo-2-(1-oxy-pyridin-2-ylmethyl)-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide hydrochloride	527.105	98% (LC/MS)
325		Cyclopropanecarboxylic acid ((S)-3-[1-oxo-2-(1-oxy-pyridin-3-ylmethyl)-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide hydrochloride	499.052	98% (LC/MS)
326		Cyclopentanecarboxylic acid ((S)-3-[1-oxo-2-(1-oxy-pyridin-3-ylmethyl)-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide hydrochloride	527.105	98% (LC/MS)
327		Cyclopropanecarboxylic acid ((S)-3-[1-oxo-2-(1-oxy-pyridin-4-ylmethyl)-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide hydrochloride	499.052	98% (LC/MS)
328		Cyclopentanecarboxylic acid ((S)-3-[1-oxo-2-(1-oxy-pyridin-4-ylmethyl)-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide hydrochloride	527.105	98% (LC/MS)







329		Cyclopentanecarboxylic acid {3-[2-(4-bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-pyridin-2-yl-propyl}-amide dihydrochloride	626.463	98% (LC/MS)
330		N-(3-[2-(4-Bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-pyridin-2-yl-propyl)-propionamide dihydrochloride	586.398	98% (LC/MS)
331		N-(3-[2-(4-Bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-pyridin-2-yl-propyl)-2-methoxyacetamide dihydrochloride	602.398	98% (LC/MS)
332		Cyclopropanecarboxylic acid {3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-pyridin-2-yl-propyl}-amide dihydrochloride	549.539	98% (LC/MS)
333		N-(3-[2-(4-Methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-pyridin-2-yl-propyl)-isobutyramide dihydrochloride	551.555	98% (LC/MS)
334		Cyclobutanecarboxylic acid {3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-pyridin-2-yl-propyl}-amide dihydrochloride	563.566	98% (LC/MS)








335		Cyclopentanecarboxylic acid {3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-pyridin-2-yl-propyl}-amide dihydrochloride	577.593	98% (LC/MS)
336		N-{3-[2-(4-Methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-pyridin-2-yl-propyl}-propionamide dihydrochloride	537.528	98% (LC/MS)
337		2-Methoxy-N-{3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-pyridin-2-yl-propyl}-acetamide dihydrochloride	553.527	98% (LC/MS)
338		Cyclopropanecarboxylic acid {3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-pyridin-2-yl-propyl}-amide dihydrochloride	597.604	98% (LC/MS)
339		N-{3-[2-(4-Methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-pyridin-2-yl-propyl}-isobutyramide dihydrochloride	599.62	98% (LC/MS)
340		Cyclobutanecarboxylic acid {3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-pyridin-2-yl-propyl}-amide dihydrochloride	611.631	98% (LC/MS)








341		Cyclopropanecarboxylic acid {3-[2-(4-bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-pyridin-2-yl-propyl}-amide dihydrochloride	598.409	98% (LC/MS)
342		N-{3-[2-(4-Bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-pyridin-2-yl-propyl}-isobutyramide dihydrochloride	600.425	98% (LC/MS)
343		Cyclobutanecarboxylic acid {3-[2-(4-bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-pyridin-2-yl-propyl}-amide dihydrochloride	612.436	98% (LC/MS)
344		Cyclopentanecarboxylic acid {3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-pyridin-2-yl-propyl}-amide dihydrochloride	625.658	98% (LC/MS)
345		N-{3-[2-(4-Methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-pyridin-2-yl-propyl}-propionamide dihydrochloride	585.593	95.2% (LC/MS)
346		N-((S)-3-[2-(4-Methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-nicotinamide	560.715	91% (HPLC)

347		(R)-Tetrahydro-furan-2-carboxylic acid {(S)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide	553.72	99% (HPLC)
348		(S)-Tetrahydro-furan-2-carboxylic acid {(S)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide	553.72	99% (HPLC)
349		Tetrahydro-furan-3-carboxylic acid {(S)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide	553.72	99% (HPLC)
350		(R)-N-((S)-3-[2-(4-Methanesulfonyl-benzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl)-2-phenyl-propionamide	587.781	84% (HPLC)
351		3-Oxo-cyclopentanecarboxylic acid {(S)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide	565.731	84% (HPLC)
352		(S)-N-((S)-3-[2-(4-Methanesulfonyl-benzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl)-2-phenyl-propionamide	587.781	86% (HPLC)








353		(R)-N-[(S)-3-(1-Oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-2-phenyl-propionamide	510.678	97% (HPLC)
354		(S)-N-[(S)-3-(1-Oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-2-phenyl-propionamide	510.678	99% (HPLC)
355		(R)-Tetrahydro-furan-2-carboxylic acid [(S)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-amide	476.617	97% (HPLC)
356		(S)-Tetrahydro-furan-2-carboxylic acid [(S)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-amide	476.617	99% (HPLC)
357		Tetrahydro-furan-3-carboxylic acid [(S)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-amide	476.617	98% (HPLC)
358		3-Oxo-cyclopentanecarboxylic acid [(S)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-amide	488.628	96% (HPLC)








359		N-[(S)-3-(1-Oxo-2-pyridin-2-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-isobutyramide	448.607	97% (HPLC)
360		N-[(S)-3-(1-Oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-isobutyramide	448.607	99% (HPLC)
361		N-[(S)-3-(1-Oxo-2-pyridin-4-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-isobutyramide	448.607	98% (HPLC)
362		N-[(S)-3-[1-Oxo-2-(1-oxy-pyridin-4-ylmethyl)-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl]-isobutyramide	464.606	90% (HPLC)
363		N-[(S)-3-[1-Oxo-2-(1-oxy-pyridin-2-ylmethyl)-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl]-isobutyramide	464.606	98% (HPLC)
364		N-[(S)-3-[1-Oxo-2-(1-oxy-pyridin-3-ylmethyl)-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl]-isobutyramide	464.606	99% (HPLC)








365		1-Methyl-cyclopentanecarboxylic acid ((S)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide	565.775	100% (LC/MS)
366		1-Methyl-cyclohexanecarboxylic acid ((S)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide	579.802	>80% (LC/MS)
367		2-Cyclopentyl-N-((S)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl)-propionamide	579.802	100% (LC/MS)
368		2-Cyclopentyl-N-((S)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl)-propionamide	579.802	100% (LC/MS)
369		1-Methyl-cyclopentanecarboxylic acid [(S)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diazaspiro[4.5]dec-8-yl)-1-phenyl-propyl]-amide	488.672	100% (LC/MS)
370		1-Methyl-cyclohexanecarboxylic acid [(S)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diazaspiro[4.5]dec-8-yl)-1-phenyl-propyl]-amide	502.699	100% (LC/MS)
371		2-Cyclopentyl-N-[(S)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diazaspiro[4.5]dec-8-yl)-1-phenyl-propyl]-propionamide	502.699	100% (LC/MS)

372		2-Cyclopentyl-N-[(S)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diazaspiro[4.5]dec-8-yl)-1-phenylpropyl]-propionamide	502.699	100% (LC/MS)
373		Cyclopropanecarboxylic acid [3-[2-(4-bromo-benzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-(2-methoxy-phenyl)-propyl]-amide hydrochloride	590.986	98% (LC/MS)
374		N-[3-[2-(4-Bromo-benzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-(2-methoxy-phenyl)-propyl]-isobutyramide hydrochloride	593.002	98% (LC/MS)
375		Cyclobutanecarboxylic acid [3-[2-(4-bromo-benzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-(2-methoxy-phenyl)-propyl]-amide hydrochloride	605.013	98% (LC/MS)
376		Tetrahydro-pyran-2-carboxylic acid {(S)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenylpropyl}-amide	567.747	99% (HPLC)
377		N-[3-[2-(4-Methoxy-benzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl]-2,2-dimethyl-propionamide hydrochloride	534.161	98% (LC/MS)
378		N-[3-[2-(4-Methanesulfonyl-benzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl]-2,2-dimethyl-propionamide hydrochloride	582.226	98% (LC/MS)








379		N-{1-(3-Chloro-phenyl)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-2,2-dimethyl-propionamide hydrochloride	562.578	93.9% (LC/MS)
380		N-{1-(3-Chloro-phenyl)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-2,2-dimethyl-propionamide hydrochloride	610.643	98% (LC/MS)
381		N-[1-(3-Chloro-phenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-propyl]-2,2-dimethyl-propionamide dihydrochloride	570.001	98% (LC/MS)
382		N-{1-(2-Chloro-phenyl)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-2,2-dimethyl-propionamide hydrochloride	610.643	98% (LC/MS)
383		N-{1-(4-Chloro-phenyl)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-2,2-dimethyl-propionamide hydrochloride	610.643	98% (LC/MS)
384		1-Methyl-cyclopropanecarboxylic acid {3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl}-amide hydrochloride	532.145	98% (LC/MS)
385		1-Methyl-cyclopropanecarboxylic acid {3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl}-amide hydrochloride	580.21	98% (LC/MS)

386		1-Methyl-cyclopropanecarboxylic acid [3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-thiophen-2-yl-propyl]-amide dihydrochloride	539.568	98% (LC/MS)
387		1-Methyl-cyclopropanecarboxylic acid {1-(3-chloro-phenyl)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-amide hydrochloride	560.562	92.4% (LC/MS)
388		1-Methyl-cyclopropanecarboxylic acid {1-(3-chloro-phenyl)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-amide hydrochloride	608.627	98% (LC/MS)
389		1-Methyl-cyclopropanecarboxylic acid [1-(3-chloro-phenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-propyl]-amide dihydrochloride	567.985	92.5% (LC/MS)
390		1-Methyl-cyclopropanecarboxylic acid {1-(2-chloro-phenyl)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-amide hydrochloride	608.627	98% (LC/MS)
391		1-Methyl-cyclopropanecarboxylic acid {1-(4-chloro-phenyl)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-amide hydrochloride	608.627	98% (LC/MS)
392		Tetrahydro-pyran-2-carboxylic acid [(S)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-amide	490.644	94% (HPLC)








393		Cyclopentanecarboxylic acid [3-[2-(4-bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(2-methoxy-phenyl)-propyl]-amide hydrochloride	619.04	98% (LC/MS)
394		N-[3-[2-(4-Bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(2-methoxy-phenyl)-propyl]-propionamide hydrochloride	578.975	98% (LC/MS)
395		N-[3-[2-(4-Bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(2-methoxy-phenyl)-propyl]-2-methoxy-acetamide hydrochloride	594.974	98% (LC/MS)
396		N-[3-[2-(4-Bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(2-methoxy-phenyl)-propyl]-2-cyclopropyl-acetamide hydrochloride	605.013	98% (LC/MS)
397		Cyclohexanecarboxylic acid [3-[2-(4-bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(2-methoxy-phenyl)-propyl]-amide hydrochloride	633.067	98% (LC/MS)
398		Cyclopropanecarboxylic acid [3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(2-methoxy-phenyl)-propyl]-amide hydrochloride	542.116	98% (LC/MS)
399		N-[3-[2-(4-Methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(2-methoxy-phenyl)-propyl]-isobutyramide hydrochloride	544.132	98% (LC/MS)








400		Cyclobutanecarboxylic acid [3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(2-methoxy-phenyl)-propyl]-amide hydrochloride	556.143	98% (LC/MS)
401		Cyclopentanecarboxylic acid [3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(2-methoxy-phenyl)-propyl]-amide hydrochloride	570.17	98% (LC/MS)
402		N-[3-[2-(4-Methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(2-methoxy-phenyl)-propyl]-propionamide hydrochloride	530.105	98% (LC/MS)
403		2-Methoxy-N-[3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(2-methoxy-phenyl)-propyl]-acetamide hydrochloride	546.104	98% (LC/MS)
404		2-Cyclopropyl-N-[3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(2-methoxy-phenyl)-propyl]-acetamide hydrochloride	556.143	98% (LC/MS)
405		Cyclohexanecarboxylic acid [3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(2-methoxy-phenyl)-propyl]-amide hydrochloride	584.196	98% (LC/MS)
406		Cyclopropanecarboxylic acid [3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(2-methoxy-phenyl)-propyl]-amide hydrochloride	590.181	98% (LC/MS)








414		N-[3-[2-(4-Bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(4-methoxy-phenyl)-propyl]-isobutyramide hydrochloride	593.002	98% (LC/MS)
415		Cyclobutanecarboxylic acid [3-[2-(4-bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(4-methoxy-phenyl)-propyl]-amide hydrochloride	605.013	98% (LC/MS)
416		Cyclopentanecarboxylic acid [3-[2-(4-bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(4-methoxy-phenyl)-propyl]-amide hydrochloride	619.04	98% (LC/MS)
417		N-[3-[2-(4-Bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(4-methoxy-phenyl)-propyl]-propionamide hydrochloride	578.975	98% (LC/MS)
418		N-[3-[2-(4-Bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(4-methoxy-phenyl)-propyl]-2-methoxy-acetamide hydrochloride	594.974	98% (LC/MS)
419		Cyclopropanecarboxylic acid [3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(4-methoxy-phenyl)-propyl]-amide hydrochloride	542.116	98% (LC/MS)
420		N-[3-[2-(4-Methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(4-methoxy-phenyl)-propyl]-isobutyramide hydrochloride	544.132	98% (LC/MS)








421		Cyclobutanecarboxylic acid [3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(4-methoxy-phenyl)-propyl]-amide hydrochloride	556.143	98% (LC/MS)
422		Cyclopentanecarboxylic acid [3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(4-methoxy-phenyl)-propyl]-amide hydrochloride	570.17	98% (LC/MS)
423		N-[3-[2-(4-Methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(4-methoxy-phenyl)-propyl]-propionamide hydrochloride	530.105	98% (LC/MS)
424		Cyclohexanecarboxylic acid [3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(2-methoxy-phenyl)-propyl]-amide hydrochloride	632.261	98% (LC/MS)
425		Cyclopentanecarboxylic acid [1-(3-methoxy-phenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-propyl]-amide dihydrochloride	577.593	98% (LC/MS)
426		N-[1-(3-Methoxy-phenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-propyl]-propionamide dihydrochloride	537.528	98% (LC/MS)
427		2-Methoxy-N-[1-(3-methoxy-phenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-propyl]-acetamide dihydrochloride	553.527	98% (LC/MS)








428		3-Hydroxy-cyclopentanecarboxylic acid ((S)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide	567.747	90% (HPLC)
429		3-Hydroxy-cyclopentanecarboxylic acid [(S)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diazaspiro[4.5]dec-8-yl)-1-phenyl-propyl]-amide	490.644	97% (HPLC)
430		Cyclopropanecarboxylic acid {1-(2-chloro-phenyl)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-propyl}-amide hydrochloride	546.535	98% (LC/MS)
431		N-{1-(2-Chloro-phenyl)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-propyl}-isobutyramide hydrochloride	548.551	98% (LC/MS)
432		Cyclobutanecarboxylic acid {1-(2-chloro-phenyl)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-propyl}-amide hydrochloride	560.562	98% (LC/MS)
433		Cyclopentanecarboxylic acid {1-(2-chloro-phenyl)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-propyl}-amide hydrochloride	574.589	98% (LC/MS)
434		N-{1-(2-Chloro-phenyl)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-propyl}-propionamide hydrochloride	534.524	98% (LC/MS)








435		N-(1-(2-Chloro-phenyl)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl)-2-methoxy-acetamide hydrochloride	550.523	98% (LC/MS)
436		Cyclohexanecarboxylic acid {1-(2-chloro-phenyl)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-amide hydrochloride	588.616	98% (LC/MS)
437		Cyclopropanecarboxylic acid {1-(2-chloro-phenyl)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-amide hydrochloride	594.6	98% (LC/MS)
438		N-(1-(2-Chloro-phenyl)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl)-isobutyramide hydrochloride	596.616	98% (LC/MS)
439		Cyclobutanecarboxylic acid {1-(2-chloro-phenyl)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-amide hydrochloride	608.627	98% (LC/MS)
440		Cyclopentanecarboxylic acid {1-(2-chloro-phenyl)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-amide hydrochloride	622.654	98% (LC/MS)
441		N-(1-(2-Chloro-phenyl)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl)-propionamide hydrochloride	582.589	98% (LC/MS)








442		N-[1-(2-Chloro-phenyl)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl]-2-methoxy-acetamide hydrochloride	598.588	98% (LC/MS)
443		Cyclohexanecarboxylic acid [1-(2-chloro-phenyl)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl]-amide hydrochloride	636.681	98% (LC/MS)
444		Cyclopropanecarboxylic acid [1-(2-chloro-phenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-propyl]-amide dihydrochloride	553.958	98% (LC/MS)
445		N-[1-(2-Chloro-phenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-propyl]-isobutyramide dihydrochloride	555.974	98% (LC/MS)
446		Cyclobutanecarboxylic acid [1-(2-chloro-phenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-propyl]-amide dihydrochloride	567.985	98% (LC/MS)
447		Cyclopentanecarboxylic acid [1-(2-chloro-phenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-propyl]-amide dihydrochloride	582.012	98% (LC/MS)
448		N-[1-(2-Chloro-phenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-propyl]-propionamide dihydrochloride	541.948	98% (LC/MS)








449		N-[1-(2-Chloro-phenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-propyl]-2-methoxy-acetamide dihydrochloride	557.946	93.6% (LC/MS)
450		Cyclohexanecarboxylic acid [1-(2-chloro-phenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-propyl]-amide dihydrochloride	596.039	98+ (LC/MS)
451		Cyclopropanecarboxylic acid {1-(4-chloro-phenyl)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-amide hydrochloride	546.535	98% (LC/MS)
452		N-{1-(4-Chloro-phenyl)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-isobutyramide hydrochloride	548.551	98% (LC/MS)
453		Cyclobutanecarboxylic acid {1-(4-chloro-phenyl)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-amide hydrochloride	560.562	98% (LC/MS)
454		Cyclopentanecarboxylic acid {1-(4-chloro-phenyl)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-amide hydrochloride	574.589	98% (LC/MS)
455		N-{1-(4-Chloro-phenyl)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-propionamide hydrochloride	534.524	98% (LC/MS)








456		N-{1-(4-Chloro-phenyl)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-2-methoxy-acetamide hydrochloride	550.523	98% (LC/MS)
457		Cyclohexanecarboxylic acid {1-(4-chloro-phenyl)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-amide hydrochloride	588.616	98% (LC/MS)
458		N-{1-(4-Chloro-phenyl)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-propionamide hydrochloride	582.589	98% (LC/MS)
459		N-{1-(4-Chloro-phenyl)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-2-methoxy-acetamide hydrochloride	598.588	98% (LC/MS)
460		Cyclohexanecarboxylic acid {1-(4-chloro-phenyl)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-amide hydrochloride	636.681	98% (LC/MS)
461		Cyclopropanecarboxylic acid [1-(4-chloro-phenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-propyl]-amide dihydrochloride	553.958	98% (LC/MS)
462		N-[1-(4-Chloro-phenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-propyl]-isobutyramide dihydrochloride	555.974	98% (LC/MS)








463		Cyclobutanecarboxylic acid [1-(4-chloro-phenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-propyl]-amide dihydrochloride	567.985	98% (LC/MS)
464		Cyclopentanecarboxylic acid [1-(4-chloro-phenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-propyl]-amide dihydrochloride	582.012	95% (LC/MS)
465		N-[1-(4-Chloro-phenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-propyl]-propionamide dihydrochloride	541.948	93.5% (LC/MS)
466		N-[1-(4-Chloro-phenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-propyl]-2-methoxy-acetamide dihydrochloride	557.946	98% (LC/MS)
467		Cyclohexanecarboxylic acid [1-(4-chloro-phenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-propyl]-amide dihydrochloride	596.039	94.4% (LC/MS)
468		Cyclopropanecarboxylic acid [3-[2-(4-bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(2-chloro-phenyl)-propyl]-amide hydrochloride	595.406	98% (LC/MS)
469		Cyclopropanecarboxylic acid [3-[2-(4-bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(4-chloro-phenyl)-propyl]-amide hydrochloride	595.406	98% (LC/MS)








470		Cyclopropanecarboxylic acid {1-(3,4-dichloro-phenyl)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-amide hydrochloride	580.98	98% (LC/MS)
471		Cyclopropanecarboxylic acid {1-(3,4-dichloro-phenyl)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-amide hydrochloride	629.045	98% (LC/MS)
472		Cyclopropanecarboxylic acid [1-(3,4-dichloro-phenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-propyl]-amide dihydrochloride	588.404	98% (LC/MS)
473		Cyclopentanecarboxylic acid [3-[2-(4-bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(2-chloro-phenyl)-propyl]-amide hydrochloride	623.459	98% (LC/MS)
474		Cyclopentanecarboxylic acid [3-[2-(4-bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(4-chloro-phenyl)-propyl]-amide hydrochloride	623.459	98% (LC/MS)
475		Cyclopentanecarboxylic acid ((S)-3-[2-(4-fluoro-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide hydrochloride	528.108	98% (LC/MS)
476		Cyclopentanecarboxylic acid ((S)-3-[2-(4-chloro-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide hydrochloride	544.563	98% (LC/MS)








477		Cyclopentanecarboxylic acid ((S)-3-[2-(4-cyano-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide hydrochloride	535.128	98% (LC/MS)
478		Cyclopentanecarboxylic acid ((S)-3-[2-(4-difluoromethoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide hydrochloride	576.124	98% (LC/MS)
479		Cyclopentanecarboxylic acid ((S)-3-[1-oxo-2-(4-trifluoromethoxy-benzyl)-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide hydrochloride	594.114	98% (LC/MS)
480		Cyclopentanecarboxylic acid ((S)-3-[2-(4-methylsulfanyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide hydrochloride	556.211	98% (LC/MS)
481		Cyclopentanecarboxylic acid ((S)-3-[1-oxo-2-(4-pyrazol-1-yl-benzyl)-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide hydrochloride	576.181	98% (LC/MS)
482		Cyclopentanecarboxylic acid ((S)-3-(2-isobutyl-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl)-amide hydrochloride	476.101	95% (LC/MS)
483		Cyclopentanecarboxylic acid ((S)-3-[2-(4-methanesulfonyl-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide hydrochloride	588.209	98% (LC/MS)








484		Cyclopentanecarboxylic acid ((S)-3-[2-(4-methoxy-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide hydrochloride	540.144	98% (LC/MS)
485		Cyclopropanecarboxylic acid ((S)-3-[2-(4-fluoro-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide hydrochloride	500.055	98% (LC/MS)
486		Cyclopropanecarboxylic acid ((S)-3-[2-(4-chloro-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide hydrochloride	516.51	98% (LC/MS)
487		Cyclopropanecarboxylic acid ((S)-3-[2-(4-cyano-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide hydrochloride	507.074	98% (LC/MS)
488		Cyclopropanecarboxylic acid ((S)-3-[2-(4-difluoromethoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide hydrochloride	548.07	98% (LC/MS)
489		Cyclopropanecarboxylic acid ((S)-3-[1-oxo-2-(4-pyrazol-1-yl-benzyl)-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide hydrochloride	548.127	98% (LC/MS)
490		Cyclopropanecarboxylic acid ((S)-3-(2-cyclohexylmethyl-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl)-amide hydrochloride	488.112	99% (LC/MS)








491		Cyclopropanecarboxylic acid ((S)-3-(2-isobutyl-1-oxo-2,8-diazaspiro[4.5]dec-8-yl)-1-phenyl-propyl)-amide hydrochloride	448.047	98% (LC/MS)
492		Cyclopropanecarboxylic acid ((S)-3-[2-(4-methanesulfonyl-benzyl)-3-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide hydrochloride	560.155	98% (LC/MS)
493		Cyclopropanecarboxylic acid ((S)-3-[2-(4-methoxy-benzyl)-3-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide hydrochloride	512.09	98% (LC/MS)
494		N-((S)-3-(2-Benzyl-1-oxo-2,8-diazaspiro[4.5]dec-8-yl)-1-phenyl-propyl)-isobutyramide hydrochloride	484.08	95% (LC/MS)
495		N-((S)-3-[2-(4-Fluoro-benzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl)-isobutyramide hydrochloride	502.07	90% (LC/MS)
496		Cyclopropanecarboxylic acid ((S)-3-[1-oxo-2-(4-trifluoromethoxy-benzyl)-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide hydrochloride	566.06	98% (LC/MS)
497		Cyclopropanecarboxylic acid ((S)-3-[2-(4-methylsulfanyl-benzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide hydrochloride	528.157	98% (LC/MS)




498		Chiral N-((S)-3-[2-(4-Chloro-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-isobutyramide hydrochloride	518.525	95% (LC/MS)
499		Chiral N-((S)-3-[2-(4-Cyano-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-isobutyramide hydrochloride	509.09	98% (LC/MS)
500		Chiral N-((S)-3-[2-(4-Difluoromethoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-isobutyramide hydrochloride	550.086	90% (LC/MS)
501		Chiral N-((S)-3-[1-Oxo-2-(4-trifluoromethoxy-benzyl)-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-isobutyramide hydrochloride	568.076	91.3% (LC/MS)
502		Chiral N-((S)-3-[2-(4-Methylsulfanyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-isobutyramide hydrochloride	530.173	90% (LC/MS)
503		Chiral N-((S)-3-[2-(4-Methoxy-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-isobutyramide hydrochloride	514.106	95% (LC/MS)
504		Chiral 2-Methoxy-cyclopent-1-enecarboxylic acid ((S)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide	579.758	87% (HPLC)


505		2-Methoxy-cyclopent-1-enecarboxylic acid [(S)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diazaspiro[4.5]dec-8-yl)-1-phenyl-propyl]-amide	502.655	84% (HPLC)
506		Cyclopentanecarboxylic acid {1-(3,4-dichloro-phenyl)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-propyl}-amide hydrochloride	609.034	98% (LC/MS)
507		Cyclopentanecarboxylic acid {1-(3,4-dichloro-phenyl)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-propyl}-amide hydrochloride	657.099	98% (LC/MS)
508		Cyclopentanecarboxylic acid [1-(3,4-dichloro-phenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diazaspiro[4.5]dec-8-yl)-propyl]-amide dihydrochloride	616.457	98% (LC/MS)
509		N-[(S)-3-[2-(4-Methoxy-benzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl]-propionamide hydrochloride	500.09	100% (LC/MS)
510		N-[(S)-3-[2-(4-Methoxy-benzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl]-2,2-dimethyl-propionamide hydrochloride	528.14	100% (LC/MS)
511		Thiophene-2-carboxylic acid {(S)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride	554.16	100% (LC/MS)

512		Thiophene-3-carboxylic acid ((S)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide hydrochloride	554.16	100% (LC/MS)
513		(R)-Tetrahydro-furan-2-carboxylic acid ((S)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide hydrochloride	542.12	100% (LC/MS)
514		(S)-Tetrahydro-furan-2-carboxylic acid ((S)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide hydrochloride	542.12	100% (LC/MS)
515		Tetrahydro-furan-3-carboxylic acid ((S)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide hydrochloride	542.12	100% (LC/MS)
516		3-Oxo-cyclopentanecarboxylic acid ((S)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide hydrochloride	554.13	100% (LC/MS)
517		4,4-Difluoro-cyclohexanecarboxylic acid ((S)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide hydrochloride	590.16	100% (LC/MS)
518		Tetrahydro-pyran-4-carboxylic acid ((S)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide hydrochloride	557.14	100% (LC/MS)

519		4,6-Dimethyl-pyrimidine-5-carboxylic acid ((S)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide trihydrochloride	651.08	100% (LC/MS)
520		Adamantane-1-carboxylic acid ((S)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide hydrochloride	606.25	90% (LC/MS)
521		N-((S)-3-[2-(4-Methanesulfonyl-benzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl)-propionamide hydrochloride	548.15	96% (LC/MS)
522		N-((S)-3-[2-(4-Methanesulfonyl-benzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl)-2,2-dimethyl-propionamide hydrochloride	576.2	100% (LC/MS)
523		Thiophene-2-carboxylic acid ((S)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide hydrochloride	602.22	100% (LC/MS)
524		Thiophene-3-carboxylic acid ((S)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide hydrochloride	602.22	100% (LC/MS)
525		4,4-Difluoro-cyclohexanecarboxylic acid ((S)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide hydrochloride	638.22	100% (LC/MS)

526		Tetrahydro-pyran-4-carboxylic acid ((S)-3-[2-(4-methanesulfonyl- benzyl)-1-oxo-2,8-diaza- spiro[4.5]dec-8-yl]-1-phenyl- propyl)-amide hydrochloride	603.82	100% (LC/MS)
527		N-((S)-3-[2-(4-Methanesulfonyl- benzyl)-1-oxo-2,8-diaza- spiro[4.5]dec-8-yl]-1-phenyl- propyl)-nicotinamide dihydrochloride	633.64	100% (LC/MS)
528		Pyrimidine-5-carboxylic acid ((S)-3- [2-(4-methanesulfonyl-benzyl)-1- oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1- phenyl-propyl)-amide trihydrochloride	671.09	100% (LC/MS)
529		4,6-Dimethyl-pyrimidine-5- carboxylic acid ((S)-3-[2-(4- methanesulfonyl-benzyl)-1-oxo- 2,8-diaza-spiro[4.5]dec-8-yl]-1- phenyl-propyl)-amide trihydrochloride	699.14	90% (LC/MS)
530		Adamantane-1-carboxylic acid ((S)-3-[2-(4-methanesulfonyl- benzyl)-1-oxo-2,8-diaza- spiro[4.5]dec-8-yl]-1-phenyl- propyl)-amide hydrochloride	654.32	100% (LC/MS)
531		N-((S)-3-[2-(4-Ethoxy-benzyl)-1- oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1- phenyl-propyl)-isobutyramide hydrochloride	528.14	100% (LC/MS)
532		Cyclopropanecarboxylic acid ((S)- 3-[2-(4-ethoxy-benzyl)-1-oxo-2,8- diaza-spiro[4.5]dec-8-yl]-1-phenyl- propyl)-amide hydrochloride	526.12	100% (LC/MS)


533		4,4-Difluoro-cyclohexanecarboxylic acid ((S)-3-[2-(4-methoxy-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide hydrochloride	590.16	100% (LC/MS)
534		2-Cyclopropyl-N-((S)-3-[2-(4-methanesulfonyl-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-acetamide hydrochloride	574.19	100% (LC/MS)
535		4,4-Difluoro-cyclohexanecarboxylic acid ((S)-3-[2-(4-methanesulfonyl-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide hydrochloride	638.22	100% (LC/MS)



5 Scheme 5.

Example 9. N-(3-[2-(4-Bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenylpropyl)-

10 **benzenesulfonamide hydrochloride (Compound 536)**



To 83 mg (100 μ mol, loading of 1.2 mmol/g) of benzenesulfonate activated ester on polymeric 4-hydroxy-2,3,5,6-tetrafluorobenzamido (TFP) resin (see preparation in J.M. Salvino et al. *J. Comb. Chem.* **2000**, 2, 691-697), preswollen with 0.5 mL of anhydrous DMF, was added 27.3 mg (60 μ mol) of 8-(3-amino-3-phenylpropyl)-2-(4-bromobenzyl)-2,8-diazaspiro[4.5]decan-1-one diluted in 1 mL of DMF. The reaction was agitated overnight at room temperature.

10 The mixture was filtered and washed with DCM (2 x 2 mL). The filtrates were collected and evaporated in vacuo. The crude was purified by semi-preparative HPLC (method A) yielding 10.6 mg (27.9%) of **Compound 536** as a colorless solid.

15 ^1H NMR (400 MHz, DMSO- d_6): δ [ppm] 9.64 (br s, 1H), 8.44 (d, 1H), 7.53 (m, 4H), 7.44 (t, 1H), 7.35 (m, 2H), 7.12 (m, 7H), 4.33 (m, 3H), 3.35 (m, 2H), 3.16 (t, 3H), 3.05 (m, 1H), 2.9 (m, 2H), 2.08 (m, 1H), 1.95 (m, 4H), 1.82 (m, 1H), 1.56 (br d, 2H).




20 LC/MS: m/z 598.1 (MH^+).

Table 4 of compounds illustrates some of the compounds of the present invention that were synthesized using the procedure described in scheme

25 5.


Table 4.

CPD #	MOLSTRUCTURE	COMPOUND NAME	MOLWT PURITY
-------	--------------	---------------	--------------



5 Scheme 6.

Example 10. 1-(3-[2-(4-Bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenylpropyl)-3-phenyl-urea hydrochloride (Compound 542)



10



To 27.3 mg (60 μ mol) of 8-(3-amino-3-phenylpropyl)-2-(4-bromobenzyl)-2,8-diaza-spiro[4.5]decan-1-one, diluted in 1 mL of anhydrous THF, was added 9.66 mg






(80 μ mol) of phenylisocyanate dissolved in 0.5 mL of anhydrous THF. The reaction mixture was agitated overnight at room temperature and evaporated in vacuo. The crude was purified by semi-preparative HPLC (method C) yielding 18.9 mg (51.5%) of **Compound 542** as a pale yellow solid.






^1H NMR (400 MHz, DMSO- d_6): δ [ppm] 9.45 (br s, 1H), 8.64 (d, 1H), 7.51 (d, 2H), 7.37 (m, 6H), 7.28 (m, 1H), 7.21–7.13 (m, 4H), 6.93 (d, 1H), 6.87 (t x t, 1H), 4.8 (m, 1H), 4.33 (s, 2H), 3.48 (br t, 2H), 3.18–2.94 (m, 5H), 2.15 (m, 2H), 1.96 (m, 4H), 1.83 (m, 1H), 1.6 (br d, 2H).






Table 5 of compounds illustrates some of the compounds of the present invention that were synthesized using the procedure described in scheme 6.






Table 5.






CPD #	MOLSTRUCTURE	COMPOUND NAME	MOLWT	PURITY
539		Piperidine-1-carboxylic acid {3-[2-(4-bromobenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride	604.03	93.5% (LC/MS)
540		Piperidine-1-carboxylic acid {3-[2-(4-methoxybenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride	555.17	94.5% (LC/MS)

541		Piperidine-1-carboxylic acid {3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}amide hydrochloride	603.224	93.3% (LC/MS)
542		1-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-3-phenyl-urea hydrochloride	612.008	98+ (LC/MS)
543		1-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-3-(2-chloro-phenyl)-urea hydrochloride	646.453	94.6% (LC/MS)
544		1-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-3-(2-methoxy-phenyl)-urea hydrochloride	642.034	98+ (LC/MS)
545		1-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-3-(3-chloro-phenyl)-urea hydrochloride	646.453	98+ (LC/MS)

546		1-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-3-(3-methoxy-phenyl)-urea hydrochloride	642.034	98+ (LC/MS)
547		1-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-3-(4-chloro-phenyl)-urea hydrochloride	646.453	98+ (LC/MS)
548		1-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-3-(4-methoxy-phenyl)-urea hydrochloride	642.034	98+ (LC/MS)
549		1-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-3-(2,6-dimethyl-phenyl)-urea hydrochloride	640.062	98+ (LC/MS)
550		1-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-3-naphthalen-1-yl-urea hydrochloride	662.068	98+ (LC/MS)

551		1-{3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-3-phenyl-urea hydrochloride	563.138	98+ (LC/MS)
552		1-(2-chlorophenyl)-3-{3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-urea hydrochloride	597.583	95+ (LC/MS)
553		1-{3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-3-(2-methoxyphenyl)-urea hydrochloride	593.164	98+ (LC/MS)
554		1-(3-chlorophenyl)-3-{3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-urea hydrochloride	597.583	98+ (LC/MS)
555		1-{3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-3-(3-methoxyphenyl)-urea hydrochloride	593.164	98+ (LC/MS)

556		-{3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-3-(4-methoxyphenyl)-urea hydrochloride	593.164	98+ (LC/MS)
557		1-(2,6-dimethylphenyl)-3-{3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-urea hydrochloride	591.192	98+ (LC/MS)
558		1-{3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-3-naphthalen-1-yl-urea hydrochloride	613.198	98+ (LC/MS)
559		1-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-3-phenyl-urea hydrochloride	611.203	98+ (LC/MS)
560		1-(2-chlorophenyl)-3-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-urea hydrochloride	645.648	98+ (LC/MS)

561		1-{3-[2-(4-methanesulfonylbenzyl)-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-3-(2-methoxyphenyl)-urea hydrochloride	641.229	98+ (LC/MS)
562		1-(3-chlorophenyl)-3-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-urea hydrochloride	645.648	98+ (LC/MS)
563		1-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-3-(3-methoxyphenyl)-urea hydrochloride	641.229	98+ (LC/MS)
564		1-(4-chlorophenyl)-3-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-urea hydrochloride	645.648	98+ (LC/MS)
565		1-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-3-(4-methoxyphenyl)-urea hydrochloride	641.229	98+ (LC/MS)







566		1-(2,6-dimethylphenyl)-3-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-urea hydrochloride	639.257	98+ (LC/MS)
567		1-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-3-naphthalen-1-yl-urea hydrochloride	661.263	98+ (LC/MS)

Table 5a of compounds illustrates some additional compounds of the present invention that were synthesized using the procedure described in scheme

5 6.


Table 5a.

CPD #	MOLSTRUCTURE	COMPOUND NAME	MOLWT	PURITY
568		Morpholine-4-carboxylic acid {(S)-3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride	557.14	100% (LC/MS)
569		Morpholine-4-carboxylic acid {(S)-3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide hydrochloride	605.2	90% (LC/MS)



5 Scheme 7.

Example 11. {3-[2-(4-Methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenylpropyl}-carbamic acid methyl ester hydrochloride (Compound 572)



To a stirred solution of 8-(3-amino-3-phenylpropyl)-2-(4-methanesulfonylbenzyl)-2,8-diaza-spiro[4.5]decan-1-one (27.3 mg, 0.06 mmol) in DMF-15 DCE (1:1, 1.0 mL) was sequentially added triethylamine (0.01 mL, 0.072 mmol) and dimethyldicarbonate (0.07 mL, 0.066 mmol). The

reaction mixture was stirred overnight at room temperature, concentrated and purified by semi-preparative HPLC (method D) affording **Compound 572** (17.2 mg, 52%) as a white powder.

- 5 ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ [ppm] 9.62 (br s, 1H), 7.88 (d, 2H), 7.44 (d, 2H), 7.33 (m, 4H), 7.25 (m, 1H), 4.59 (m, 1H), 4.47 (s, 2H), 3.50 (s, 3H), 3.42 (m, 2H), 3.22 (t, 2H), 3.19 (s, 3H), 3.09–2.91 (m, 4H), 2.12–1.95 (m, 6H), 1.86 (t, 1H), 1.64 (br d, 2H).
- 10 LC/MS: m/z 513.6 (MH^+).

Table 6 of compounds illustrates some of the compounds of the present invention that were synthesized using the procedure described in scheme 7.

20 Table 6.















CPD #	MOLSTRUCTURE	COMPOUND NAME	MOLWT	PURITY
572		{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-carbamic acid methyl ester hydrochloride	550.116	98+ (LC/MS)
573		{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-carbamic acid ethyl ester hydrochloride	564.143	98+ (LC/MS)








Table 6a of compounds illustrates some additional compounds of the present invention that were synthesized using the procedure described in scheme 7.

5

Table 6a.








CPD #	MOLSTRUCTURE	COMPOUND NAME	MOLWT	PURITY
574		{3-[2-(4-Methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-pyridin-2-yl-propyl}-carbamic acid cyclohexyl ester	582.77	83% (LC/MS)
575		Chiral {(S)-3-[2-(4-Methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-carbamic acid cyclohexyl ester	581.78	99% (LC/MS)
576		Chiral {(S)-3-[2-(4-Methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-carbamic acid cyclobutyl ester	553.73	99% (LC/MS)
577		Chiral {(S)-3-[2-(4-Methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-carbamic acid cyclopentyl ester	567.75	99% (LC/MS)
578		Chiral {(S)-3-(1-Oxo-2-pyridin-2-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl}-carbamic acid cyclobutyl ester	476.62	98% (LC/MS)








579		[(S)-3-(1-Oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-carbamic acid cyclopentyl ester	490.65	99% (LC/MS)
580		[(S)-3-(1-Oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-carbamic acid 1-methyl-cyclopentyl ester	504.68	97% (LC/MS)
581		[(S)-3-(1-Oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-carbamic acid cyclohexyl ester	504.68	100% (LC/MS)
582		{3-[2-(4-Bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl}-carbamic acid ethyl ester hydrochloride	570.98	98+ (LC/MS)
583		{3-[2-(4-Methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl}-carbamic acid ethyl ester hydrochloride	522.11	98+ (LC/MS)
584		[3-(1-Oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-thiophen-2-yl-propyl]-carbamic acid ethyl ester dihydrochloride	529.53	98+ (LC/MS)
585		{1-(2-Chloro-phenyl)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-carbamic acid ethyl ester hydrochloride	550.52	98+ (LC/MS)








586		{1-(2-Chloro-phenyl)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-carbamic acid ethyl ester hydrochloride	598.59	98+ (LC/MS)
587		[1-(2-Chloro-phenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-propyl]-carbamic acid ethyl ester dihydrochloride	557.95	98+ (LC/MS)
588		[3-[2-(4-Bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(3-chloro-phenyl)-propyl]-carbamic acid ethyl ester hydrochloride	599.4	98+ (LC/MS)
589		{1-(3-Chloro-phenyl)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-carbamic acid ethyl ester hydrochloride	550.52	98+ (LC/MS)
590		{1-(3-Chloro-phenyl)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-carbamic acid ethyl ester hydrochloride	598.59	98+ (LC/MS)
591		[1-(3-Chloro-phenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-propyl]-carbamic acid ethyl ester dihydrochloride	557.95	98+ (LC/MS)
592		{1-(4-Chloro-phenyl)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-carbamic acid ethyl ester hydrochloride	550.52	98+ (LC/MS)








593		[1-(4-Chloro-phenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-propyl]-carbamic acid ethyl ester dihydrochloride	557.95	98+ (LC/MS)
594		{3-[2-(4-Bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl}-carbamic acid methyl ester hydrochloride	556.95	98+ (LC/MS)
595		{3-[2-(4-Methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl}-carbamic acid methyl ester hydrochloride	508.08	98+ (LC/MS)
596		{3-[2-(4-Methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl}-carbamic acid methyl ester hydrochloride	556.14	98+ (LC/MS)
597		[3-(1-Oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-thiophen-2-yl-propyl]-carbamic acid methyl ester dihydrochloride	515.5	98+ (LC/MS)
598		{1-(2-Chloro-phenyl)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-carbamic acid methyl ester hydrochloride	536.5	98+ (LC/MS)
599		{1-(2-Chloro-phenyl)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-carbamic acid methyl ester hydrochloride	584.56	98+ (LC/MS)

600		[1-(2-Chloro-phenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-propyl]-carbamic acid methyl ester dihydrochloride	543.92	98+ (LC/MS)
601		[3-[2-(4-Bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(3-chloro-phenyl)-propyl]-carbamic acid methyl ester hydrochloride	585.37	98+ (LC/MS)
602		{1-(3-Chloro-phenyl)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-carbamic acid methyl ester hydrochloride	536.5	98+ (LC/MS)
603		{3-[2-(4-Bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-pyridin-2-yl-propyl}-carbamic acid ethyl ester hydrochloride	602.41	98% (LC/MS)
604		{3-[2-(4-Methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-pyridin-2-yl-propyl}-carbamic acid ethyl ester dihydrochloride	553.53	98% (LC/MS)
605		[3-[2-(4-Bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(4-methoxy-phenyl)-propyl]-carbamic acid ethyl ester hydrochloride	594.99	98% (LC/MS)
606		[3-[2-(4-Methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(4-methoxy-phenyl)-propyl]-carbamic acid ethyl ester hydrochloride	546.11	98% (LC/MS)


607		[3-[2-(4-Methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(4-methoxy-phenyl)-propyl]-carbamic acid ethyl ester hydrochloride	594.17	98% (LC/MS)
608		[1-(4-Methoxy-phenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-propyl]-carbamic acid ethyl ester dihydrochloride	553.53	98% (LC/MS)
609		[3-[2-(4-Bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(3,4-dimethoxy-phenyl)-propyl]-carbamic acid ethyl ester hydrochloride	625.01	98% (LC/MS)
610		{1-(3,4-Dimethoxy-phenyl)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-carbamic acid ethyl ester hydrochloride	576.14	98% (LC/MS)
611		{1-(3,4-Dimethoxy-phenyl)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-carbamic acid ethyl ester hydrochloride	624.2	98% (LC/MS)
612		[1-(3,4-Dimethoxy-phenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-propyl]-carbamic acid ethyl ester dihydrochloride	583.56	98% (LC/MS)
613		[3-[2-(4-Bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(3-methoxy-phenyl)-propyl]-carbamic acid ethyl ester hydrochloride	594.99	98% (LC/MS)

614		[3-[2-(4-Methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(3-methoxy-phenyl)-propyl]-carbamic acid ethyl ester hydrochloride	546.11	98% (LC/MS)
615		[3-[2-(4-Methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(3-methoxy-phenyl)-propyl]-carbamic acid ethyl ester hydrochloride	594.17	98% (LC/MS)
616		[1-(3-Methoxy-phenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-propyl]-carbamic acid ethyl ester dihydrochloride	553.53	98% (LC/MS)
617		[3-[2-(4-Bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(4-methoxy-phenyl)-propyl]-carbamic acid methyl ester hydrochloride	580.96	98% (LC/MS)
618		[3-[2-(4-Methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(4-methoxy-phenyl)-propyl]-carbamic acid methyl ester hydrochloride	532.08	98% (LC/MS)
619		[3-[2-(4-Methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(4-methoxy-phenyl)-propyl]-carbamic acid methyl ester hydrochloride	580.15	98% (LC/MS)
620		[3-[2-(4-Bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(3,4-dimethoxy-phenyl)-propyl]-carbamic acid methyl ester hydrochloride	610.99	98% (LC/MS)

621		{1-(3,4-Dimethoxy-phenyl)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-carbamic acid methyl ester hydrochloride	562.11	98% (LC/MS)
622		{1-(3,4-Dimethoxy-phenyl)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-carbamic acid methyl ester hydrochloride	610.17	98% (LC/MS)
623		[1-(3,4-Dimethoxy-phenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-propyl]-carbamic acid methyl ester dihydrochloride	569.53	98% (LC/MS)
624		[3-[2-(4-Bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(3-methoxy-phenyl)-propyl]-carbamic acid methyl ester hydrochloride	580.96	98% (LC/MS)
625		[3-[2-(4-Methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(3-methoxy-phenyl)-propyl]-carbamic acid methyl ester hydrochloride	532.08	98% (LC/MS)
626		[3-[2-(4-Methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(3-methoxy-phenyl)-propyl]-carbamic acid methyl ester hydrochloride	580.15	98% (LC/MS)
627		[1-(3-Methoxy-phenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-propyl]-carbamic acid methyl ester dihydrochloride	539.51	98% (LC/MS)

628		{1-(3-Chloro-phenyl)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-carbamic acid methyl ester hydrochloride	584.56	98+ (LC/MS)
629		[1-(3-Chloro-phenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-propyl]-carbamic acid methyl ester dihydrochloride	543.92	98+ (LC/MS)
630		{1-(4-Chloro-phenyl)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-carbamic acid methyl ester hydrochloride	536.5	98+ (LC/MS)
631		{1-(4-Chloro-phenyl)-3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-carbamic acid methyl ester hydrochloride	584.56	98+ (LC/MS)
632		[1-(4-Chloro-phenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-propyl]-carbamic acid methyl ester dihydrochloride	543.92	98+ (LC/MS)
633		[3-[2-(4-Bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(2-methoxy-phenyl)-propyl]-carbamic acid methyl ester hydrochloride	580.96	98+ (LC/MS)
634		[3-[2-(4-Bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(2-methoxy-phenyl)-propyl]-carbamic acid ethyl ester hydrochloride	594.99	98+ (LC/MS)


635		[3-[2-(4-Methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(2-methoxy-phenyl)-propyl]-carbamic acid methyl ester hydrochloride	532.08	98+ (LC/MS)
636		[3-[2-(4-Methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(2-methoxy-phenyl)-propyl]-carbamic acid ethyl ester hydrochloride	546.11	98+ (LC/MS)
637		[3-[2-(4-Methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(2-methoxy-phenyl)-propyl]-carbamic acid methyl ester hydrochloride	580.15	98+ (LC/MS)
638		[3-[2-(4-Methanesulfonyl-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(2-methoxy-phenyl)-propyl]-carbamic acid ethyl ester hydrochloride	594.17	98+ (LC/MS)



Scheme 8.

Preparation 10

8-(3,3-Diphenylpropyl)-2,8-diaza-spiro[4.5]decan-1-one
5 one




To a mixture of 1.49 g (7.8 mmol) of 2,8-diaza-spiro[4.5]decan-1-one hydrochloride, 2.39 g (8.6 mmol) of 3,3-diphenylpropyl bromide and 3.23 g (23.4
10 mmol) of potassium carbonate was added 40 mL of anhydrous DMF. The reaction mixture was stirred for 8 hours at 60°C. Then 10 mL of water was added and the solution was extracted with DCM (2 x 100 mL). The combined organic layers were dried over sodium
15 sulfate, filtered and evaporated *in vacuo*. The yellow crude oil was purified by flash chromatography on silica gel (DCM/methanol 100:0 to 90:10) and 8-(3,3-diphenylpropyl)-2,8-diaza-spiro[4.5]decan-1-one was isolated as a pale yellow
20 solid (1.22 g, 44.9%).

¹H NMR (400 MHz, DMSO-*d*₆): δ [ppm] 7.49 (br s, 1H), 7.3-7.22 (m, 8H), 7.13 (m, 2H), 3.97 (t, 1H), 3.09 (t, 2H), 2.67 (m, 2H), 2.13 (m, 4H), 1.86 (m, 4H), 1.63 (t x d, 2H), 1.25 (br d, 2H).

25


Preparation 11

8-(3,3-Diphenylpropyl)-2,8-diaza-spiro[4.5]decane



- 400 mg (1.14 mmol) of 8-(3,3-diphenylpropyl)-2,8-diaza-spiro[4.5]decan-1-one were dissolved in 15 mL of anhydrous THF followed by 3.44 mL of a 1M
- 5 solution of LAH in THF. The reaction mixture was refluxed for 5 hours and cooled. 5 mL of water and 10 mL of aqueous solution of sodium hydroxide (1N) were successively added and the solution was stirred for an additional one hour before filtering on
- 10 celite. The filtrate was extracted with DCM (2 x 10 mL). The organic layers were dried over sodium sulfate, filtered and evaporated *in vacuo* to yield 8-(3,3-diphenylpropyl)-2,8-diaza-spiro[4.5]decane as a yellow oil (365.1 mg, 95.7%).
- 15 ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ [ppm] 7.29-7.22 (m, 8H), 7.12 (m, 2H), 3.95 (t, 1H), 3.34 (br s, 1H), 2.72 (t, 2H), 2.46 (s, 2H), 2.24-2.07 (m, 8H), 1.38 (m, 6H).


Example 12. (4-Bromophenyl)-[8-(3,3-diphenylpropyl)-
2,8-diaza-spiro[4.5]dec-2-yl]-methanone
hydrochloride
(Compound 639)



5


To 100 mg (100 μ mol, loading of 1 mmol/g) of 4-bromophenylcarboxyl activated ester on polymeric 4-hydroxy-2,3,5,6-tetrafluorobenzamido (TFP) resin (see preparation in J.M. Salvino et al. *J. Comb.*
 10 *Chem.* **2000**, 2, 691-697), preswollen with 0.5 mL of anhydrous DMF, was added 20 mg (60 μ mol) of 8-(3,3-diphenylpropyl)-2,8-diaza-spiro[4.5]decane diluted in 1 mL of DMF. The reaction was agitated overnight at room temperature. The mixture was filtered and
 15 washed with DCM (2 x 2 mL). The filtrates were collected and evaporated *in vacuo*. The crude was purified by semi-preparative HPLC (method B) yielding **Compound 639** as a colorless solid (9.8 mg, 29.5%).
 20 ^1H NMR (400 MHz, DMSO- d_6): δ [ppm] 9.9 (br s, 1H), 7.61 (d, 2H), 7.47 (d x d, 1H), 7.43 (d, 1H), 7.3 (m, 8H), 7.18 (t, 2H), 3.96 (t, 1H), 3.52-3.28 (m, 8H), 2.94 (m, 3H), 2.79 (m, 1H), 1.89-1.63 (m, 6H).
 LC/MS: m/z 519.0 (MH^+).

25



Scheme 9.

5 **Example 13. 4-[2-(4-Bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-2-phenyl-butyric acid methyl ester**
(Compound 640)




- 10 To a mixture of 500 mg (1.39 mmol) of 2-(4-bromobenzyl)-2,8-diaza-spiro[4.5]decan-1-one hydrochloride in 10 mL of anhydrous DMF was added 484 μ L (2.78 mmol) of DIPEA followed by a solution of 4-bromo-2-phenyl-butyric acid methyl ester (357
- 15 mg, 1.39 mmol) in 4 mL of anhydrous DMF. Then 576 mg (4.17 mmol) of potassium carbonate were added and the reaction mixture was stirred overnight at 60°C. After cooling, the mixture was poured in water and extracted with ethyl acetate. The combined organic
- 20 layers were washed with brine and dried over sodium sulfate. The crude was purified by flash

chromatography on silica gel, eluting with ethyl acetate and DCM/methanol (9:1), and yielding 555 mg of **Compound 640** as a colorless oil (80%).

¹H NMR (400 MHz, CD₂Cl₂): δ [ppm] 7.47 (d, 2H), 7.34-7.24 (m, 5H), 7.11 (d, 2H), 4.38 (s, 2H), 3.73 (m, 1H), 3.66 (s, 3H), 3.13 (t, 2H), 2.85 (m, 1H), 2.72 (m, 1H), 2.35-2.24 (m, 3H), 2.07-1.81 (m, 7H), 1.37 (br d, 2H).

10 Preparation 12


4-[2-(4-Bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-2-phenyl-butyric acid



To a mixture of 521 mg (1.043 mmol) of 4-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-2-phenyl-butyric acid methyl ester in 10 mL of methanol was added 101 mg (1.56 mmol) of potassium hydroxide in 5 mL of water. The reaction mixture was refluxed for 5 hours, cooled to room temperature, diluted with water (10 mL) and treated with concentrated acetic acid. The mixture was stirred for 30 minutes and left at room temperature to allow crystallisation. 4-[2-(4-Bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-2-phenyl-butyric acid was collected as a white solid (390 mg, 77%) by filtration.

¹H NMR (400 MHz, DMSO-*d*₆): δ [ppm] 7.51 (d, 2H), 7.32-7.2 (m, 5H), 7.12 (d, 2H), 4.32 (s, 2H), 3.58 (t, 1H), 3.43 (br s, 1H), 3.12 (t, 2H), 2.77 (m, 2H), 2.3-1.99 (m, 5H), 1.83 (t, 2H), 1.73 (m, 3H), 1.33 (d, 2H).

Example 14. 4-[2-(4-Bromobenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-*N*-cyclohexyl-2-phenyl-butyramide hydrochloride (Compound 646)



10






To a mixture of 24.2 mg (50 μmol) of 4-[2-(4-bromobenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-2-phenyl-butyric acid in 0.5 mL of DCE was added 6.4 mg (65 μmol) of cyclohexylamine in 0.5 mL of DCE and 13.4 mg (65 μmol) of DCC in 0.5 mL of DCE. The reaction mixture was stirred at room temperature for 16 hours and concentrated. The crude mixture was purified by semi-preparative HPLC (method E) yielding 11.9 mg (39%) of **Compound 646** as a pale yellowish solid.







¹H NMR (400 MHz, CD₃OD): δ [ppm] 7.49 (d, 2H), 7.38-7.25 (m, 5H), 7.16 (d, 2H), 4.41 (d, 2H), 3.65-3.27 (m, 8H), 3.11-2.95 (m, 3H), 2.41 (m, 1H), 2.24-2.05 (m, 4H), 1.96-1.85 (m, 2H), 1.77-1.59 (m, 5H), 1.39-1.04 (m, 5H).







Table 7 of compounds illustrates some of the compounds of the present invention that were synthesized using the procedure described in scheme 9.







5

Table 7.

CPD #	MOLSTRUCTURE	COMPOUND NAME	MOLWT	PURITY
640		4-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-2-phenyl-butyric acid methyl ester	499.446	100% (LC/MS)
641		4-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-2-phenyl-butyric acid methyl ester	498.641	100% (LC/MS)
642		4-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-2-phenyl-butyric acid methyl ester	450.576	>90% (HNMR)
643		4-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-2,N-diphenyl-butyramide hydrochloride	596.994	98+ (LC/MS)
644		N-benzyl-4-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-2-phenyl-butyramide hydrochloride	611.02	98+ (LC/MS)

645		2-(4-bromobenzyl)-8-(4-oxo-3-phenyl-4-piperidin-1-yl-butyl)-2,8-diaza-spiro[4.5]decan-1-one hydrochloride	589.014	98+ (LC/MS)
646		4-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-N-cyclohexyl-2-phenyl-butylamide hydrochloride	603.041	98+ (LC/MS)
647		4-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-N-cyclohexyl-n-methyl-2-phenyl-butylamide hydrochloride	617.068	98+ (LC/MS)
648		4-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-N-cyclopropyl-2-phenyl-butylamide hydrochloride	560.961	98+ (LC/MS)
649		4-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-N-cyclobutyl-2-phenyl-butylamide hydrochloride	574.987	98+ (LC/MS)
650		N-cyclohexyl-4-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-n-methyl-2-phenyl-butylamide hydrochloride	616.262	98+ (LC/MS)

651		N-cyclopropyl-4-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-2-phenylbutyramide hydrochloride	560.155	98+ (LC/MS)
652		N-cyclobutyl-4-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-2-phenylbutyramide hydrochloride	574.182	98+ (LC/MS)
653		4-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-N-cyclopentyl-2-phenylbutyramide hydrochloride	589.014	98+ (LC/MS)
654		4-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-N-isopropyl-2-phenylbutyramide hydrochloride	562.976	98+ (LC/MS)
655		N-benzyl-4-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-2-phenylbutyramide hydrochloride	610.215	98+ (LC/MS)
656		2-(4-methanesulfonylbenzyl)-8-(4-oxo-3-phenyl-4-piperidin-1-ylbutyl)-2,8-diaza-spiro[4.5]decan-1-one hydrochloride	588.209	98+ (LC/MS)

657		N-cyclohexyl-4-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-2-phenylbutyramide hydrochloride	602.236	98+ (LC/MS)
658		N-cyclopentyl-4-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-2-phenylbutyramide hydrochloride	588.209	98+ (LC/MS)
659		N-isopropyl-4-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-2-phenylbutyramide hydrochloride	562.171	98+ (LC/MS)
660		4-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-2,N-diphenylbutyramide hydrochloride	548.123	90.6% (LC/MS)
661		N-benzyl-4-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-2-phenylbutyramide hydrochloride	562.15	98+ (LC/MS)
662		2-(4-methoxybenzyl)-8-(4-oxo-3-phenyl-4-piperidin-1-yl-butyl)-2,8-diaza-spiro[4.5]decan-1-one hydrochloride	540.144	98+ (LC/MS)


















663		N-cyclohexyl-4-[2-(4-methoxybenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-2-phenylbutyramide hydrochloride	554.171	98+ (LC/MS)
664		N-cyclopropyl-4-[2-(4-methoxybenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-2-phenylbutyramide hydrochloride	512.09	98+ (LC/MS)
665		N-cyclobutyl-4-[2-(4-methoxybenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-2-phenylbutyramide hydrochloride	526.117	98+ (LC/MS)
666		N-cyclopentyl-4-[2-(4-methoxybenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-2-phenylbutyramide hydrochloride	540.144	98+ (LC/MS)
667		N-isopropyl-4-[2-(4-methoxybenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-2-phenylbutyramide hydrochloride	514.106	98+ (LC/MS)






Table 8 of compounds illustrates some of the compounds of the present invention that can be synthesized using the procedure described in schemes








5 1-9.








5 Table 8.








CPD #	MOLSTRUCTURE	COMPOUND NAME	MOLWT
668		Cyclopropanecarboxylic acid {(S)-1-(3-chloro-phenyl)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-amide hydrochloride	546.54
669		Cyclopropanecarboxylic acid {(S)-1-(3-fluoro-phenyl)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-amide hydrochloride	530.09
670		Cyclopropanecarboxylic acid {(S)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl}-amide hydrochloride	518.12
671		Cyclopropanecarboxylic acid {(S)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-thiophen-3-yl-propyl}-amide hydrochloride	518.12
672		N-[(S)-1-(3-Chloro-phenyl)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl]-isobutyramide hydrochloride	548.56








673		N-((S)-1-(3-Fluoro-phenyl)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl)-isobutyramide hydrochloride	532.1
674		N-((S)-3-[2-(4-Methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl)-isobutyramide hydrochloride	520.14
675		N-((S)-3-[2-(4-Methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-thiophen-3-yl-propyl)-isobutyramide hydrochloride	520.14
676		N-((S)-3-[2-(4-Chloro-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-isobutyramide hydrochloride	518.53
677		N-((S)-3-[2-(4-Fluoro-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-isobutyramide hydrochloride	502.08
678		N-((S)-3-[2-(4-Cyano-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-isobutyramide hydrochloride	509.1
679		N-((S)-3-[2-(4-Ethoxy-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-isobutyramide hydrochloride	528.14








680		N-((S)-3-[2-(4-Difluoromethoxy-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-isobutyramide hydrochloride	550.09
681		N-((S)-3-[3-Oxo-2-(4-trifluoromethoxy-benzyl)-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-isobutyramide hydrochloride	568.08
682		N-((S)-3-[3-Oxo-2-(4-trifluoromethyl-benzyl)-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-isobutyramide hydrochloride	552.08
683		N-((S)-3-[3-Oxo-2-(4-pyrazol-1-yl-benzyl)-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-isobutyramide hydrochloride	550.15
684		Cyclopropanecarboxylic acid ((S)-3-[2-(4-chloro-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide hydrochloride	516.52

685		Cyclopropanecarboxylic acid ((S)-3-[2-(4-fluoro-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide hydrochloride	500.06
686		Cyclopropanecarboxylic acid ((S)-3-[2-(4-cyano-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide hydrochloride	507.08
687		Cyclopropanecarboxylic acid ((S)-3-[2-(4-ethoxy-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide hydrochloride	526.12
688		Cyclopropanecarboxylic acid ((S)-3-[2-(4-difluoromethoxy-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide hydrochloride	548.08
689		Cyclopropanecarboxylic acid ((S)-3-[2-(4-trifluoromethoxy-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide hydrochloride	566.07
690		Cyclopropanecarboxylic acid ((S)-3-[2-(4-trifluoromethyl-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide hydrochloride	550.07
691		Cyclopropanecarboxylic acid ((S)-3-[3-oxo-2-(4-pyrazol-1-yl-benzyl)-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide hydrochloride	548.13

692		2-Cyclopropyl-N-((S)-3-[2-(4-methoxy-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-acetamide hydrochloride	526.12
693		N-((S)-3-[2-(4-Chloro-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-2-cyclopropyl-acetamide hydrochloride	530.54
694		N-((S)-3-[2-(4-Fluoro-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-2-cyclopropyl-acetamide hydrochloride	514.09
695		N-((S)-3-[2-(4-Cyano-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-2-cyclopropyl-acetamide hydrochloride	521.11
696		N-((S)-3-[2-(4-Ethoxy-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-2-cyclopropyl-acetamide hydrochloride	540.15
697		N-((S)-3-[2-(4-Difluoromethoxy-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-2-cyclopropyl-acetamide hydrochloride	562.1
698		N-((S)-3-[2-(4-Trifluoromethoxy-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-2-cyclopropyl-acetamide hydrochloride	580.09

699		N-((S)-3-[2-(4-Trifluoromethyl-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-2-cyclopropyl-acetamide hydrochloride	564.1
700		2-Cyclopropyl-N-((S)-3-[3-oxo-2-(4-pyrazol-1-yl-benzyl)-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-acetamide hydrochloride	562.16
701		4,4-Difluoro-cyclohexanecarboxylic acid ((S)-3-[2-(4-chloro-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide hydrochloride	594.58
702		4,4-Difluoro-cyclohexanecarboxylic acid ((S)-3-[2-(4-fluoro-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide hydrochloride	578.12
703		4,4-Difluoro-cyclohexanecarboxylic acid ((S)-3-[2-(4-cyano-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide hydrochloride	585.14
704		4,4-Difluoro-cyclohexanecarboxylic acid ((S)-3-[2-(4-ethoxy-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide hydrochloride	604.19
705		4,4-Difluoro-cyclohexanecarboxylic acid ((S)-3-[3-oxo-2-(4-pyrazol-1-yl-benzyl)-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide hydrochloride	626.19

706		Cyclopropanecarboxylic acid {(S)-1-(3-chloro-phenyl)-3-[2-(4-methoxy-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-amide hydrochloride	546.54
707		Cyclopropanecarboxylic acid {(S)-1-(3-fluoro-phenyl)-3-[2-(4-methoxy-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-amide hydrochloride	530.09
708		Cyclopropanecarboxylic acid {(S)-3-[2-(4-methoxy-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl}-amide hydrochloride	518.12
709		Cyclopropanecarboxylic acid {(S)-3-[2-(4-methoxy-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-thiophen-3-yl-propyl}-amide hydrochloride	518.12
710		N-((S)-1-(3-Chloro-phenyl)-3-[2-(4-methoxy-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl)-isobutyramide hydrochloride	548.56
711		N-((S)-1-(3-Fluoro-phenyl)-3-[2-(4-methoxy-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl)-isobutyramide hydrochloride	532.1
712		N-((S)-3-[2-(4-Methoxy-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl)-isobutyramide hydrochloride	520.14

713		N-((S)-3-[2-(4-Methoxy-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-thiophen-3-yl-propyl)-isobutyramide hydrochloride	520.14
714		Propane-2-sulfonic acid ((S)-3-[2-(4-methoxy-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide hydrochloride	550.16
715		3-((S)-3-[2-(4-Methoxy-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-1,1-dimethyl-urea hydrochloride	515.1
716		Morpholine-4-carboxylic acid ((S)-3-[2-(4-methoxy-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide hydrochloride	557.14
717		3,3-Difluoro-pyrrolidine-1-carboxylic acid ((S)-3-[2-(4-methoxy-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide hydrochloride	577.12
718		((S)-3-[2-(4-Methoxy-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-carbamic acid methyl ester hydrochloride	502.06
719		((S)-3-[2-(4-Methoxy-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-carbamic acid ethyl ester hydrochloride	516.08

Example 15. The following assay methods are suitable for evaluating the compounds of the invention.

Chemokine Binding assay: Membranes (1µg/well) from
5 human embryonic kidney (HEK-293) cells expressing human CCR5 were incubated with 0.1 nM ¹²⁵I-labeled MIP-1α (Amersham) in the presence of varying concentrations of a test compound (10000-0.01 nM) in buffer (50 mM Hepes, pH 7.3/5 mM MgCl₂/1 mM
10 CaCl₂/0.5% BSA) for 90 min at room temperature. Reaction mixtures (100 µL) were filtered through Multiscreen GFB filters (Millipore) and washed six times with cold wash buffer (50 mM Hepes, pH 7.3/0.5 M NaCl, 0.1% BSA). Bound ¹²⁵I-MIP-1α was quantitated
15 by liquid scintillation counting. The nonspecific binding of ¹²⁵I-labeled MIP-1α to the membrane was determined based on the radioactivity from the wells added with 100 nM non-radiolabeled MIP-1α. IC₅₀ and K_D values were calculated by using GRAPHPAD PRISM
20 software (Intuitive Software for Science, San Diego).

HIV-1 Replication in PBMC Cultures. Isolated PBMC were stimulated *in vitro* with 5 µg/ml
25 phytohemagglutinin and 50 units/ml IL-2 for 3 days. The cells were resuspended at 4 × 10⁶/ml in complete medium (RPMI, 10% FBS/50 units/ml IL-2), seeded into 96-well plates (2 × 10⁵/well), incubated with inhibitor for 1 h at 37°C, and infected in
30 triplicate with 25-100 tissue culture 50% infective


dose (TCID₅₀) per well of the R5 HIV-1_{JR-FL} strain for 3-4 h. The cells were washed twice in PBS to remove residual virus and cultured in the presence of inhibitor for 4-6 days. HIV-1 replication was
5 determined by the presence of viral RT activity in harvested supernatant fluid. The IC₅₀ values for the virus were determined by using GRAPHPAD PRISM software.

The preceding examples can be repeated with similar
10 success by substituting the generically or specifically described reactants and/or operating conditions of this invention for those used in the preceding examples.

From the foregoing description, one skilled in the
15 art can easily ascertain the essential characteristics of this invention and, without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and
20 conditions.

CLAIMS:

1. A compound according to formula (I):



(I)

or a pharmaceutically acceptable salt, hydrate or solvate thereof,


wherein

Y, Z and X are each independently CH₂, C=O or CR₄R₅;

W is H, optionally substituted C₁₋₁₀ alkyl (e.g. C₁₋₆ alkyl) optionally substituted C₂₋₁₀ alkenyl (e.g. C₂₋₆ alkenyl), optionally substituted C₂₋₁₀ alkynyl (e.g. C₂₋₆ alkynyl), optionally substituted C₆₋₁₂ aryl, optionally substituted 3 to 10 membered heterocycle, optionally substituted C₆₋₁₂ aralkyl or optionally substituted C₃₋₁₀ heteroaralkyl;

R₁ is H, OH, optionally substituted C₁₋₁₀ alkyl, optionally substituted C₂₋₁₀ alkenyl, optionally substituted C₂₋₁₀ alkynyl, optionally substituted C₆₋₁₂ aryl, NR₈R₉, optionally substituted O-C₁₋₆ alkyl,

optionally substituted O-C₆₋₁₂ aryl, optionally substituted O-C₆₋₁₂ aralkyl,



5

R₂ is optionally substituted C₁₋₁₀ alkyl, optionally substituted C₂₋₁₀ alkenyl, optionally substituted C₂₋₁₀ alkynyl, optionally substituted C₆₋₁₂ aryl or
 10 optionally substituted 3 to 10 membered heterocycle;


R₃ is H, optionally substituted C₁₋₁₀ alkyl, optionally substituted C₂₋₁₀ alkenyl, optionally substituted C₂₋₁₀ alkynyl, or optionally substituted
 15 C₆₋₁₂ aryl;

R₄ and R₅ are each independently H, optionally substituted C₁₋₁₀ alkyl, optionally substituted C₂₋₁₀ alkenyl, optionally substituted C₂₋₁₀ alkynyl, or
 20 optionally substituted C₆₋₁₂ aryl;

R_6 and R''_6 are each, independently, H, optionally substituted C_{1-10} alkyl optionally substituted C_{2-10} alkenyl, or optionally substituted C_{2-10} alkynyl and R_7 is H, optionally substituted C_{1-10} alkyl,
 5 optionally substituted C_{2-10} alkenyl, optionally substituted C_{2-10} alkynyl, optionally substituted C_{6-12} aryl, optionally substituted 3 to 10 membered heterocycle, optionally substituted C_{6-12} aralkyl or optionally substituted 3 to 10 membered
 10 heteroaralkyl, or R''_6 and R_7 can be taken together to form an optionally substituted 3 to 10 membered heterocycle; and


R_8 and R_9 are each independently H, optionally substituted C_{1-10} alkyl, optionally substituted C_{2-10} alkenyl, or optionally substituted C_{2-10} alkynyl.

2. A compound according to claim 1, wherein said compound is of formula (Ia):




or a pharmaceutically acceptable salt, hydrate or solvate thereof.

3. A compound according to claim 1, wherein said compound is of formula (Ib):




or a pharmaceutically acceptable salt, hydrate or
5 solvate thereof.

4. A compound according to claim 1, wherein said compound is of formula (Ic):



10 or a pharmaceutically acceptable salt, hydrate or
solvate thereof.


5. A compound according to claim 1, wherein said compound is of formula (Id):



(Id)

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

- 5 6. A compound according to claim 1, wherein said compound is an (S)-enantiomer of formula (Ie):



(Ie)

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

10

7. A compound according to any one of claims 1 to 6, wherein W is C₆₋₁₂ aryl or 3 to 10 membered heterocycle.


- 15 8. A compound according to any one of claims 1 to 6, wherein W is C₆₋₁₂ aryl.

9. A compound according to any one of claims 1 to 6, wherein W is 3 to 10 membered heterocycle.


10. A compound according to any one of claims 1 to 9, wherein W is phenyl, phenyl substituted in the para (p) position, phenyl substituted with a halogen, phenyl substituted with Br, phenyl substituted with F, phenyl substituted with Cl, phenyl substituted with at least one halogen, phenyl substituted with a C₁₋₃ alkoxy, phenyl substituted with methoxy, phenyl substituted with SO₂C₁₋₃alkyl, phenyl substituted with methanesulfonyl, phenyl substituted with halogenated C₁₋₆ alkyl, phenyl substituted with CHF₂, phenyl substituted with halogenated C₁₋₆ alkoxy, phenyl substituted with OCF₃, or pyridine.

11. A compound according to any one of claims 1 to 10, wherein R₁ is:


20




(II)



(III)




(IV)



(VI)


12. A compound according to any one of claims 1 to 10, wherein R₁ is:



(II)

wherein R_7 is C_{1-10} alkyl, C_{6-12} aryl or 3 to 10
5 membered heterocycle.


13. A compound according to any one of claims
1 to 10, wherein R_1 is:



(II) , and

10 R_7 is methyl, ethyl, isopropyl, cyclopropyl,
cyclobutyl, cyclopentyl, cyclohexyl, 4,4-
difluorocyclohexyl, cycloheptyl, CH_2 -cyclopropyl,
 CH_2 -cyclobutyl, CH_2 -cyclopentyl, or CH_2 -cyclohexyl.

15 14. A compound according to any one of claims
1 to 10, wherein R_1 is:




(II) , and

R_7 is phenyl, phenyl substituted with methyl, phenyl
substituted with at least one methyl, phenyl

substituted with a halogen, phenyl substituted with
 at least one halogen, phenyl substituted with Cl,
 phenyl substituted with Br, phenyl substituted with
 F, phenyl substituted with at least one Cl, or
 5 phenyl substituted with methoxy.

15. A compound according to any one of claims
 1 to 10, wherein R_1 is:




(II) , and

10 R_7 is benzyl, benzyl substituted with methyl, benzyl
 substituted with at least one methyl, benzyl
 substituted with a halogen, benzyl substituted with
 at least one halogen, benzyl substituted with Cl,
 benzyl substituted with Br, benzyl substituted with
 15 F, benzyl substituted with at least one Cl, benzyl
 substituted with methoxy, or pyridine.

16. A compound according to any one of claims
 1 to 10, wherein R_1 is:


20



(III)

wherein R_6 and R''_6 are each independently H or C_{1-4} alkyl, R_7 is C_{6-12} aryl, or R''_6 and R_7 taken together form a 3 to 10 membered heterocycle.

- 5 17. A compound according to any one of claims 1 to 10, wherein R_1 is:



(III)


- 10 wherein

R_6 and R''_6 are each, independently, H or C_{1-4} alkyl, and

- R_7 is phenyl, phenyl substituted with methyl, phenyl substituted with at least one methyl, phenyl substituted with a halogen, phenyl substituted with at least one halogen, phenyl substituted with Cl, phenyl substituted with Br, phenyl substituted with F, phenyl substituted with at least one Cl, phenyl substituted with methoxy, or naphthyl, or R''_6 and R_7 taken together form a piperidine.
- 15
20

18. A compound according to any one of claims 1 to 10, wherein R_1 is:


25



(IV)

wherein R_6 is H or C_{1-4} alkyl and R_7 is C_{1-10} alkyl.


19. A compound according to any one of claims
5 1 to 10, wherein R_1 is:



(IV)

wherein R_6 is H or C_{1-4} alkyl, and R_7 is methyl,
ethyl, *tert*-butyl, cyclobutyl, cyclopentyl, or
10 cyclohexyl.

20. A compound according to any one of claims
1 to 10, wherein R_1 is:




15 (V)

wherein R_6 is H or C_{1-4} alkyl, and R_7 is optionally
substituted C_{1-10} alkyl, optionally substituted C_{6-12}

aryl or optionally substituted 3 to 10 membered heterocycle.


21. A compound according to any one of claims
5 1 to 10, wherein R_1 is:



(V)

- wherein R_6 is H or C_{1-4} alkyl, and R_7 is optionally substituted phenyl or optionally substituted C_{1-10}
10 alkyl.

22. A compound according to any one of claims
1 to 10, wherein R_1 is:




(VI)

15

- wherein R_6'' is H or C_{1-4} alkyl, and R_7 is C_{1-10} alkyl or C_{6-12} aryl.

23. A compound according to any one of claims
20 1 to 10, wherein R_1 is:



(VI)

wherein R_6 is H or C_{1-4} alkyl, and R_7 is cyclohexyl or phenyl.

5 24. A compound according to any one of claims 1 to 10, wherein R_2 is C_{6-12} aryl or 3 to 10 membered heterocycle.

25. A compound according to any one of claims
10 1 to 24, wherein R_2 is C_{6-12} aryl.

26. A compound according to any one of claims 1 to 24, wherein R_2 is phenyl, phenyl substituted with halogen, phenyl substituted with Cl, phenyl
15 substituted with at least one halogen, phenyl substituted with methoxy, or phenyl substituted with at least one methoxy.

27. A compound according to any one of claims
20 1 to 24, wherein R_2 is 3 to 10 membered heterocycle.

28. A compound according to any one of claims 1 to 24, wherein R_2 is thienyl or pyridyl.

25

29. A compound according to any one of claims
1 to 24, wherein R₃ is H or C₁₋₄ alkyl.

30. A compound according to any one of claims
5 1 to 24, wherein R₃ is H or methyl.

31. A compound according to claim 1, wherein
said compound is selected from:

- 2-(4-bromobenzyl)-8-(3-phenyl-propyl)-2,8-diaza-
10 spiro[4.5]decan-1-one;
8-(3-phenylpropyl)-2-(4-trifluoromethyl-benzyl)-2,8-
diazaspiro[4.5]decan-1-one;
2-(4-chlorobenzyl)-8-(3-phenyl-propyl)-2,8-diaza-
spiro[4.5]decan-1-one;
15 2-(4-fluorobenzyl)-8-(3-phenyl-propyl)-2,8-diaza-
spiro[4.5]decan-1-one;
8-(3-phenyl-propyl)-2-(4-trifluoromethoxy-benzyl)-
2,8-diazaspiro[4.5]decan-1-one;
2-(4-methylbenzyl)-8-(3-phenyl-propyl)-2,8-diaza-
20 spiro[4.5]decan-1-one;
4-[1-oxo-8-(3-phenyl-propyl)-2,8-diaza-
spiro[4.5]dec-2-ylmethyl]-benzonitrile;
2-biphenyl-4-ylmethyl-8-(3-phenyl-propyl)-2,8-diaza-
spiro[4.5]decan-1-one;
25 2-naphthalen-2-ylmethyl-8-(3-phenyl-propyl)-2,8-
diazaspiro[4.5]decan-1-one;
2-(4-bromobenzyl)-8-(3-phenyl-butyl)-2,8-diaza-
spiro[4.5]decan-1-one;
2-(4-bromobenzyl)-8-(3,3-diphenyl-propyl)-2,8-diaza-
30 spiro[4.5]decan-1-one;

8-(3,3-diphenyl-propyl)-2-(4-trifluoromethoxy-
 benzyl)-2,8-diaza-spiro[4.5]decan-1-one;
 2-(4-bromobenzyl)-8-(3,3-diphenyl-propyl)-2,8-diaza-
 spiro[4.5]decan-3-one;
 5 8-(3,3-diphenyl-propyl)-2-(3-phenyl-propyl)-2,8-
 diaza-spiro[4.5]decan-1-one;
 8-(3,3-diphenyl-propyl)-2-pyridin-4-ylmethyl-2,8-
 diaza-spiro[4.5]decan-1-one;
 8-(3,3-diphenyl-propyl)-2-(4-methoxy-benzyl)-2,8-
 10 diaza-spiro[4.5]decan-1-one;
 8-(3,3-diphenyl-propyl)-2-(4-pyrazol-1-yl-benzyl)-
 2,8-diaza-spiro[4.5]decan-1-one;
 2-benzothiazol-2-ylmethyl-8-(3,3-diphenyl-propyl)-
 2,8-diaza-spiro[4.5]decan-1-one;
 15 8-(3,3-diphenyl-propyl)-2-(4-methanesulfonyl-
 benzyl)-2,8-diaza-spiro[4.5]decan-1-one;
 8-(3,3-diphenyl-propyl)-2-(3-phenyl-allyl)-2,8-
 diaza-spiro[4.5]decan-1-one;
 8-(3,3-diphenyl-propyl)-2-phenethyl-2,8-diaza-
 20 spiro[4.5]decan-1-one;
 2-(4-benzyloxy-benzyl)-8-(3,3-diphenyl-propyl)-2,8-
 diaza-spiro[4.5]decan-1-one;
 2-benzofuran-2-ylmethyl-8-(3,3-diphenyl-propyl)-2,8-
 diaza-spiro[4.5]decan-1-one;
 25 8-(3,3-diphenyl-propyl)-2-(4-isopropyl-benzyl)-2,8-
 diaza-spiro[4.5]decan-1-one;
 2-(5-chloro-benzo[b]thiophen-3-ylmethyl)-8-(3,3-
 diphenyl-propyl)-2,8-diaza-spiro[4.5]decan-1-one;
 8-(3,3-diphenyl-propyl)-2-(4-nitro-benzyl)-2,8-
 30 diaza-spiro[4.5]decan-1-one;

2-(4-bromo-benzyl)-8-(3-pyridin-2-yl-propyl)-2,8-
 diaza-spiro[4.5]decan-1-one;
 2-[1-(4-bromophenyl)-ethyl]-8-(3,3-diphenyl-propyl)-
 2,8-diaza-spiro[4.5]decan-1-one;
 5 8-(3,3-diphenyl-propyl)-2-pyridin-3-ylmethyl-2,8-
 diaza-spiro[4.5]decan-1-one;
 N-{4-[8-(3,3-diphenyl-propyl)-1-oxo-2,8-diaza-
 spiro[4.5]dec-2-ylmethyl]-phenyl}-acetamide;
 8-(3,3-diphenyl-propyl)-2-(6-trifluoromethyl-
 10 pyridin-3-ylmethyl)-2,8-diaza-spiro[4.5]decan-1-one;
 4-[8-(3,3-diphenyl-propyl)-1-oxo-2,8-diaza-
 spiro[4.5]dec-2-ylmethyl]-benzoic acid;
 8-(3,3-diphenyl-propyl)-2-pyridin-2-ylmethyl-2,8-
 diaza-spiro[4.5]decan-1-one;
 15 8-(3,3-diphenyl-propyl)-2-(4-
 trifluoromethylsulfanyl-benzyl)-2,8-diaza-
 spiro[4.5]decan-1-one;
 8-(3,3-diphenyl-propyl)-2-(4-methyl-
 cyclohexylmethyl)-2,8-diaza-spiro[4.5]decan-1-one;
 20 4-[8-(3,3-diphenyl-propyl)-1-oxo-2,8-diaza-
 spiro[4.5]dec-2-ylmethyl]-benzoic acid methyl ester;
 8-(3,3-diphenyl-propyl)-2-(5-trifluoromethyl-furan-
 2-ylmethyl)-2,8-diaza-spiro[4.5]decan-1-one;
 8-(3,3-diphenyl-propyl)-2-(4-iodo-benzyl)-2,8-diaza-
 25 spiro[4.5]decan-1-one;
 2-(4-methanesulfonylbenzyl)-8-(3-phenyl-butyl)-2,8-
 diaza-spiro[4.5]decan-1-one;
 2-(4-bromobenzyl)-8-[3-hydroxy-3-(2-methoxyphenyl)-
 3-phenyl-propyl]-2,8-diaza-spiro[4.5]decan-1-one;
 30 2-(4-bromobenzyl)-8-[3-hydroxy-3-(3-methoxyphenyl)-
 3-phenyl-propyl]-2,8-diaza-spiro[4.5]decan-1-one;

2-(4-bromobenzyl)-8-(3-hydroxy-3-phenyl-3-thiophen-
 2-yl-propyl)-2,8-diaza-spiro[4.5]decan-1-one;
 2-(4-bromobenzyl)-8-(3-hydroxy-3-phenyl-butyl)-2,8-
 diaza-spiro[4.5]decan-1-one;
 5 2-(4-bromobenzyl)-8-[3-(2-methoxyphenyl)-3-phenyl-
 propyl]-2,8-diaza-spiro[4.5]decan-1-one;
 2-(4-bromobenzyl)-8-[3-(3-chlorophenyl)-3-hydroxy-3-
 phenyl-propyl]-2,8-diaza-spiro[4.5]decan-1-one;
 2-(4-bromobenzyl)-8-[3-(4-chlorophenyl)-3-hydroxy-3-
 10 phenyl-propyl]-2,8-diaza-spiro[4.5]decan-1-one;
 2-(4-bromobenzyl)-8-[3-(3-chlorophenyl)-3-phenyl-
 propyl]-2,8-diaza-spiro[4.5]decan-1-one;
 2-(4-bromobenzyl)-8-(3-phenyl-3-thiophen-2-yl-
 propyl)-2,8-diaza-spiro[4.5]decan-1-one;
 15 2-(4-bromobenzyl)-8-[3-(4-chlorophenyl)-3-phenyl-
 propyl]-2,8-diaza-spiro[4.5]decan-1-one;
 {3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-
 8-yl]-1-phenyl-propyl}-carbamic acid tert-butyl
 ester;
 20 N-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-
 spiro[4.5]dec-8-yl]-1-phenyl-propyl}-benzamide;
 N-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-
 spiro[4.5]dec-8-yl]-1-phenyl-propyl}-2,6-dimethyl-
 benzamide;
 25 cyclohexanecarboxylic acid {3-[2-(4-bromobenzyl)-1-
 oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-
 amide;
 N-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-
 spiro[4.5]dec-8-yl]-1-phenyl-propyl}-2-phenyl-
 30 acetamide;

N-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-
 spiro[4.5]dec-8-yl]-1-phenyl-propyl}-2-(2,4,6-
 trimethyl-phenyl)-acetamide;
 N-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-
 5 spiro[4.5]dec-8-yl]-1-phenyl-propyl}-3-phenyl-
 propionamide;
 {3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-
 8-yl]-1-phenyl-propyl}-methyl-carbamic acid tert-
 butyl ester;
 10 N-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-
 spiro[4.5]dec-8-yl]-1-phenyl-propyl}-N-methyl-
 benzamide;
 cyclohexanecarboxylic acid {3-[2-(4-bromo-benzyl)-1-
 oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-
 15 methyl-amide;
 N-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-
 spiro[4.5]dec-8-yl]-1-phenyl-propyl}-N-methyl-2-
 phenyl-acetamide;
 N-{3-[2-(4-bromo-benzyl)-1-oxo-2,8-diaza-
 20 spiro[4.5]dec-8-yl]-1-phenyl-propyl}-N-methyl-2-
 (2,4,6-trimethyl-phenyl)-acetamide;
 N-{3-[2-(4-bromo-benzyl)-1-oxo-2,8-diaza-
 spiro[4.5]dec-8-yl]-1-phenyl-propyl}-N-methyl-2-
 (2,4,6-trimethyl-phenyl)-acetamide;
 25 {3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-
 spiro[4.5]dec-8-yl)-1-phenyl-propyl}-carbamic acid
 tert-butyl ester;
 {3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diaza-
 spiro[4.5]dec-8-yl]-1-phenyl-propyl}-carbamic acid
 30 tert-butyl ester;

- [3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(3-chloro-phenyl)-propyl]-carbamic acid tert-butyl ester;
- N-(3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-
- 5 spiro[4.5]dec-8-yl]-1-phenyl-propyl)-acetamide;
- cyclopropanecarboxylic acid (3-[2-(4-bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide;
- N-(3-[2-(4-bromo-benzyl)-1-oxo-2,8-diaza-
- 10 spiro[4.5]dec-8-yl]-1-phenyl-propyl)-isobutyramide;
- N-(3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-3-methyl-butyramide;
- N-(3-[2-(4-bromo-benzyl)-1-oxo-2,8-diaza-
- 15 spiro[4.5]dec-8-yl]-1-phenyl-propyl)-2-chloro-benzamide;
- N-(3-[2-(4-bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-2-methoxy-benzamide;
- 20 pyridine-2-carboxylic acid (3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide;
- N-(3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-3-chloro-
- 25 benzamide;
- N-(3-[2-(4-bromo-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-3-methoxy-benzamide;
- N-(3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-
- 30 spiro[4.5]dec-8-yl]-1-phenyl-propyl)-nicotinamide;

- N-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-
spiro[4.5]dec-8-yl]-1-phenyl-propyl}-4-chloro-
benzamide;
- 5 N-{3-[2-(4-bromo-benzyl)-1-oxo-2,8-diaza-
spiro[4.5]dec-8-yl]-1-phenyl-propyl}-4-methoxy-
benzamide;
- N-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-
spiro[4.5]dec-8-yl]-1-phenyl-propyl}-
isonicotinamide;
- 10 N-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-
spiro[4.5]dec-8-yl]-1-phenyl-propyl}-3,4-dichloro-
benzamide;
- N-{3-[2-(4-bromo-benzyl)-1-oxo-2,8-diaza-
spiro[4.5]dec-8-yl]-1-phenyl-propyl}-3,4-dimethoxy-
15 benzamide;
- N-{3-[2-(4-bromo-benzyl)-1-oxo-2,8-diaza-
spiro[4.5]dec-8-yl]-1-phenyl-propyl}-2-(2-chloro-
phenyl)-acetamide;
- N-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-
20 spiro[4.5]dec-8-yl]-1-phenyl-propyl}-2-(2-methoxy-
phenyl)-acetamide;
- N-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-
spiro[4.5]dec-8-yl]-1-phenyl-propyl}-2-(3-chloro-
phenyl)-acetamide;
- 25 N-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-
spiro[4.5]dec-8-yl]-1-phenyl-propyl}-2-(3-methoxy-
phenyl)-acetamide;
- N-{3-[2-(4-bromo-benzyl)-1-oxo-2,8-diaza-
spiro[4.5]dec-8-yl]-1-phenyl-propyl}-2-pyridin-3-yl-
30 acetamide;

N-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-
 spiro[4.5]dec-8-yl]-1-phenyl-propyl}-2-(4-methoxy-
 phenyl)-acetamide;
 N-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-
 5 spiro[4.5]dec-8-yl]-1-phenyl-propyl}-2-(3,4-
 dichloro-phenyl)-acetamide;
 tetrahydro-pyran-4-carboxylic acid {3-[2-(4-
 bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-
 phenyl-propyl}-amide;
 10 cyclopentanecarboxylic acid {3-[2-(4-bromobenzyl)-1-
 oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-
 amide;
 cyclobutanecarboxylic acid {3-[2-(4-bromobenzyl)-1-
 oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-
 15 amide;
 cycloheptanecarboxylic acid {3-[2-(4-bromobenzyl)-1-
 oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-
 amide;
 N-{3-[2-(4-bromo-benzyl)-1-oxo-2,8-diaza-
 20 spiro[4.5]dec-8-yl]-1-phenyl-propyl}-2-cyclohexyl-
 acetamide;
 N-{3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-
 spiro[4.5]dec-8-yl]-1-phenyl-propyl}-acetamide;
 cyclopropanecarboxylic acid {3-[2-(4-methoxybenzyl)-
 25 1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-
 propyl}-amide;
 N-{3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-
 spiro[4.5]dec-8-yl]-1-phenyl-propyl}-isobutyramide;
 N-{3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-
 30 spiro[4.5]dec-8-yl]-1-phenyl-propyl}-3-methyl-
 butyramide;

2-chloro-N-(3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-
 spiro[4.5]dec-8-yl]-1-phenyl-propyl)-benzamide;
 2-methoxy-N-(3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-
 spiro[4.5]dec-8-yl]-1-phenyl-propyl)-benzamide;
 5 pyridine-2-carboxylic acid (3-[2-(4-methoxybenzyl)-
 1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-
 propyl)-amide;
 3-chloro-N-(3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-
 spiro[4.5]dec-8-yl]-1-phenyl-propyl)-benzamide;
 10 3-methoxy-N-(3-[2-(4-methoxybenzyl)-1-oxo-2,8-
 diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-
 benzamide;
 N-(3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-
 spiro[4.5]dec-8-yl]-1-phenyl-propyl)-nicotinamide;
 15 4-chloro-N-(3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-
 spiro[4.5]dec-8-yl]-1-phenyl-propyl)-benzamide;
 4-methoxy-N-(3-[2-(4-methoxybenzyl)-1-oxo-2,8-
 diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-
 benzamide;
 20 N-(3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-
 spiro[4.5]dec-8-yl]-1-phenyl-propyl)-
 isonicotinamide;
 (R)-cyclohexanecarboxylic acid (3-[2-(4-
 bromobenzyl)-1-oxo-2,8-diaza-spiro [4.5]dec-8-yl]-
 25 1(R)-phenyl-propyl)-amide;
 3,4-dichloro-N-(3-[2-(4-methoxybenzyl)-1-oxo-2,8-
 diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-
 benzamide;
 3,4-dimethoxy-N-(3-[2-(4-methoxybenzyl)-1-oxo-2,8-
 30 diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-
 benzamide;

2-(2-chloro-phenyl)-N-{3-[2-(4-methoxybenzyl)-1-oxo-
2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-
acetamide;

N-{3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-
5 spiro[4.5]dec-8-yl]-1-phenyl-propyl}-2-(2-methox-
phenyl)-acetamide;

2-(3-chlorophenyl)-N-{3-[2-(4-methoxybenzyl)-1-oxo-
2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-
acetamide;

10 N-{3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-
spiro[4.5]dec-8-yl]-1-phenyl-propyl}-2-(3-
methoxyphenyl)-acetamide;

N-{3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-
spiro[4.5]dec-8-yl]-1-phenyl-propyl}-2-pyridin-3-yl-
15 acetamide;

N-{3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-
spiro[4.5]dec-8-yl]-1-phenyl-propyl}-2-(4-
methoxyphenyl)-acetamide;

20 2-(3,4-dichlorophenyl)-N-{3-[2-(4-methoxybenzyl)-1-
oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-
acetamide;

tetrahydro-pyran-4-carboxylic acid{3-[2-(4-
methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-
1-phenyl-propyl}-amide;

25 cyclopentanecarboxylic acid {3-[2-(4-methoxybenzyl)-
1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-
propyl}-amide;

cyclobutanecarboxylic acid {3-[2-(4-methoxybenzyl)-
1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-
30 propyl}-amide;

cycloheptanecarboxylic acid {3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide;

2-cyclohexyl-N-{3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-acetamide;

(S)-cyclohexanecarboxylic acid {3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide;

10 N-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-2-cyclopentyl-acetamide;

furan-2-carboxylic acid {3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide;

15 N-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-2-ethyl-butyramide;

thiophene-2-carboxylic acid {3-[2-(4-brom-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide;

20 N-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-2-(3,4-dimethoxyphenyl)-acetamide;

25 2-cyclopentyl-N-{3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-acetamide;

furan-2-carboxylic acid {3-[2-(4-methox-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide;

30

2-ethyl-N-{3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-
 spiro[4.5]dec-8-yl]-1-phenyl-propyl}-butyramide;
 thiophene-2-carboxylic acid {3-[2-(4-methoxybenzyl)-
 1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-
 5 propyl}-amide;
 2-(3,4-dimethoxy-phenyl)-N-{3-[2-(4-methoxybenzyl)-
 1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-
 propyl}-acetamide;
 cyclohexanecarboxylic acid {3-[2-(4-methoxybenzyl)-
 10 1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-
 propyl}-amide;
 N-{3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-
 spiro[4.5]dec-8-yl]-1-phenyl-propyl}-benzamide;
 N-{3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-
 15 spiro[4.5]dec-8-yl]-1-phenyl-propyl}-2-phenyl-
 acetamide;
 N-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-
 spiro[4.5]dec-8-yl]-1-phenyl-propyl}-acetamide;
 cyclopropanecarboxylic acid {3-[2-(4-
 20 methanesulfonylbenzyl)-1-oxo-2,8-diaza-
 spiro[4.5]dec-8-yl]-1-phenyl-propyl} amide;
 N-{3-[2-(4-methanesulfonyl-benzyl)-1-oxo-2,8-diaza-
 spiro[4.5]dec-8-yl]-1-phenyl-propyl}-isobutyramide;
 N-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-
 25 spiro[4.5]dec-8-yl]-1-phenyl-propyl}-3-methyl-
 butyramide;
 2-chloro-N-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-
 2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-
 benzamide;

N-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-
 spiro[4.5]dec-8-yl]-1-phenyl-propyl}-2-methoxy-
 benzamide;
 pyridine-2-carboxylic acid {3-[2-(4-
 5 methanesulfonylbenzyl)-1-oxo-2,8-diaza-
 spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide;
 3-chloro-N-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-
 2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-
 benzamide;
 10 N-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-
 spiro[4.5]dec-8-yl]-1-phenyl-propyl}-3-methoxy-
 benzamide;
 N-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-
 spiro[4.5]dec-8-yl]-1-phenyl-propyl}-nicotinamide;
 15 4-chloro-N-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-
 2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-
 benzamide;
 N-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-
 spiro[4.5]dec-8-yl]-1-phenyl-propyl}-4-methoxy-
 20 benzamide;
 N-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-
 spiro[4.5]dec-8-yl]-1-phenyl-propyl}-
 isonicotinamide;
 3,4-dichloro-N-{3-[2-(4-methanesulfonylbenzyl)-1-
 25 oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-
 benzamide;
 N-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-
 spiro[4.5]dec-8-yl]-1-phenyl-propyl}-3,4-dimethoxy-
 benzamide;

2-(2-chlorophenyl)-N-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl}-acetamide;
 N-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl}-2-(2-methoxyphenyl)-acetamide;
 5 2-(3-chlorophenyl)-N-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl}-acetamide;
 N-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl}-2-(3-methoxyphenyl)-acetamide;
 10 N-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl}-2-(3-methoxyphenyl)-acetamide;
 N-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl}-benzamide;
 15 (S)-cyclohexanecarboxylic acid {3-(2-benzyl-1-oxo-2,8-diazaspiro[4.5]dec-8-yl)-1-phenyl-propyl}-amide;
 N-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl}-2-(4-methoxyphenyl)-acetamide;
 20 N-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl}-2-phenylacetamide;
 2-(3,4-dichlorophenyl)-N-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl}-acetamide;
 25 cyclopentanecarboxylic acid {3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide;

- cyclobutanecarboxylic acid {3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide;
- cycloheptanecarboxylic acid {3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide;
- 5 2-cyclohexyl-N-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl}-acetamide;
- 10 2-cyclopentyl-N-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl}-acetamide;
- furan-2-carboxylic acid {3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide;
- 15 2-ethyl-N-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl}-butyramide;
- thiophene-2-carboxylic acid {3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide;
- 20 2-(3,4-dimethoxyphenyl)-N-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl}-acetamide;
- 25 cyclohexanecarboxylic acid {3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide;
- 4-methyl-cyclohexanecarboxylic acid {3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide;
- 30

2-methoxy-N-[3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-benzamide;

3-chloro-N-[3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-benzamide;

5 4-chloro-N-[3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-benzamide;

4-methoxy-N-[3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-benzamide;

10 benzamide;

cyclohexanecarboxylic acid [3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(3-chlorophenyl)-propyl]-amide;

N-[3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(3-chlorophenyl)-propyl]-benzamide;

15 benzamide;

N-[3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(3-chlorophenyl)-propyl]-2-phenyl-acetamide;

20 {1-(3-chlorophenyl)-3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-carbamic acid tert-butyl ester;

{1-(3,4-dichlorophenyl)-3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-carbamic acid tert-butyl ester;

25 benzamide;

N-[3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-acetamide;

cyclopropanecarboxylic acid [3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-amide;

30 benzamide;

- N-[3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-isobutyramide;
3-methyl-N-[3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-butyramide;
5 2-chloro-N-[3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-benzamide;
pyridine-2-carboxylic acid [3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-amide;
10 3-methoxy-N-[3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-benzamide;
N-[3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-nicotinamide;
15 N-[3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-isonicotinamide;
3,4-dichloro-N-[3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-
20 benzamide;
3,4-dimethoxy-N-[3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-benzamide;
2-(2-chlorophenyl)-N-[3-(1-oxo-2-pyridin-3-ylmethyl-
25 2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-acetamide;
2-(2-methoxyphenyl)-N-[3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-acetamide;
30 N-[3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-benzamide;

- 2-(3-chloro-phenyl)-N-[3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-acetamide;
- 2-(3-methoxyphenyl)-N-[3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-acetamide;
- 5 2-(4-methoxyphenyl)-N-[3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-acetamide;
- 10 N-[3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-2-phenyl-acetamide;
- 2-(3,4-dichloro-phenyl)-N-[3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-acetamide;
- 15 cyclopentanecarboxylic acid [3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-amide;
- {1-(3-chlorophenyl)-3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-carbamic acid tert-butyl ester;
- 20 cyclobutanecarboxylic acid [3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-amide;
- 25 cycloheptanecarboxylic acid [3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-amide;
- 2-cyclohexyl-N-[3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-acetamide;
- 30

2-cyclopentyl-N-[3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-acetamide;

furan-2-carboxylic acid [3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-amide;

2-ethyl-N-[3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-butyramide;

thiophene-2-carboxylic acid [3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-amide;

2-(3,4-dimethoxyphenyl)-N-[3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-acetamide;

cyclohexanecarboxylic acid [3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-amide;

4-methyl-cyclohexanecarboxylic acid [3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-phenyl-propyl]-amide;

[3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(3-methoxyphenyl)-propyl]-carbamic acid tert-butyl ester;

[3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(3-methoxyphenyl)-propyl]-carbamic acid tert-butyl ester;

(S)-N-[3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl]-acetamide;

(S)-cyclopropanecarboxylic acid [3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl]-amide;

- (S)-N-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-isobutyramide;
- (S)-N-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-isobutyramide;
- 5 (S)-N-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-3-methyl-butyramide;
- (S)-cyclopentanecarboxylic acid {3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide;
- 10 (S)-cyclobutanecarboxylic acid {3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide;
- {3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(4-methoxyphenyl)-propyl}-carbamic acid tert-butyl ester;
- 15 {3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-pyridin-2-yl-propyl}-carbamic acid tert-butyl ester;
- 20 {3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-pyridin-2-yl-propyl}-carbamic acid tert-butyl ester;
- {1-(3,4-dichlorophenyl)-3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-carbamic acid tert-butyl ester;
- 25 2-cyclopropyl-N-{3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-acetamide;

2-cyclopropyl-N-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-acetamide;

[3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(4-methoxyphenyl)-propyl]-carbamic acid
5 tert-butyl ester;

N-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-2-cyclopropyl-acetamide;

10 [3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(3,4-dimethoxyphenyl)-propyl]-carbamic acid tert-butyl ester;

{1-(3,4-dimethoxyphenyl)-3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-carbamic
15 acid tert-butyl ester;

tetrahydro-pyran-4-carboxylic acid {3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide;

[3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(3-methoxy-phenyl)-propyl]-
20 carbamic acid tertbutyl ester;

(S)-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-carbamic acid tert-butyl ester;

25 {3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-pyridin-2-yl-propyl}-carbamic acid tert-butyl ester;

{1-(3,4-dimethoxyphenyl)-3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-carbamic acid tert-butyl
30 ester;

{1-(4-chlorophenyl)-3-[2-(4-methoxybenzyl)-1-oxo-
 2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-carbamic acid
 tert-butyl ester;
 {1-(2-chlorophenyl)-3-[2-(4-methoxybenzyl)-1-oxo-
 5 2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-carbamic acid
 tert-butyl ester;
 {3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-
 spiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl}-carbamic
 acid tert-butyl ester;
 10 [3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-
 spiro[4.5]dec-8-yl]-1-(4-methoxyphenyl)-propyl]-
 carbamic acid tert-butyl ester;
 [3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-
 8-yl]-1-(4-chlorophenyl)-propyl]-carbamic acid tert-
 15 butyl ester;
 [3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-
 8-yl]-1-(2-chlorophenyl)-propyl]-carbamic acid tert-
 butyl ester;
 {3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-
 20 8-yl]-1-thiophen-2-yl-propyl}-carbamic acid tert-
 butyl ester;
 {1-(4-chlorophenyl)-3-[2-(4-methanesulfonylbenzyl)-
 1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-carbamic
 acid tert-butyl ester;
 25 {1-(2-chlorophenyl)-3-[2-(4-methanesulfonylbenzyl)-
 1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl}-carbamic
 acid tert-butyl ester;
 {3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-
 spiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl}-carbamic
 30 acid tert-butyl ester;

- (S)-N-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-isobutyramide;
- 3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(2-methoxyphenyl)-propyl]-carbamic acid
5 tert-butyl ester;
- 3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(2-methoxy-phenyl)-propyl]-carbamic acid tert-butyl ester;
- 10 [1-(2-chlorophenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-propyl]-carbamic acid tert-butyl ester;
- [1-(3-chlorophenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-propyl]-carbamic acid
15 tert-butyl ester;
- [1-(3,4-dichlorophenyl)-3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-propyl]-carbamic acid tert-butyl ester;
- [3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-thiophen-2-yl-propyl]-carbamic
20 acid tert-butyl ester;
- (S)-8-[3-(cyclopropanecarbonyl-amino)-3-phenyl-propyl]-2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]decane;
- 25 (S)-8-[3-(cyclopentanecarbonyl-amino)-3-phenyl-propyl]-2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]decane;
- (S)-8-[3-(cyclohexanecarbonyl-amino)-3-phenyl-propyl]-2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-
30 spiro[4.5]decane;

- (S)-8-[3-(cyclopropanecarbonyl-amino)-3-phenyl-propyl]-2-(4-methoxybenzyl)-1-oxo-2,8-diazaspiro[4.5]decane;
- (S)-8-(3-isobutyrylamino-3-phenyl-propyl)-2-(4-methoxybenzyl)-1-oxo-2,8-diazaspiro[4.5]decane;
- 5 (S)-8-[3-(cyclopentanecarbonyl-amino)-3-phenyl-propyl]-2-(4-methoxybenzyl)-1-oxo-2,8-diazaspiro[4.5]decane;
- (S)-8-[3-(cyclohexanecarbonyl-amino)-3-phenyl-propyl]-2-(4-methoxybenzyl)-1-oxo-2,8-diazaspiro[4.5]decane;
- 10 N-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl}-isobutyramide;
- 15 cyclobutanecarboxylic acid {3-[2-(4-bromobenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl}-amide;
- cyclopentanecarboxylic acid {3-[2-(4-bromobenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl}-amide;
- 20 N-{3-[2-(4-bromo-enzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl}-propionamide;
- N-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl}-2-methoxy-acetamide;
- 25 cyclohexanecarboxylic acid {3-[2-(4-bromobenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl}-amide;

- cyclopropanecarboxylic acid {3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl}-amide;
- N-{3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-
- 5 spiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl}-isobutyramide;
- {3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(2-methoxyphenyl)-propyl}-carbamic acid tert-butyl ester;
- 10 cyclobutanecarboxylic acid {3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl}-amide;
- cyclopentanecarboxylic acid {3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-thiophen-2-yl-
- 15 propyl}-amide;
- N-{3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl}-propionamide;
- 2-methoxy-N-{3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-
- 20 spiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl}-acetamide;
- cyclohexanecarboxylic acid {3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl}-amide;
- 25 cyclopropane carboxylic acid{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl}-amide;
- N-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl}-
- 30 isobutyramide;

- cyclobutanecarboxylic acid {3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl}-amide;
- cyclopentanecarboxylic acid {3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl}-amide;
- 5 N-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl}-propionamide;
- 10 N-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl}-2-methoxy-acetamide;
- cyclohexanecarboxylic acid {3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diazaspiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl}-amide;
- 15 cyclohexanecarboxylic acid [3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-thiophen-2-yl-propyl]-amide;
- N-[3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-thiophen-2-yl-propyl]-isobutyramide;
- 20 cyclobutanecarboxylic acid [3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-thiophen-2-yl-propyl]-amide;
- 25 cyclopentanecarboxylic acid [3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-thiophen-2-yl-propyl]-amide;
- N-[3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-thiophen-2-yl-propyl]-propionamide;
- 30

- cyclohexanecarboxylic acid [3-(1-oxo-2-pyridin-3-ylmethyl-2,8-diaza-spiro[4.5]dec-8-yl)-1-thiophen-2-yl-propyl]-amide;
- cyclopropanecarboxylic acid [3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(3-chlorophenyl)-propyl]-amide;
- 5 N-[3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(3-chlorophenyl)-propyl]-isobutyramide;
- 10 cyclobutanecarboxylic acid [3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(3-chlorophenyl)-propyl]-amide;
- cyclopentanecarboxylic acid [3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(3-chlorophenyl)-propyl]-amide;
- 15 N-[3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(3-chlorophenyl)-propyl]-propionamide;
- N-[3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-(3-chlorophenyl)-propyl]-2-methoxy-acetamide;
- 20 piperidine-1-carboxylic acid {3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide;
- 25 piperidine-1-carboxylic acid {3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-amide;
- piperidine-1-carboxylic acid {3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}amide;
- 30

1-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-
 spiro[4.5]dec-8-yl]-1-phenyl-propyl}-3-phenyl-urea;
 1-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-
 spiro[4.5]dec-8-yl]-1-phenyl-propyl}-3-(2-chloro-
 5 phenyl)-urea;
 1-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-
 spiro[4.5]dec-8-yl]-1-phenyl-propyl}-3-(2-methoxy-
 phenyl)-urea;
 1-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-
 10 spiro[4.5]dec-8-yl]-1-phenyl-propyl}-3-(3-chloro-
 phenyl)-urea;
 1-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-
 spiro[4.5]dec-8-yl]-1-phenyl-propyl}-3-(3-methoxy-
 phenyl)-urea;
 15 1-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-
 spiro[4.5]dec-8-yl]-1-phenyl-propyl}-3-(4-chloro-
 phenyl)-urea;
 1-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-
 spiro[4.5]dec-8-yl]-1-phenyl-propyl}-3-(4-methoxy-
 20 phenyl)-urea;
 1-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-
 spiro[4.5]dec-8-yl]-1-phenyl-propyl}-3-(2,6-
 dimethyl-phenyl)-urea;
 1-{3-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-
 25 spiro[4.5]dec-8-yl]-1-phenyl-propyl}-3-naphthalen-1-
 yl-urea;
 1-{3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-
 spiro[4.5]dec-8-yl]-1-phenyl-propyl}-3-phenyl-urea;
 1-(2-chlorophenyl)-3-{3-[2-(4-methoxybenzyl)-1-oxo-
 30 2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-urea;

1-{3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-
 spiro[4.5]dec-8-yl]-1-phenyl-propyl}-3-(2-
 methoxyphenyl)-urea;
 1-(3-chlorophenyl)-3-{3-[2-(4-methoxybenzyl)-1-oxo-
 5 2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-urea;
 1-{3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-
 spiro[4.5]dec-8-yl]-1-phenyl-propyl}-3-(3-
 methoxyphenyl)-urea;
 -(3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-
 10 spiro[4.5]dec-8-yl]-1-phenyl-propyl)-3-(4-
 methoxyphenyl)-urea;
 1-(2,6-dimethylphenyl)-3-{3-[2-(4-methoxybenzyl)-1-
 oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-
 urea;
 15 1-{3-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-
 spiro[4.5]dec-8-yl]-1-phenyl-propyl}-3-naphthalen-1-
 yl-urea;
 1-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-
 spiro[4.5]dec-8-yl]-1-phenyl-propyl}-3-phenyl-urea;
 20 1-(2-chlorophenyl)-3-{3-[2-(4-
 methanesulfonylbenzyl)-1-oxo-2,8-diaza-
 spiro[4.5]dec-8-yl]-1-phenyl-propyl}-urea;
 1-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-
 spiro[4.5]dec-8-yl]-1-phenyl-propyl}-3-(2-
 25 methoxyphenyl)-urea;
 1-(3-chlorophenyl)-3-{3-[2-(4-
 methanesulfonylbenzyl)-1-oxo-2,8-diaza-
 spiro[4.5]dec-8-yl]-1-phenyl-propyl}-urea;
 1-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-
 30 spiro[4.5]dec-8-yl]-1-phenyl-propyl}-3-(3-
 methoxyphenyl)-urea;

1-(4-chlorophenyl)-3-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-urea;
 1-(3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-3-(4-methoxyphenyl)-urea;
 5 1-(2,6-dimethylphenyl)-3-{3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-urea;
 10 1-(3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-3-naphthalen-1-yl-urea;
 {3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-carbamic acid
 15 methyl ester;
 {3-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl}-carbamic acid ethyl ester;
 4-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-2-phenyl-butyric acid methyl ester;
 20 4-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-2-phenyl-butyric acid methyl ester;
 4-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-2-phenyl-butyric acid methyl ester;
 25 4-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-2,N-diphenyl-butyramide;
 N-benzyl-4-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-2-phenyl-butyramide;
 30

2-(4-bromobenzyl)-8-(4-oxo-3-phenyl-4-piperidin-1-yl-butyl)-2,8-diaza-spiro[4.5]decan-1-one;
 4-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-N-cyclohexyl-2-phenyl-butyramide;
 5 4-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-N-cyclohexyl-N-methyl-2-phenyl-butyramide;
 4-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-N-cyclopropyl-2-phenyl-butyramide;
 4-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-N-cyclobutyl-2-phenyl-butyramide;
 10 N-cyclohexyl-4-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-N-methyl-2-phenyl-butyramide;
 N-cyclopropyl-4-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-2-phenyl-butyramide;
 15 N-cyclobutyl-4-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-2-phenyl-butyramide;
 4-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-N-cyclopentyl-2-phenyl-butyramide;
 20 4-[2-(4-bromobenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-N-isopropyl-2-phenyl-butyramide;
 N-benzyl-4-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-2-phenyl-butyramide;
 2-(4-methanesulfonylbenzyl)-8-(4-oxo-3-phenyl-4-piperidin-1-yl-butyl)-2,8-diaza-spiro[4.5]decan-1-one;
 25 N-cyclohexyl-4-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-2-phenyl-butyramide;
 N-cyclopentyl-4-[2-(4-methanesulfonylbenzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-2-phenyl-butyramide;
 30

N-isopropyl-4-[2-(4-methanesulfonylbenzyl)-1-oxo-
 2,8-diaza-spiro[4.5]dec-8-yl]-2-phenyl-butyramide;
 4-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-
 spiro[4.5]dec-8-yl]-2,N-diphenyl-butyramide;
 5 N-benzyl-4-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-
 spiro[4.5]dec-8-yl]-2-phenyl-butyramide;
 2-(4-methoxybenzyl)-8-(4-oxo-3-phenyl-4-piperidin-1-
 yl-butyl)-2,8-diaza-spiro[4.5]decan-1-one;
 N-cyclohexyl-4-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-
 10 spiro[4.5]dec-8-yl]-2-phenyl-butyramide;
 N-cyclopropyl-4-[2-(4-methoxybenzyl)-1-oxo-2,8-
 diaza-spiro[4.5]dec-8-yl]-2-phenyl-butyramide;
 N-cyclobutyl-4-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-
 spiro[4.5]dec-8-yl]-2-phenyl-butyramide;
 15 N-cyclopentyl-4-[2-(4-methoxybenzyl)-1-oxo-2,8-
 diaza-spiro[4.5]dec-8-yl]-2-phenyl-butyramide;
 N-isopropyl-4-[2-(4-methoxybenzyl)-1-oxo-2,8-diaza-
 spiro[4.5]dec-8-yl]-2-phenyl-butyramide;
 and pharmaceutically acceptable salts, hydrates and
 20 solvates thereof.

32. A compound according to claim 1, wherein
 said compound is selected from:

Cyclopropanecarboxylic acid ((S)-1-(3-chloro-
 25 phenyl)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-
 spiro[4.5]dec-8-yl]-propyl)-amide;
 Cyclopropanecarboxylic acid ((S)-1-(3-fluoro-
 phenyl)-3-[2-(4-methoxy-benzyl)-1-oxo-2,8-diaza-
 spiro[4.5]dec-8-yl]-propyl)-amide;
 30 Cyclopropanecarboxylic acid ((S)-3-[2-(4-methoxy-
 benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-

thiophen-2-yl-propyl)-amide;
Cyclopropanecarboxylic acid ((S)-3-[2-(4-methoxy-
benzyl)-1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-
thiophen-3-yl-propyl)-amide;

5 N-((S)-1-(3-Chloro-phenyl)-3-[2-(4-methoxy-benzyl)-
1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl)-
isobutyramide;
N-((S)-1-(3-Fluoro-phenyl)-3-[2-(4-methoxy-benzyl)-
1-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl)-

10 isobutyramide;
N-((S)-3-[2-(4-Methoxy-benzyl)-1-oxo-2,8-diaza-
spiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl)-
isobutyramide;
N-((S)-3-[2-(4-Methoxy-benzyl)-1-oxo-2,8-diaza-

15 spiro[4.5]dec-8-yl]-1-thiophen-3-yl-propyl)-
isobutyramide;
N-((S)-3-[2-(4-Chloro-benzyl)-3-oxo-2,8-diaza-
spiro[4.5]dec-8-yl]-1-phenyl-propyl)-isobutyramide;
N-((S)-3-[2-(4-Fluoro-benzyl)-3-oxo-2,8-diaza-

20 spiro[4.5]dec-8-yl]-1-phenyl-propyl)-isobutyramide;
N-((S)-3-[2-(4-Cyano-benzyl)-3-oxo-2,8-diaza-
spiro[4.5]dec-8-yl]-1-phenyl-propyl)-isobutyramide;
N-((S)-3-[2-(4-Ethoxy-benzyl)-3-oxo-2,8-diaza-

25 N-((S)-3-[2-(4-Difluoromethoxy-benzyl)-3-oxo-2,8-
diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-
isobutyramide;
N-((S)-3-[3-Oxo-2-(4-trifluoromethoxy-benzyl)-2,8-

30 isobutyramide;
N-((S)-3-[3-Oxo-2-(4-trifluoromethyl-benzyl)-2,8-

diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-
 isobutyramide;
 N-((S)-3-[3-oxo-2-(4-pyrazol-1-yl-benzyl)-2,8-diaza-
 spiro[4.5]dec-8-yl]-1-phenyl-propyl)-isobutyramide;
 5 Cyclopropanecarboxylic acid ((S)-3-[2-(4-chloro-
 benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-
 phenyl-propyl)-amide;
 Cyclopropanecarboxylic acid ((S)-3-[2-(4-fluoro-
 benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-
 10 phenyl-propyl)-amide;
 Cyclopropanecarboxylic acid ((S)-3-[2-(4-cyano-
 benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-
 phenyl-propyl)-amide;
 Cyclopropanecarboxylic acid ((S)-3-[2-(4-ethoxy-
 15 benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-
 phenyl-propyl)-amide;
 Cyclopropanecarboxylic acid ((S)-3-[2-(4-
 difluoromethoxy-benzyl)-3-oxo-2,8-diaza-
 spiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide;
 20 Cyclopropanecarboxylic acid ((S)-3-[2-(4-
 trifluoromethoxy-benzyl)-3-oxo-2,8-diaza-
 spiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide;
 Cyclopropanecarboxylic acid ((S)-3-[2-(4-
 trifluoromethyl-benzyl)-3-oxo-2,8-diaza-
 25 spiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide;
 Cyclopropanecarboxylic acid ((S)-3-[3-oxo-2-(4-
 pyrazol-1-yl-benzyl)-2,8-diaza-spiro[4.5]dec-8-yl]-
 1-phenyl-propyl)-amide;
 2-Cyclopropyl-N-((S)-3-[2-(4-methoxy-benzyl)-3-oxo-
 30 2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-
 acetamide;

N-((S)-3-[2-(4-Chloro-benzyl)-3-oxo-2,8-diaza-
 spiro[4.5]dec-8-yl]-1-phenyl-propyl)-2-cyclopropyl-
 acetamide;

5 N-((S)-3-[2-(4-Fluoro-benzyl)-3-oxo-2,8-diaza-
 spiro[4.5]dec-8-yl]-1-phenyl-propyl)-2-cyclopropyl-
 acetamide;

N-((S)-3-[2-(4-Cyano-benzyl)-3-oxo-2,8-diaza-
 spiro[4.5]dec-8-yl]-1-phenyl-propyl)-2-cyclopropyl-
 acetamide;

10 N-((S)-3-[2-(4-Ethoxy-benzyl)-3-oxo-2,8-diaza-
 spiro[4.5]dec-8-yl]-1-phenyl-propyl)-2-cyclopropyl-
 acetamide;

N-((S)-3-[2-(4-Difluoromethoxy-benzyl)-3-oxo-2,8-
 diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-2-
 15 cyclopropyl-acetamide;

N-((S)-3-[2-(4-Trifluoromethoxy-benzyl)-3-oxo-2,8-
 diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-2-
 cyclopropyl-acetamide;

N-((S)-3-[2-(4-Trifluoromethyl-benzyl)-3-oxo-2,8-
 20 diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-2-
 cyclopropyl-acetamide;

2-Cyclopropyl-N-((S)-3-[3-oxo-2-(4-pyrazol-1-yl-
 benzyl)-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-
 propyl)-acetamide;

25 4,4-Difluoro-cyclohexanecarboxylic acid ((S)-3-[2-
 (4-chloro-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-
 yl]-1-phenyl-propyl)-amide;


4,4-Difluoro-cyclohexanecarboxylic acid ((S)-3-[2-
 (4-fluoro-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-
 30 yl]-1-phenyl-propyl)-amide;

4,4-Difluoro-cyclohexanecarboxylic acid ((S)-3-[2-


- (4-cyano-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide;
- 4,4-Difluoro-cyclohexanecarboxylic acid {(S)-3-[2-(4-ethoxy-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide;
- 5 4,4-Difluoro-cyclohexanecarboxylic acid {(S)-3-[3-oxo-2-(4-pyrazol-1-yl-benzyl)-2,8-diaza-spiro[4.5]dec-8-yl]-1-phenyl-propyl)-amide;
- Cyclopropanecarboxylic acid {(S)-1-(3-chloro-phenyl)-3-[2-(4-methoxy-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl)-amide;
- 10 Cyclopropanecarboxylic acid {(S)-1-(3-fluoro-phenyl)-3-[2-(4-methoxy-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl)-amide;
- 15 Cyclopropanecarboxylic acid {(S)-3-[2-(4-methoxy-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl)-amide;
- Cyclopropanecarboxylic acid {(S)-3-[2-(4-methoxy-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-thiophen-3-yl-propyl)-amide;
- 20 N-[(S)-1-(3-Chloro-phenyl)-3-[2-(4-methoxy-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl]-isobutyramide;
- N-[(S)-1-(3-Fluoro-phenyl)-3-[2-(4-methoxy-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-propyl]-isobutyramide;
- 25 N-[(S)-3-[2-(4-Methoxy-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-thiophen-2-yl-propyl]-isobutyramide;
- 30 N-[(S)-3-[2-(4-Methoxy-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-thiophen-3-yl-propyl]-

isobutyramide;
Propane-2-sulfonic acid {(S)-3-[2-(4-methoxy-
benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-
phenyl-propyl}-amide;
5 3-[(S)-3-[2-(4-Methoxy-benzyl)-3-oxo-2,8-diaza-
spiro[4.5]dec-8-yl]-1-phenyl-propyl]-1,1-dimethyl-
urea;
Morpholine-4-carboxylic acid {(S)-3-[2-(4-methoxy-
benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-8-yl]-1-
10 phenyl-propyl}-amide;
3,3-Difluoro-pyrrolidine-1-carboxylic acid {(S)-3-
[2-(4-methoxy-benzyl)-3-oxo-2,8-diaza-spiro[4.5]dec-
8-yl]-1-phenyl-propyl}-amide;
{(S)-3-[2-(4-Methoxy-benzyl)-3-oxo-2,8-diaza-
15 spiro[4.5]dec-8-yl]-1-phenyl-propyl}-carbamic acid
methyl ester;
{(S)-3-[2-(4-Methoxy-benzyl)-3-oxo-2,8-diaza-
spiro[4.5]dec-8-yl]-1-phenyl-propyl}-carbamic acid
ethyl ester;
20
and pharmaceutically acceptable salts, hydrates or
solvates thereof.


33. A compound according to claim 1, wherein:
25 Y, Z and X are each, independently, CH₂, C=O or
CR₄R₅;
W is H, C₁₋₆ alkyl, C₆₋₁₂ aryl, 3 to 10 membered
heterocycle, C₆₋₁₂ aralkyl or C₃₋₁₀ heteroaralkyl;
R₁ is H, C₁₋₆ alkyl, C₆₋₁₂ aryl, OH, NR₈R₉, O-C₁₋₆ alkyl,
30 O-C₆₋₁₂ aryl, O-C₆₋₁₂ aralkyl,




(II)




(III)



(IV)



(V)



(VI)

R₂ is C₁₋₁₀ alkyl, C₆₋₁₂ aryl or 3 to 10 membered heterocycle;

5 R₃ is H, C₁₋₆ alkyl or C₆₋₁₂ aryl;

R₄ and R₅ are each, independently, H, C₁₋₆ alkyl or C₆₋₁₂ aryl;

R₆ is H or C₁₋₄ alkyl;

R₇ is H, C₁₋₁₀ alkyl, C₆₋₁₂ aryl, 3 to 10 membered

10 heterocycle, C₆₋₁₂ aralkyl or 3 to 10 membered heteroaralkyl; or

R''₆ and R₇ can also be taken together to form a 3 to 10 membered heterocycle; and

R₈ and R₉ are each, independently, H or C₁₋₆ alkyl.

15

34. A method of modulating chemokine receptor activity in a subject comprising administering to the subject an effective amount of a compound of according to claim 1.

20

35. A method of preventing or treating at least one disease associated with the modulation of chemokine receptor activity in a subject in need of such treatment comprising administering to the
5 subject a therapeutically effective amount of a compound of according to claim 1.

36. A method of preventing or treating at least one inflammatory disease, immunoregulatory
10 disease, organ transplantation reaction, or infectious disease in a subject in need of such treatment comprising administering to the subject a therapeutically effective amount of a compound of according to claim 1.

15
37. A method of preventing or treating an HIV infection in a subject in need of such treatment comprising administering to the subject a therapeutically effective amount of a compound of
20 according to claim 1.

38. A method of preventing or treating at least one disease associated with the modulation of CCR5 chemokine receptor activity in a subject in
25 need of such treatment comprising administering to the subject a therapeutically effective amount of a compound of according to claim 1.

39. A method of blocking cellular entry of HIV
30 in a subject in need thereof comprising administering to the subject an effective amount of

a compound according to claim 1 to block HIV from cellular entry in said subject.

40. A method of delaying the onset of AIDS or
5 treating AIDS in a subject in need of such treatment comprising administering to the subject a therapeutically effective amount of a compound according to claim 1.

10 41. A method of preventing or treating of a disease associated with the modulation of chemokine receptor activity in a subject in need of such treatment comprising administering to the subject a therapeutically effective amount of a combination of
15 a compound according to claim 1 and at least one further therapeutic agent.

42. A method of preventing or treating of a disease associated with the modulation of CCR5
20 chemokine receptor activity in a subject in need of such treatment comprising administering to the subject a therapeutically effective amount of a combination of a compound according to claim 1 and at least one further therapeutic agent.

25 43. A method of blocking cellular entry of HIV in a subject or for the prevention or treatment of HIV infections in a subject in need of such treatment comprising administering to the subject a
30 therapeutically effective amount of a combination of

a compound according to claim 1 and at least one further therapeutic agent.

44. A method for delaying the onset of AIDS or
5 treating AIDS in a subject in need of such treatment comprising administering to the subject a therapeutically effective amount of a combination of a compound according to claim 1 and at least one further therapeutic agent.

10

45. A method according to claim 34, wherein said compound is administered in an amount of 0.1 - 750 mg/kg of body weight per day.

15 46. A method according to claim 35, wherein said compound is administered in an amount of 0.1 - 750 mg/kg of body weight per day.

47. A method according to claim 36, wherein
20 said compound is administered in an amount of 0.1 - 750 mg/kg of body weight per day.

48. A method according to claim 37, wherein
said compound is administered in an amount of 0.1 -
25 750 mg/kg of body weight per day.

49. A method according to claim 38, wherein
said compound is administered in an amount of 0.1 -
750 mg/kg of body weight per day.

30

50. A method according to claim 39, wherein
said compound is administered in an amount of 0.1 -
750 mg/kg of body weight per day.

5 51. A method according to claim 40, wherein
said compound is administered in an amount of 0.1 -
750 mg/kg of body weight per day.

52. A method according to claim 41, wherein
10 said compound is administered in an amount of 0.1 -
750 mg/kg of body weight per day.

53. A method according to claim 42, wherein
said compound is administered in an amount of 0.1 -
15 750 mg/kg of body weight per day.

54. A method according to claim 43, wherein
said compound is administered in an amount of 0.1 -
750 mg/kg of body weight per day.

20

55. A method according to claim 44, wherein
said compound is administered in an amount of 0.1 -
750 mg/kg of body weight per day.

25 56. A method according to claim 34, wherein
said subject is a human.

57. A method according to claim 35, wherein
said subject is a human.

30

58. A method according to claim 36, wherein
said subject is a human.

59. A method according to claim 37, wherein
5 said subject is a human.

60. A method according to claim 38, wherein
said subject is a human.

10 61. A method according to claim 39, wherein
said subject is a human.

62. A method according to claim 40, wherein
said subject is a human.

15 63. A method according to claim 41, wherein
said subject is a human.

64. A method according to claim 42, wherein
20 said subject is a human.

65. A method according to claim 43, wherein
said subject is a human.

25 66. A method according to claim 44, wherein
said subject is a human.

67. A pharmaceutical composition comprising a
compound according to any one of claims 1 to 33, or
30 a pharmaceutically acceptable salt, solvate or

hydrate thereof, and a pharmaceutically acceptable carrier.

68. A composition according to claim 67,
5 further comprising at least one further therapeutic agent.

69. A pharmaceutical combination comprising a compound according to any one of claims 1 to 33, or a
10 pharmaceutically acceptable salt, solvate or hydrate thereof, and at least one further therapeutic agent.

70. A combination according to claim 69,
wherein
15 said at least one further therapeutic agent is an antiviral agent.

71. A combination according to claim 69,
wherein
20 said at least one further therapeutic agent is selected from nucleoside and nucleotide analog reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, attachment and fusion inhibitors,
25 integrase inhibitors and maturation inhibitors.

72. A combination according to claim 70,
wherein
said antiviral agent is selected from 3TC
30 (lamivudine, Epivir®), AZT (zidovudine, Retrovir®), Emtricitabine (Coviracil®, formerly FTC), d4T

(2',3'-dideoxy-2',3'-didehydro-thymidine, stavudine and Zerit®), tenofovir (Viread®), 2',3'-dideoxyinosine (ddl, didanosine, Videx®), 2',3'-dideoxycytidine (ddC, zalcitabine, Hivid®),
5 Combivir® (AZT/3TC or zidovudine/lamivudine combination), Trivizir® (AZT/3TC/abacavir or zidovudine/lamivudine/abacavir combination), abacavir (1592U89, Ziagen®), SPD-754, ACH-126,443 (Beta-L-Fd4C), Alovudine (MIV-310), DAPD
10 (amdoxovir), Racivir, 9-[(2-hydroxymethyl)-1,3-dioxolan-4-yl]guanine and 2-amino-9-[(2-hydroxymethyl)-1,3-dioxolan-4-yl]adenine.

73. A combination according to claim 70,
15 wherein
said antiviral agent is selected from Nevirapine (Viramune®, NVP, BI-RG-587), delavirdine (Rescriptor®, DLV), efavirenz (DMP 266, Sustiva®), (+)-Calanolide A, Capravirine (AG1549, formerly S-
20 1153), DPC083, MIV-150, TMC120, TMC125 or BHAP (delavirdine), calanolides or L-697,661 (2-Pyridinone 3benzoxazolMeNH derivative).

74. A combination according to claim 70,
25 wherein
said antiviral agent is selected from nelfinavir (Viracept®, NFV), amprenavir (141W94, Agenerase®), indinavir (MK-639, IDV, Crixivan®), saquinavir (Invirase®, Fortovase®, SQV), ritonavir (Norvir®,
30 RTV), lopinavir (ABT-378, Kaletra®), Atazanavir (BMS232632), mozenavir (DMP-450), fosamprenavir

(GW433908), RO033-4649, Tipranavir (PNU-140690),
TMC114 and VX-385.

75. A combination according to claim 70,
5 wherein
said antiviral agent is selected from T-20
(enfuvirtide, Fuzeon®), T-1249, Schering C (SCH-C),
Schering D (SCH-D), FP21399, PRO-140, PRO 542, PRO
452, TNX-355, GW873140 (AK602), TAK-220, UK-427,857
10 or soluble CD4, CD4 fragments, CD4-hybrid molecules,
BMS-806, BMS-488043, AMD3100, AMD070 and KRH-2731.

76. A combination according to claim 70,
wherein
15 said antiviral agent is selected from S-1360, L-
870,810, L-870,812 and C-2507.

77. A combination according to claim 70,
wherein
20 said antiviral agent is PA-457.

78. A combination according to claim 70,
wherein
said antiviral agent is azodicarbonamide (ADA).
25

79. A combination according to claim 70,
wherein
said antiviral agent is HGTV43.

30

80. A combination according to claim 70,
wherein
said antiviral agent is selected from interleukin-2
(IL-2, Aldesleukin, Proleukin), granulocyte
5 macrophage colony stimulating factor (GM-CSF),
erythropoietin, Multikine, Ampligen, thymomodulin,
thymopentin, foscarnet, HE2000, Reticulose,
Murabutide, Resveratrol, HRG214, HIV-1 Immunogen
(Remune) and EP HIV-1090.

10

81. A combination according to claim 70,
wherein
said antiviral agent is selected from 2',3'-
dideoxyadenosine, 3'-deoxythymidine, 2',3'-dideoxy-
15 2',3'-didehydrocytidine, ribavirin, acyclovir,
ganciclovir, alpha-, beta- and gamma-interferon,
probenecid, TIBO drugs, HEPT, and TSAO derivatives.

82. A compound of any one of claims 1 to 33,
20 or a pharmaceutically acceptable salt, solvate or
hydrate thereof for use in modulating chemokine
receptor activity in a subject.

83. Use of a compound of any one of claims 1
25 to 33, or a pharmaceutically acceptable salt,
solvate or hydrate thereof, in the manufacture of a
medicament for preventing or treating at least one
disease associated with the modulation of chemokine
receptor activity in a subject in need of such
30 treatment.

84. Use of a compound of any one of claims 1 to 33, or a pharmaceutically acceptable salt, solvate or hydrate thereof, in the manufacture of a medicament for preventing or treating at least one inflammatory disease, immunoregulatory disease, organ transplantation reaction, or infectious disease in a subject in need of such treatment.

85. Use of a compound of any one of claims 1 to 33, or a pharmaceutically acceptable salt, solvate or hydrate thereof, in the manufacture of a medicament for preventing or treating an HIV infection in a subject in need of such treatment.

86. Use of a compound of any one of claims 1 to 33, or a pharmaceutically acceptable salt, solvate or hydrate thereof, in the manufacture of a medicament for preventing or treating at least one disease associated with the modulation of CCR5 chemokine receptor activity in a subject in need of such treatment.

87. Use of a compound of any one of claims 1 to 33, or a pharmaceutically acceptable salt, solvate or hydrate thereof, in the manufacture of a medicament for blocking cellular entry of HIV in a subject in need thereof.

88. Use of a compound of any one of claims 1 to 33, or a pharmaceutically acceptable salt, solvate or hydrate thereof, in the manufacture of a medicament

for delaying the onset of AIDS or treating AIDS in a subject in need of such treatment.

89. Use of a compound of any one of claims 1 to
5 33, or a pharmaceutically acceptable salt, solvate or hydrate thereof, in the manufacture of a medicament for preventing or treating of a disease associated with the modulation of chemokine receptor activity in a subject in need of such treatment.

10

90. Use of a compound of any one of claims 1 to
33, or a pharmaceutically acceptable salt, solvate or hydrate thereof, in the manufacture of a medicament for preventing or treating of a disease associated
15 with the modulation of CCR5 chemokine receptor activity in a subject in need of such treatment.

91. Use of a compound of any one of claims 1 to
33, or a pharmaceutically acceptable salt, solvate or
20 hydrate thereof, in the manufacture of a medicament for blocking cellular entry of HIV in a subject or for the prevention or treatment of HIV infections in a subject in need of such treatment.

92. Use of a compound of any one of claims 1 to
25 33, or a pharmaceutically acceptable salt, solvate or hydrate thereof, in the manufacture of a medicament for delaying the onset of AIDS or treating AIDS in a subject in need of such treatment.

30

93. A compound of formula (I), as defined in
any one of claims 1 to 33, or a pharmaceutically
acceptable salt, solvate or hydrate thereof, for use
5 in medical therapy.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA2004/001048

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D471/10 A61K31/437 A61P31/18

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
X	E. JUCKER ET. AL.: "Über neuartige Spiro-succinimide" ARCHIV DER PHARMAZIE, vol. 294, 1961, pages 210-220, XP009042111 page 213, compound 16; page 211, paragraph 1	1-3,29, 30,33, 67,93
A	----- US 6 291 469 B1 (FISHER ET. AL.) 18 September 2001 (2001-09-18) column 1, line 15 - column 2, line 15; claims; examples	1-93
A	----- WO 01/30780 A (COR THERAPEUTICS) 3 May 2001 (2001-05-03) page 1, line 9 - line 31; claims; examples ----- -/--	1-93



Further documents are listed in the continuation of box C



Patent family members are listed in annex

* Special categories of cited documents

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *8* document member of the same patent family

Date of the actual completion of the international search

4 January 2005

Date of mailing of the international search report

12/01/2005

Name and mailing address of the ISA

European Patent Office, P B 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel (+31-70) 340-2040, Tx 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Helps, I

INTERNATIONAL SEARCH REPORT

International Application No
PCT/CA2004/001048

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
A	US 5 962 462 A (MILLS ET. AL.) 5 October 1999 (1999-10-05) column 1, line 12 - column 3, line 23; claims; examples -----	1-93
A	WO 03/037271 A (MILLENIUM PHARMACEUTICALS INC.) 8 May 2003 (2003-05-08) Table 7, compounds 16-3, 16-4; pages 1-2; claims -----	1-93

INTERNATIONAL SEARCH REPORT

International application No.
PCT/CA2004/001048

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 34-66 (part)
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 34-66 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CA2004/001048

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 6291469	B1	18-09-2001	US 2003171373 A1	11-09-2003
			US 2002013325 A1	31-01-2002
			AT 274499 T	15-09-2004
			AU 713235 B2	25-11-1999
			AU 7382896 A	17-04-1997
			CA 2233204 A1	03-04-1997
			DE 69633245 D1	30-09-2004
			EP 0854869 A1	29-07-1998
			JP 11512723 T	02-11-1999
			NZ 320963 A	30-08-1999
			WO 9711940 A1	03-04-1997
WO 0130780	A	03-05-2001	AT 250604 T	15-10-2003
			AU 1244001 A	08-05-2001
			CA 2389034 A1	03-05-2001
			DE 60005545 D1	30-10-2003
			EP 1224186 A2	24-07-2002
			JP 2003514777 T	22-04-2003
			WO 0130780 A2	03-05-2001
			US 2003055244 A1	20-03-2003
US 5962462	A	05-10-1999	AU 5803398 A	03-07-1998
			WO 9825605 A1	18-06-1998
WO 2003037271	A	08-05-2003	WO 03037271 A2	08-05-2003